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Novel Immunoregulatory Elements in a Murine Model of Epicutaneous Chemical 
Sensitization 
 
Carrie Mae Long 
 
Toluene diisocyanate (TDI) is a low molecular weight chemical sensitizer and a major cause 
of occupational allergic disease and asthma. The roles of immunomodulatory elements such as 
microRNAs, which alter gene expression, and regulatory T cells (Tregs), which suppress T cell-
mediated responses, in chemical sensitization are not fully elucidated. In order to further investigate 
the functional role of miR-210 and Tregs during TDI sensitization, BALB/c mice were dermally 
exposed to a single, sensitizing dose of TDI (0.5-4% v/v) and evaluated for immunologic endpoints.  
dLN Tregs were phenotyped during TDI sensitization and a heterogeneous, expanded population was 
observed. To examine Treg functionality, a carboxyfluorescein succinimidyl ester-based Treg 
suppression assay was conducted. Tregs isolated from the dLNs of TDI sensitized mice were more 
suppressive than their control counterparts. The Treg population was then depleted prior to TDI 
sensitization by in vivo administration of a CD25-targeting antibody. The sensitization response was 
intensified following Treg depletion, as evidenced by amplified total dLN cellularity, Th2 expansion, 
and IL-4 mRNA production.  This data suggests that Tregs are important negative regulators of the 
TDI sensitization response.   
We have previously shown that miR-210 expression in the draining lymph node (dLN) is 
augmented during TDI sensitization and several putative mRNA targets identified for this miRNA 
(foxp3 and runx3) were directly related to Treg differentiation and function. Therefore, we 
hypothesized that miR-210 targets transcription factors central to Treg development and function, 
antagonizing the development and functional role of this subset during TDI sensitization.  In this 
work, we show that miR-210 expression is increased in the mouse dLN and Treg subsets during TDI 
sensitization.  Putative miR-210-target/key player interactions were examined using an ex vivo 
stimulation system in which miR-210 mimics were transfected into primary, stimulated dLN cells; 
decreases in multiple Treg-related genes were observed via qPCR analysis.  Alterations in dLN and 
Treg mRNA and protein expression of foxp3, runx3, ctla4, and cd25 were observed at multiple time 
points following TDI exposure. These molecules are directly involved in Treg expansion and 
function; therefore, miR-210 may potentially negatively target Treg differentiation and function 
during TDI sensitization.  In order to examine the effect of miR-210 modulation on Treg functionality 
we performed a carboxyfluorescein succinimidyl ester-based Treg suppression assay using dLN Tregs 
from naïve mice transfected with miR-210 mimic.  While the suppressive ability of TDI/mimic Tregs 
was increased compared to the acetone/mimic counterparts, the TDI/mimic samples had less 
expression of miR-210 compared to the acetone/mimic controls suggesting other factors, such as 
additional miRNAs, might be involved in the regulation of the functional capabilities of these cells.  
These novel findings indicate that Tregs likely play an important role in modulating allergic responses 
during TDI sensitization and that miR-210 may have an inhibitory role in this process.  Because the 
functional roles of miRNAs and Tregs have not been previously elucidated in a model of chemical 
sensitization, these data contribute to the understanding of the immunologic mechanisms of chemical 
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CHAPTER 1  

















Occupational allergic disease is a serious public health burden whose prevalence is growing 
worldwide.   Workplace exposures can result in a number of allergic diseases and approximately 11 
million American workers are potentially exposed to agents that can cause allergic disease (1).  
Asthma, allergic contact dermatitis, rhinitis, hypersensitivity pneumonitis, urticaria, eczema, and 
folliculitis can occur as a result of respiratory and dermal exposures in the workplace (1).  
Specifically, occupational exposures are responsible for approximately 9-25% of all adult onset 
asthma cases (2, 3) while occupational contact dermatitis represents 90% of all cases of work-related 
cutaneous disorders (4).  These conditions may be detrimental to a worker’s health and workplace 
performance, causing economic losses (5).  Occupational asthma is sometimes more severe than 
general asthma as evidenced by persistence of symptoms despite treatment, reports of deaths 
following sensitization and repeated exposures, and the significantly increased use of medical 
resources by occupational asthmatics compared to those with non-occupationally related conditions 
(6).   
A variety of agents can cause occupational allergic disease, including animal products (7), 
chemicals (1), drugs (8), foods (9), metals (4), molds (10), plant products (4), and venoms (11).  
Although both irritant and allergic conditions can be induced by occupational allergens, this work 
will focus on immune-mediated conditions such as allergic contact dermatitis and asthma caused by 
exposure to allergic sensitizers.  Over 250 causative agents of occupational asthma have been 
reported (12), approximately 400 allergens are available for contact dermatitis patch testing in 
humans (4), and over 3000 contact allergens have been identified (13), demonstrating the breadth of 
potential allergens found in the workplace.  Typically, these agents are classified as high or low 




in their allergenicity, dermal penetration, and allergic mechanism of action.   Many workplace factors 
may influence allergic disease, including barrier dysregulation caused by repetitive movements and 
irritants such as hand washing and contact with disinfectants, and occupational-induced stress which 
may contribute to the development and/or persistence of immune responses (14).    
 
1.2. TYPES OF HYPERSENSITIVITY REACTIONS 
Many occupationally-relevant allergic agents are known as sensitizers, indicating that 
repeated exposures will result in immune sensitization followed by the elicitation of allergic disease.  
This biphasic allergic process is characterized by two distinct phases: sensitization and elicitation.  
Sensitization is thought to occur because of numerous complex host and allergen-associated factors.  
The interplay of mucosal surfaces and allergens is an important concept directly related to the 
development of sensitization and many cell types are thought to be involved in this response, 
depending on the site of exposure and the individual’s unique immune microenvironment.   
Following epithelial access by an allergen, a variety of downstream effects can occur.  In the 
context of hypersensitivity reactions, which indicate an augmented and potentially damaging 
immune response, there are four basic hypersensitivity reactions as classified by Patrick Gell and 
Robin Coombs (15).  These distinct responses were characterized based on the primary effector 
molecules and immune cells thought to be involved in each reaction.  A summary of the four 
hypersensitivity reactions can be found in Table 1.1.  These reactions are grouped based on humoral 
(I-III) or cell-mediated (IV) primary effector mechanisms.  Although it was proposed over 50 years 
ago and several revision attempts have been made to update the classification scheme, the Gell and 
Coombs hypersensitivity classification is still widely accepted as the most valid scheme for 
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1.2.1. Type I Hypersensitivity Reaction  
Type I hypersensitivity reactions are perhaps the most recognizable, due to an association 
with a number of prevalent allergic diseases and atopy.  Type I reactions are mediated by IgE and 
mast cells and are sometimes called immediate-type hypersensitivity reactions.  The progression of 
antigen recognition, T cell activation, and B cell antibody production is very similar to the classic 
mechanism that is observed in a general IgG-mediated humoral response; however, in a T 
ype I hypersensitivity response, the primary cytotropic antibody produced in response to antigen is 
IgE.  A type I reaction can be described beginning with the recognition and uptake of allergen by 
APCs, presentation of antigen fragments to CD4+ T cells via MHC II, and the initiation of a Th2 
allergic response.  Th2 cytokines such as IL-4 and IL-13 are produced and secreted by CD4+ T cells, 
leading to antibody class switching and IgE production by B cells.  Once activated by the Th2 
microenvironment, basophils are thought to play an important role in the secretion of allergic 
cytokines and antibody class switching (16).   
Antibody class switching is a dynamic process that involves several steps; for IgE in 
particular two signals are required (16).  The first is provided by IL-4 or IL-13 through binding to 
their respective receptors on B cells, leading to activation of transcription at the IgE-specific Sε 
switch region.  The second signal is provided by CD40 (on B cells) – CD40 ligand (on T cells) 
binding, which activates DNA switch recombination.  Additional factors such as the expression of 
activation-induced deaminase (AID) influence class switching to IgE.  IgE class switching is thought 
to occur primarily in the germinal centers of secondary lymphoid organs such as the lymph nodes 
during allergic responses (16).  It is important to note that atopic individuals who are particularly 
susceptible to develop Type I reactions have high circulating levels of baseline IgE, which may be 




an allergic antibody due to its ability to bind to high affinity FcεR1 receptors on mast cells and 
basophils (16).  Once IgE is produced and secreted by plasma cells, it binds to mast cells and 
basophils via the high affinity FcεR1 receptor. Allergen binds to cell-bound IgE, crosslinking the 
IgE and activating these cells.   
Once activated, mast cells and basophils degranulate and release soluble allergic mediators 
such as histamine, heparin, cytokines, prostaglandins, leukotrienes, and proteases which act on 
smooth muscles, sensory nerves, mucous glands, arteries, and eosinophils (16, 17).  The mechanisms 
of action of these mediators are listed in further detail in Table 1.2.  Common clinical outcomes of 
Type I reactions include increased vascular permeability, smooth muscle cell contraction, and 
vasodilation, which can be experienced in one or more organs, depending on the site(s) and 
frequency of allergen exposure.  From a broad perspective, it appears that Type I responses may 
have evolved in order to prevent pathogens from surviving in the respiratory and gastrointestinal 
(GI) tracts (18).  Clinically, IgE-mediated responses are common in response to helminthic and 
parasitic infections but are not usually involved in responses to non-parasitic antigens.  It is 
imperative to note that Type I reactions typically require a sensitization phase of initial antigen 
exposure in order to allow the immune system to develop clonal specificity and IgE responses upon 
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Table 1.2: Secreted Mediators of Type I Hypersensitivity 
 
*Primary and Secondary Mediator indicates whether the substance is made before degranulation 
(primary) or synthesized after cellular activation/released by the breakdown of membrane 
components during degranulation (secondary) 
 





1.2.2. Type II Hypersensitivity Reaction 
Type II hypersensitivity reactions are humorally-mediated, and are characterized by the 
production of antibodies that cause cellular destruction.  Antibodies bound to cell surface antigens 
can activate the complement cascade, resulting in cellular damage via formation of pores in the cell 
membrane or antibody-dependent cell-mediated cytotoxicity (ADCC: natural killer cell or 
macrophage-mediated cell death) (17).  Typically, neutrophils are recruited to opsonized antibody-
antigen complexes and are major mediators of inflammatory symptoms.  Clinical features of Type 
II reactions may include allergic hemolytic anemia, agranulocytosis, fever, purpura, and 
thrombocytopenia.  An example of a Type II response is a penicillin reaction which is characterized 
by penicillin-red blood cell complexing, leading to an antibody response and activation of the 
complement cascade.  Type II responses may have developed as a defense strategy against small 
extracellular pathogens that are susceptible to neutrophil-mediated killing (18).     
 
1.2.3. Type III Hypersensitivity Reaction 
Type III hypersensitivity reactions are mediated by the formation of antibody-antigen 
complexes, which typically lead to antigen clearance by phagocytic and red blood cells.  In the case 
of a hypersensitivity reaction, large quantities of these immune complexes can lead to activation of 
the complement system and an inflammatory response characterized by neutrophil infiltration.  This 
response can be very damaging to the body’s tissues and both the magnitude and breadth of the 
reaction depends on the number of immune complexes and their location (localized or systemic).  
The immune complexes alone can cause tissue damage due to their deposition in blood vessel walls 
and other tissues.  Additionally, the complement component C3b opsonizes the immune complexes, 




membranes then phagocytosis is impeded, leading to the release of large amounts of lytic enzymes 
that are very destructive to the surrounding tissue (17).  The membrane attack complex (MAC) can 
also be formed, causing additional tissue destruction and cellular damage.  A classic example of a 
Type III hypersensitivity reaction is serum sickness, which is caused by the introduction of foreign 
antiserum into an organism, resulting in the formation of antiserum-specific antibodies and immune 
complexes comprised of both self-antibodies and foreign antiserum.  Serum sickness may lead to 
arthritis, fever, rashes, and vasculitis as a result of immune complex deposition and inflammatory 
mechanisms (17).  This response typically develops in 9-11 days following the transfer of sera (19).         
 
1.2.4. Type IV Hypersensitivity Reaction 
The final hypersensitivity classification is characterized by T cell-mediated and delay 
observed between antigen exposure and outward symptoms.  Many intracellular pathogens and 
contact antigens can induce Type IV responses, including Mycobacterium tuberculosis, Candida 
albicans, Variola spp. (Smallpox), and poison ivy (17).  Type IV responses are diverse and involve 
a number of effector cells and molecules.   
An initial sensitization phase is required following the first contact with antigen in order to 
activate T cells and allow for their clonal expansion.  APC-T cell interaction is required for the 
development of Type IV responses via MHC presentation.  Typically CD4+ Th1 cells are the primary 
T cell subset involved in Type IV responses but Th2 and CD8+ T cells have also been implicated in 
the development of Type IV responses (1, 17).  Following effective sensitization, subsequent 
antigenic exposures result in the elicitation or effector phase of the Type IV response, characterized 
by the secretion of pro-inflammatory cytokines (GM-CSF, IFNγ, IL-3, IL-12, and TNF-β) by Th1 




cytokines to attract and activate macrophages at sites of exposure the effector phase typically occurs 
24 hours following exposure and it generally peaks in magnitude at 48-72 hours after exposure (17).  
This phase of the response is characterized by the action of both clonally-specific Th1 cells and non-
specific immune effectors such as macrophages.  A well-managed Type IV response countering a 
pathogen can be beneficial to the host, resulting in pathogen clearance and minimal host cell damage; 
however, if the response is prolonged and not well controlled (as is the case in a hypersensitivity 
reaction) then severe tissue damage can occur.  Contact dermatitis is an example of an allergen-
induced Type IV hypersensitivity reaction.  This condition can be caused by a variety of molecules, 
including metals, chemicals, and natural substances such as poison ivy.  Many of these allergens are 
small in size and are able to permeate the skin and combine with skin proteins, forming antigen-
protein complexes.  These complexes are recognized by the immune system, allowing a Type IV 
response to develop.          
Due to the known plasticity of T cell development and function, it can be assumed that 
numerous T-helper (Th) subsets can potentially be involved in Type IV responses.  As previously 
mentioned, Th1, Th2, and cytotoxic CD8+ T cells have been associated with Type IV 
hypersensitivity reactions.  Accordingly, four Type IV subclasses have been proposed due to the 
wide breadth of responses involved in this type of hypersensitivity.  These subclasses include IVa-
d.  IVa reactions are thought to involve Th1 cells and monocytes and rely on the secretion of IL-1 
and IL-2.  IVb reactions are associated with Th2 cells and eosinophils along with the expression of 
IL4, IL-5, and IL-13.  Skin sensitization and asthmatic reactions to toluene diisocyanate (TDI) likely 
involve Type IVb components, based on the strong Th2 response paired with the disputed role of 
IgE.  The major effector cells of type IVc reactions are cytotoxic CD8+ T cells which utilize FasL, 




reactions involve T cells, neutrophils, and the production of IL-8, a neutrophil chemotactic factor.  
The necessity of multiple Type IV subtypes illustrates the diverse effector pathways involved in 
Type IV reactions.  Even classical Type IV reactions encompass both IVa and IVc reactions, 
illustrating the complexity of these responses and the need for elucidation of the complete 
immunologic mechanisms underlying disease as diagnosis and treatment of these conditions will be 
greatly enhanced by increased understanding of these complex mechanisms.  
 
1.2.5. Gell and Coomb’s Classification: Modern Validity? 
           Although the Gell and Coomb’s classification is a seminal work which has withstood decades 
of evolution in immunologic knowledge, its current validity has been questioned.  The landscape of 
immunology has been dramatically altered since the 1960s when the classification was proposed; 
therefore, one would expect the need for mechanistic updates to the classification, which have been 
absent.  In the context of drug reactions and chemical allergy, the Gell and Coombs classification 
does not encompass all reactions, including hypersensitivity pneumonitis and certain instances of 
chemical-induced asthma (19).  The idea that more than one defined hypersensitivity mechanism 
may be involved in a given reaction has been proposed as well.  Penicillin reactions have been shown 
to encompass a wide variety of defined hypersensitivity reactions, including anaphylaxis, 
angioneurotic edema, eosinophilia, fever, interstitial nephritis, respiratory symptoms, serum 
sickness, and skin rashes (20).  This does not completely invalidate the hypersensitivity mechanisms 
presented by Gell and Coombs; rather, it emphasizes the flexibility of the classification system, 
which is not generally emphasized. 
The Gell and Coombs classification is still valid for a number of reactions that are classically 




conditions, the inverse also holds true; many conditions do not fit into the current classification based 
on specific immune effectors as defined by Gell and Coombs.  The broad clinical usage of this 
classification presents several concerns, including the dismissal of underlying immune mechanisms 
involved in certain conditions based on their simple classification.  Admittedly, the understanding 
of immunologic mechanisms underlying many hypersensitivity reactions remains limited; however, 
current knowledge points to the need for a reevaluation of the current classification system based on 
the complexity of hypersensitivity reactions.  Type I-III reactions are defined based on the 
involvement of antibody.  While this effector mechanism remains valid, the T cell response 
preceding the humoral reaction (and acting in concert with this reaction) is also of significance.  Our 
current knowledge of immunology has revealed the dynamic nature of the immune system; the 
discovery of a multitude of CD4+ T cell subsets involved in a wide spectrum of immune responses 
has necessitated the examination of this component of the immune system for inclusion in 
hypersensitivity classification.  The model proposed by Gell and Coombs is still valid for many 
conditions but should not be utilized as a “one size fits all” classification system, as many conditions 
do not fall into the classification and much knowledge has been gained regarding the mechanisms of 
related immune responses.   
 
1.3. CHEMICAL-INDUCED SENSITIZATION 
As previously stated, allergens are commonly categorized as HMW or LMW; generally, 
protein allergens fall into the HMW range and chemical allergens are in the LMW range.  These two 
classes of molecules differ in their reactivity and antigenicity.  HMW protein allergens are 
functionally immunogenic due to their large size whereas LMW chemical allergens are not innately 




immunogenic hapten complexes that serve as functioning antigens (21).  Typically, IgE-mediated 
allergic responses are induced by HMW protein antigens but this type of immunologic response is 
also seen following exposure to certain LMW chemical allergens.  Human studies have revealed that 
HMW-induced occupational asthma cases are generally characterized by an early or dual asthmatic 
reaction, while LMW-induced occupational asthma cases generally exhibit delayed reactions (6).  
Additionally, a recent study suggested that occupational asthma induced by LMW agents may be 
more severe than that caused by HMW agents, based on specific inhalation challenge results and 
diagnostic severity classification in a cohort of patients with asthma of each etiology (6).   
Metal ions are constitute an additional type of allergen which includes chromium, cobalt, 
copper, nickel, palladium, platinum, and potassium dichromate; compared to protein allergens much 
less is known regarding the immune response underlying metal allergy (22, 23).  Several metals 
including nickel sulfate, cobalt chloride, and potassium dichromate are significant causative agents 
of allergic contact dermatitis (22).  Much like LMW chemical allergens, metal allergens such as 
nickel have displayed binding capabilities with MHC-bound proteins (usually via histidine residues) 
and in the case of nickel, this binding is hypothesized to occur on metal-binding motifs on self-
peptides complexed with the MHC molecule (22).  This concept of direct and/or reversible MHC or 
TCR-to-drug binding (non-covalent) has been termed “p-i” or pharmacological interaction with 
immune receptors and has been well studied in terms of drug-induced hypersensitivity reactions; 
ultimately, this process may result in the activation of drug-specific T cells (24).  Other metal 
allergens may induce these changes via MHC peptide stripping (palladium) or more indirect 
modifications of the self-peptide-MHC complexes (beryllium) (22).  Common haptenation 
mechanisms may be at play for certain metal allergens; for example, nickel-reactive human CD4+ T 




LMW chemical, and metal allergens likely utilize divergent mechanisms to cause allergic disease, 
co-exposures to multiple chemical classes and metals is a reality in the workplace and this may 
produce responses of altered severity with unique mechanisms.  
Although many substances can cause allergic and hypersensitivity reactions mediated by 
sensitization, LMW chemical sensitizers represent a substantial portion of causative agents of 
allergic diseases.  Typically, LMW chemical allergens cause dermal or respiratory allergic 
manifestations including contact dermatitis and asthma.  While the most common cause of dermal 
sensitization leading to contact dermatitis is exposure to metal salts, exposure to various LMW 
chemicals such as rubber additives, plastics and resins, biocides, and cosmetics are also significant 
causes of allergic contact dermatitis (4), which accounts for 10-15% of all occupational diseases (3).  
Additionally, it is estimated that the prevalence of contact allergy due to at least one sensitizing 
chemical in North America and Western Europe is approximately 20% (26).  Allergic respiratory 
diseases are associated with high levels of worker morbidity and are a global health burden; it is 
estimated that 9-25% of all cases of adult-onset asthma are associated with occupational exposures, 
which is equivalent to 250-300 cases per million of occupational-related adult-onset asthma each 
year (3).  Flour was the most common cause of occupational asthma in the UK in 1998; however, 
isoycanates represented the second most common cause, illustrating the relevance of chemicals as 
causative agents of occupational allergic disease.  The range of LMW chemicals that can cause 
occupational allergy is wide and is summarized in Table 1.3.  This table is not exhaustive yet it 
illustrates the fact that these sensitizing chemicals are utilized in a wide variety of industries and for 






 Specific Classification Chemical Name Product Occupation Allergic 
Disease 
Caused 
Acrylic Resin Monomers 




Care , Automobile 
workers 
Asthma (12), 
ACD (27)  
 Acrylamides  Dyes, Polyacrylamide 
synthesis 
Polymer synthesis, 
Paper and Textile, 
Waste Treatment 
ACD (27) 
 Cyanoacrylates  Glues Dentistry Asthma (28), 
ACD (27) 
 Methacrylates     
  2-hydroxyethyl 
methacrylate 
(2-HEMA) 















  2-hydroxypropyl 
methacrylate  
(2-HPMA) 




 Aliphatic Amines and 
Polyamines 




  Chemical Workers ACD (29) 
 Aromatic Amines   Textiles, Pesticides ACD (29) 
Anhydrides 
 Dioctyl-phthalate  Plastics, Wood 
coatings, Medical 
devices 
PVC Production Asthma (12) 





 Aldehydes     
  Formaldehyde and 
Formaldehyde-based 
materials 
Adhesive resin, Fiber 











  Furfuryl Alcohol Rocket engine fuel, 
Solvent, Intermediate 









 Chloramine T N-chloro 4-
methylbenzenesulfon
amide sodium salt 





 Dialdehydes     








Disinfectant Healthcare, Lab Asthma and 
ACD (38) 
 Fungicides     
  1,2-benzisothiazolin-
3-one 








Pesticide Lawn Care ACD (40) 













 Quaternary Ammonium 
Compounds 





 Cocamidopropyl betaine  Surfactant Hairdressers ACD (45) 
 Dyes, Fragrances, and 
Perfumes  
  Sales, Hairdressers Asthma (2, 
12), ACD 
(46) 
 Glyceryl thioglycolate  Hair Perm Solutions Hairdressers ACD (47) 
 Methyldibromo 
glutaronitrile 
 Preservative  ACD (48) 
 Parabens   Preservative  ACD (49, 50) 
 p-Phenylenediamine  Dye Hairdressers, 
Polymer synthesis 
ACD (51) 
 Persulfates  Denture cleaner, 









 Diisocyanates     







































 Polyfunctional aziridine  Paints, Coatings, 
Varnishes, and Inks 
Painters, Builders Asthma (59), 
ACD (60) 
 Triglycid isocyanurate  Paints, Laminates, and 
Varnishes 
Painters Asthma (61), 
ACD (62) 
 Acrylates  Paints, Varnishes, 
Glues, Inks 
Painters, Printers, 






 Acrylamides   Polymer synthesis, 
Paper and Textile, 
Waste Treatment 
ACD (27) 
 Cyanoacrylates  Glues Dentistry Asthma (28), 
ACD (27) 
 Methacrylates     
  2-hydroxyethyl 
methacrylate 
(2-HEMA) 
Glues Dentistry ACD (27) 
  Ethyleneglycol 
dimethacrylate 
(EGDMA) 
Glues Dentistry ACD (27) 
  2-hydroxypropyl 
methacrylate  
(2-HPMA) 
Glues Dentistry ACD (27) 
 Aliphatic Amines     
  Aliphatic 
Polyamines 
 Chemical Workers Asthma (12), 
ACD (29) 
  Cycloaliphatic 
Polyamines 
 Chemical Workers ACD (29) 
 Aromatic Amines   Textiles, Pesticides ACD (29) 
 Anhydrides     
  Dioctyl-phthalate  PVC Production Asthma (12) 




 Epoxy and phenolic 
monomers 
 Paints, Flooring 
Products 
Painters, Builders Asthma (63), 
ACD (64) 
Rubber Additives 
 Accelerators     





















  Thioureas Organic Synthesis, 
Rubber Synthesis 
Chemical Workers ACD (67) 
  Thiurams Rubber Synthesis Chemical Workers ACD (68, 69) 










Table 1.3: Summary of LMW Chemicals Causing Occupational Allergy 
 
The initiation of sensitization begins with exposure and antigen recognition.  In order to gain 




penetrate the epithelium.  In the skin, LMW chemical allergens may be absorbed through the stratum 
corneum, hair follicles, and sebaceous glands (71), accessing internal cells without physical 
alteration of the epithelium due to their small size.  This is a departure from the mechanism of HMW 
protein allergens which can physically disrupt the epithelium through the utilization of factors like 
proteases (72).  Both HMW and LMW sensitizers may take advantage of a compromised epithelium.  
Absorbance of LMW chemical allergens may be increased following exposure to solvents which are 
commonly used in a variety of workplaces (1).  A widely-accepted concept explaining the 
immunogenicity of LMW chemical allergens involves a haptenation step, combining with and 
altering a self-protein, causing an allergic response following recognition by antigen presenting cells 
(APCs) (21, 73, 74).  According to this hypothesis, in order for a LMW chemical to cause 
sensitization, skin penetration should occur at a rate that is quick enough to ensure that an ample 
amount of chemical may combine with self-proteins to produce sufficiently immunogenic conjugates 
sometimes involving conformational changes of the LMW chemical and the self-protein.  Epithelial 
activation and disruption is an initial step in the activation of innate immune cells by secreted factors 
such as cytokines and chemokines, eventually involving APCs followed by an adaptive component.  
Following the establishment of sensitization, subsequent exposures may lead to elicitation, which is 
manifested in the form of allergic diseases like asthma and contact dermatitis.  LMW chemicals have 
been reported to cause both contact dermatitis and occupational asthma, in the form of early and late 
asthmatic responses (75). 
It should be noted that two additional classes of non-reactive chemical allergens exist; 
prohaptens are converted to reactive contact allergens by enzymes including those of the cytochrome 




multidrug-resistance related proteins and prehaptens may acquire allergenicity via auto-oxidation 
(13). 
 
1.3.1. Dermal and Respiratory Chemical Sensitizers 
As evidenced by Table 1.3, LMW chemical allergens are diverse in structure, reactivity, and 
application; however, there are several common attributes that are associated with immunogenicity 
including haptenation potential (protein reactivity), ability to access the epithelium, and irritancy 
induction (76).  The route of exposure, exposure intensity, and duration/frequency of exposure are 
additional factors that impact chemical allergenicity (3).  Traditionally, LMW chemical sensitizers 
have been classified as either respiratory or dermal sensitizers, based on their ability to sensitize via 
the respiratory tract or skin and their ability to induce Th2 or Th1-dominated immune responses, 
respectively (77).  Thousands of chemicals have been identified as causative agents of skin 
sensitization resulting in allergic contact dermatitis such as dinitrochlorobenzene, while substantially 
fewer respiratory chemical allergens (<100) have been identified as causative agents of respiratory 
sensitization preceding asthma (78, 79).  Major chemical respiratory sensitizers include acid 
anhydrides, chloroplatinate salts, diisocyanates, and certain reactive dyes (80).  In general, the 
majority of chemical sensitizers are capable of causing dermal sensitization but do not cause 
respiratory sensitization (76); however, many respiratory sensitizers can also cause skin 
sensitization, leading to both skin allergy and/or asthma following skin sensitization.  These 
observations are intriguing, given the rigid skin/respiratory classification scheme that is commonly 
used to identify these agents based on their sensitization potential.  It is important to note that many 
respiratory sensitizers that have not been observed to cause dermal allergy in humans (despite high 




skin sensitization (76).  Phthalic anhydride is a poignant example of this concept, as it has rarely 
been observed to be a human skin sensitizer yet it elicits a positive response in both guinea pig and 
mouse-based skin sensitization tests (76).  The cause of this discrepancy has not yet been elucidated.   
The juxtaposition between dermal and respiratory sensitizers has been investigated in a 
variety of contexts.  This concept has been inspected in the realm of protein binding selectivity.  It 
has been shown that contact sensitizers preferentially associate with cellular proteins, while 
respiratory sensitizers prefer to bind to soluble proteins (81).  These observations require further 
analysis from a biologic perspective; however, protein binding selectivity may influence downstream 
allergic responses.  In a related vein, both contact and respiratory sensitizers have been investigated 
in the context of preferential chemical reaction and mechanism.  It has been suggested that the 
presence of multiple functional groups on a chemical may be directly related to its ability to cause 
respiratory sensitization.  Contrary to this hypothesis several respiratory chemical sensitizers do not 
contain multiple functional groups such as abeitic acid, phthalic anhydride, and vinyl benzene (82).  
Further investigating the electrophilic chemical reactions associated with respiratory sensitization 
potential, one in silico study profiled the chemical reactions associated with 10 respiratory chemical 
sensitizers (82).  This study revealed diverse mechanisms involved in chemical-protein interaction 
among respiratory sensitizers along with varying electrophilicity/cross-linking reactivity potential 
requirements needed to cause respiratory sensitization specific to each class of electrophilic reaction.  
The divergence between dermal and respiratory sensitizers has also been investigated in the 
context of Langerhans cell activity following topical administration of a dermal (2,4-
dinitrochlorobenzene (DNCB)) and respiratory (trimellitic anhydride (TMA)) sensitizer (83).  TMA 
was associated with early increased IL-10 expression (presumably resulting in decreased IL-12 




expression by Langerhans cells (leading to increased Th1 and Th17 differentiation in the dLN), 
illustrating early divergence in the innate immune response to both types of sensitizer.  Langerhans 
cells exhibited delayed migration in response to TMA compared to DNCB; this was confirmed to be 
due to increased immunosuppressive IL-10 and decreased IL-1β expression following TMA 
exposure.  The authors hypothesized that these dichotomous epidermal responses resulted in the 
altered polarization of the immune response following exposure to each of the representative 
sensitizers.  Approaching the same concept from a different perspective, the DNA methylation status 
of the lymph node following cutaneous application of DNCB or TMA was investigated in a recent 
work by Chapman, et al.  (84).  This data revealed distinct DNA methylation patterns induced by 
chemical exposure, specifically in regard to key Th1 and Th2 -associated genes, implicating 
epigenetic factors in the development of contact or respiratory sensitization.  In any case, the factors 
differentiating dermal and respiratory sensitizers are a subject of much discussion.   
It has been established that dermal sensitizers preferentially elicit a Th1-mediated cellular 
immune response, while respiratory sensitizers preferentially elicit a Th2-mediated cellular immune 
response (85-87), yet the specific chemical properties that define each type of sensitizer have not 
been identified.  Dermal sensitizers are thought to provoke a Th1-based immune response, grossly 
conforming to the Type IV hypersensitivity reaction described by Gell and Coombs (88).  CD4+ Th1 
and Th17 cells along with CD8+ T cells are commonly implicated as key players involved in the 
dermal sensitization response.  Alternatively, respiratory sensitizers are thought to elicit a Th2-based 
immune response and are generally associated with the Type I atopic hypersensitivity reaction (88).  
These observations are true for both humans and rodents.  The controversial role of IgE in the 
pathogenesis of many respiratory chemical sensitizers along with the mixed Th1/Th2 response 




some of these reactions do not fit perfectly within the Gell and Coombs classification due to the 
complicating presence of a mixed T cell response in the case of certain respiratory sensitizers.  
Clearly, the dermal/respiratory classification scheme is useful in many regards but may be confusing 
and invalid as a rigid, mutually exclusive categorization system for all chemical sensitizers.    
 
1.3.2. Hazard Identification Strategies for Chemical Sensitizers 
Due to the environmental, occupational, and clinical significance of chemical sensitizers, the 
use of rapid and sensitive methods for hazard identification are necessary.  A human -based assay 
known as the human repeated insult patch test (HIRPT) has been used to identify skin allergens; 
however, due to ethical concerns and alternate methods the use of this assay has been eliminated in 
many countries (87).  Two guinea pig-based assays have been utilized to predict chemical sensitizers 
including the guinea pig maximization test (GPMT) and the Buehler assay; these assays are 
recommended for use by the Organization for Economic Cooperation and Development (OECD) 
guideline #406 (89).  The GPMT utilizes intradermal administration of a test chemical combined 
with or without Freund’s complete adjuvant followed by topical administration of the test chemical.  
Two weeks post topical dosing the animals are challenged by patch test of the flank and the allergic 
reaction on the skin is assessed to measure sensitization potential (89).  The Buehler assay also 
utilizes a guinea pig model of elicitation,  animals are exposed to the test agent for 6 hours for three 
consecutive weeks and two weeks after the final patch exposure the animals are challenged by patch 
test of the flank for 6 hours (89).  The GPMT and Buehler assays measure the elicitation phase of 
allergy, complicating these test models beyond the sensitization phase, which is a noted limitation 
of these assays.  Further limitations of these assays include limited dose selection range (based on 




dose response or threshold data (90).  In spite of these limitations, guinea pig-based sensitization 
assessment assays also have significant utility, including a substantial database of test data, allowing 
for comparisons to new test agents and information regarding the challenge phase of allergy (90).    
Currently, the gold standard for hazard identification of dermal sensitizers is the local lymph 
node assay (LLNA).  This assay has been validated by among independent laboratories (91, 92), 
with the USA-based Interagency Coordinating Committee on the Validation of Alternative Methods 
(ICCVAM) (93) and the European-based European Center for the Validation of Alternative Methods 
(ECVAM) (87).  Additionally, in April 2002 the LLNA was incorporated into the Test Guideline 
429 by the OECD (94).  The LLNA is based on the concept that repeated dermal exposure to 
sensitizers causes lymphocyte proliferation in lymph nodes draining the site of chemical application 
and that this proliferation can be quantified by utilizing tritiated thymidine (3H) which is incorporated 
into dLN DNA. Figure 1.1 illustrates the basic protocol of the LLNA.  The assay utilizes female 
mice (preferably of the CBA/Ca or CBA/J strain) at a minimum of four per group.  These mice are 
dermally exposed to 25 µL of vehicle, increasing concentrations of the test agent (a minimum of 
three concentrations), and a positive control per ear for three consecutive days.  After three days of 
rest (on day six) the mice are intravenously injected with 3H.  Five hours following 3H injection mice 
are euthanized and the dLNs are excised and processed into a single cell suspension.  These 
suspensions are tested for 3H incorporation based on disintegration per minute (DPM) readings as 
quantified using a liquid β-scintillation counter.  Results are expressed as the stimulation index (SI) 
which is obtained by dividing the radioactive incorporation for each treatment group over each 
vehicle control group or alternatively, by dividing mean DPM/mouse within each treatment group 
by the mean DPM/mouse for the vehicle control group.  A test substance is generally considered a 




proliferation.  This value indicates a three-fold or greater increase in dLN cell proliferation compared 
with vehicle-control mice.  In general, predictive tests exhibit certain limitations and results must be 
interpreted accordingly.  The LLNA is not effective in identifying nickel salts (presumably due to 
variation in TLR4 signaling between mice and humans), exhibits false positives (specifically 
regarding non-sensitizing irritants) (94, 95), and cannot distinguish dermal and respiratory 
sensitizers.  Regardless, the LLNA exhibits many advantages over other sensitization assays, 
including quick turnover and cost effectiveness, less animal trauma, an end point directly associated 
with sensitization, dose response analysis yielding an index of potency (EC3 value), and close 
correlation between EC3 and human skin sensitization data (90).   
 
Figure 1.4 Pictorial overview of the LLNA 
 
Recently, much experimental focus has been allocated to the development of non-animal 
alternatives to the LLNA.  The major challenge in the development of in chemico, in silico, and in 




in vivo environment of an organism undergoing sensitization.  In an effort to address this concept, 
several assays are being developed to model haptenation, keratinocyte activation, and dendritic and 
T cell proliferation and interaction (87).  In silico methods focused on predicting chemical reactivity 
based on the known in vivo reactivity of chemicals bearing structural significance are known as 
quantitative structural activity relationship.  Additional efforts have been made to determine the 
sensitization potential of a chemical based on its electrophilic reactivity (96).   Perhaps the most 
well-developed in chemico assay showing potential for differentiation of respiratory chemical 
sensitizers is the Direct Peptide Reactivity Assay (DPRA).  This assay characterizes the reactivity of 
chemicals with model peptides (synthetic cysteine and lysine solutions) as surrogate nucleophiles, 
mimicking the covalent binding of electrophilic chemical allergens to nucleophilic centers in self-
proteins based on the hapten hypothesis of chemical immunogenicity.  This assay was initially 
developed by Gerberick, et al in 2004 and has been refined since then (97).  In 2013 this assay was 
recommended for use by the ECVAM in skin sensitization testing (98) and draft guidelines were 
approved in early 2015 (99).  These guidelines recommended use of this assay with additional tests 
due to the complex nature of skin sensitization prediction.  Several in vitro assays are in the process 
of development for the purpose of skin sensitization hazard identification.  Many of these assays are 
based on immunologic events that take place during sensitization including keratinocyte and 
dendritic cell activation (87).  Endpoints such as cytokine production and cellular phenotyping are 
frequently utilized with these assays.  While these approaches are promising, the LLNA remains the 







1.3.3. Challenges Regarding the Investigation of Respiratory Chemical Sensitizers 
Not surprisingly, several characteristics of dermal and respiratory chemical sensitizers make 
these substances difficult to regulate.  The lack of information regarding the immunologic 
mechanisms of respiratory sensitizers paired with the difficulty of setting reasonable exposure limits 
for these chemicals pose significant challenges for risk assessors and hazard identifiers when 
working with sensitizing chemicals.  As described above, several validated hazard identification 
assays exist for skin sensitizers including the guinea pig maximization test and LLNA, among other 
assays (87).  Although these assays are relatively effective and sensitive for dermal sensitizers, they 
are not validated for respiratory sensitizers.  
Positive results in the LLNA are usually ascertained for respiratory sensitizers but this assay 
is not specific for respiratory responses and is conducted utilizing a dermal exposure model, creating 
problems regarding the interpretation and application of this assay to respiratory sensitizers.  
Modified lymph node proliferation-based assays have been tested for protein allergens following 
intratracheal and oropharyngeal aspiration exposures (100); however, these assays are hampered by 
concerns regarding vehicle and have yet to be established for respiratory chemical sensitizers.  
Another complicating factor contributing to the failure to develop a respiratory chemical allergen 
screening assay is the limited understanding of the mechanisms involved in sensitization (101).  
Because of this, there have been numerous experimental efforts to develop an assay capable of 
distinguishing respiratory sensitizers but none have been validated or universally applied.   
Antibody production has been proposed as an endpoint for the identification of respiratory 
chemical sensitizers.  The mouse IgE test is characterized by increases in total serum IgE following 
topical application as a function of a chemical’s ability to cause respiratory sensitization.  This test 




among non-respiratory sensitizers and among different mouse strains (103).  In a similar fashion, 
Maentz and Meade developed a comprehensive flow cytometry-based assay in 1999 meant to 
identify and differentiate chemicals based on their ability to elicit irritation, IgE- (respiratory), or T 
cell-(dermal) mediated hypersensitivity responses (103).  This assay is based on ear swelling and the 
phenotype of dLN B220+ B cells, specifically, their expression of IgE following 10 days of dermal 
exposure to the chemical of interest.  These studies revealed discriminatory expression of B220 and 
IgE, allowing for identification of respiratory or dermal sensitizers.  B220 has also been utilized as 
a discriminatory marker to distinguish allergens and irritants in the LNNA as irritants may induce 
significant dLN proliferation, causing false positives in the LLNA (104). 
Cytokine profiling, T cell fingerprinting, and dLN gene expression have been proposed as 
methods of differentiating dermal and respiratory chemical allergens due to the dichotomy in Th1 
and Th2 responses observed for each class of chemical.  A variety of murine in vivo experiments 
have demonstrated preferential lymph node protein expression of IFN-у and IL-12 (Th1-dermal) vs 
IL-4, IL-5, IL-10, and IL-13 (Th2-respiratory) following topical exposure to various panels of 
chemical sensitizers (101).  Plitnick, et al. described a ribonuclease protection assay that quantified 
dLN cytokine messenger RNA (mRNA) levels from dermally exposed mice in an effort to 
distinguish contact and respiratory sensitizers (105, 106).  These studies demonstrated differential 
Th1 and Th2-skewed dLN cytokine mRNA profiles following dermal and respiratory sensitizer 
application, suggesting the potential utility of this assay in the identification of respiratory chemical 
sensitizers.  Unfortunately, dose selection parameters were difficult to pair with LLNA data and 
necessitated further modification.  Additional efforts have been made to examine cytokine 
fingerprinting in the dLN following both respiratory and skin exposure to a panel of respiratory and 




or epicutaneous exposure was predicative of most respiratory sensitizers (107).  Additional studies 
measured gene expression responses in the dLN following the LLNA exposure protocol revealing 
differential gene expression for mast cell proteases in respiratory sensitizers compared to contact 
sensitizers (108).   Accordingly, several authors have noted that an initial LLNA conducted prior to 
cytokine fingerprinting may aid in dose selection rationale and prescreening.  This method was 
initially proposed over 15 years ago and has not been validated, presumably due to variability 
associated with cytokine detection methods and results.   
While many in vitro assays have been proposed for skin sensitization as a replacement for in 
vivo assays such as the LLNA, few comparable assays have been developed specifically for 
respiratory chemical sensitizers.  The DPRA has revealed altered amino acid preferences in some 
cases when comparing dermal and respiratory sensitizers; which seem to prefer to binding to cysteine 
and lysine residues, respectively (109).  While this trend was repeated, it was not always followed 
by known respiratory sensitizers; diisocyanates displayed low levels of lysine depletion in 
comparison to cysteine depletion, indicating that these chemicals had a reactivity profile similar to 
dermal sensitizers (78).  This phenomena may be explained by a process known as “isocyanate 
exchange” characterized by reversible covalent conjugation to cysteine thiol followed by hydrolysis 
and transfer to a lysine residue (110, 111).  Thus, the reactivity between multiple nucleophiles must 
be considered when evaluating the DPRA as an assay for identification of respiratory sensitizers 
based on lysine preference.  The data presented here show that the DPRA may be a useful 
supplemental assay in the identification of respiratory sensitizers based on reactivity profiling.  It is 
important to note that this assay was validated for use in dermal sensitization studies, as mentioned 




Another recently developed in vitro assay has shown considerable promise in the 
identification of respiratory sensitizers; this assay is known as the Genomic Allergen Rapid 
Detection (GARD) assay.  This assay was developed by Johansson, et al. and utilizes a human 
myeloid cell line, MUTZ-3, and a genomic biomarker signature following chemical stimulation 
(112).  This assay was originally developed as an in vitro alternative to the LLNA but has shown 
utility in the identification of respiratory sensitizers with the use of a separate GARD Respiratory 
Prediction Signature (GRPS) (113).  This assay demonstrated sensitivity, specificity, and accuracy 
values of 67%, 89%, and 84%, respectively, respectable metrics that surpass other attempted 
methods of hazard identification classification of respiratory sensitizers (113).      
Although there continues to be progress made in the development of chemical sensitization 
identification assays, both in vitro and in vivo, the limited knowledge of the immunologic 
mechanisms of sensitization induced by chemical sensitizers continues to complicate the 
development of these assays.  Currently, the LLNA remains the gold standard for LMW sensitizer 
hazard identification and additional strategies need to be investigated in order to differentiate 
respiratory and dermal sensitizers beyond this assay.  Novel molecules and mechanisms involved in 
allergic disease should be examined in order to elucidate specific entities that can be utilized for the 
development of hazard identification assays for respiratory sensitizers.      
 
1.4. NOVEL MEDIATORS OF ALLERGIC DISEASE 
Recently, the emergence of many novel cellular subsets and molecules involved in 
immunological responses has occurred, shedding light on unexplored realms of the immune system 
and their potential involvement in a variety of disease states, including allergic disease.  These novel 




Currently, the general understanding of the mechanisms of LMW chemical sensitization are limited 
to Gell and Coombs classification.  Typically, dermal sensitizers are considered Type IV inducers 
and respiratory sensitizers are considered Type I inducers.  While the respective immune 
mechanisms may be valid for certain chemical sensitizers, many do not induce immune responses 
that fit into these categories.  For example, TDI is a potent respiratory sensitizer that evokes a mixed 
Th1/Th2 immune response, leading to sensitization via the skin or respiratory tract, and ultimately 
asthma.  In murine models, IgE is a major player in the sensitization and elicitation process, but in 
human TDI asthmatics the role of IgE is contested, complicating the Type I classification of the 
immune response caused by this chemical.  Due to the complexity of mechanisms involved in 
chemical allergy and the lack of knowledge regarding these mechanisms, the investigation of novel 
cellular subsets and molecules involved is imperative for the greater understanding of these 
conditions and the development of hazard identification strategies for chemical sensitizers. 
T cells are recognized as important mediators of allergic responses and chemical 
sensitization.  Many factors can influence the phenotype and function of a T cell, including the 
immune microenvironment, the level and duration of TCR signaling, and the presence of signaling 
molecules such as cytokines.  The cellular phenotype and effector functions of a T cell help 
determine its unique subset.  Our knowledge of T cells has increased exponentially in the past thirty 
years, since Mosmann and Coffmann proposed the seminal T cell classification scheme, including 
Th1 and Th2 cells (114).  The existence of regulatory T cells (Tregs) had also been recognized at this 
time and this subset was known as the suppressor T cell subset.  Currently, there are many generally 
recognized T cell subsets, including the CD4+ Th1, Th2, Th9, Th17, Th22, T follicular helper (TFH), 









Effector Function Inducer 
Cytokines/Stimulus 
Cytokines Produced 
Th1 Stat4-Tbet Intracellular 
pathogen defense 
IL-12 IFNγ, IL-10, TNF-β 
Th2 Stat6-Gata3 Large extracellular 
pathogen defense, 
Allergic reactions 











IL-2,IL-4, TGF-β IL-9, IL-13 
Th17 Stat3-Rorγt Mucosal immunity,  
Autoimmunity 
IL-6 and TGF-β IL-8, IL-17A and F, IL-21, 
IL-22 
Th22 AHR Skin immunity and 
inflammation 
IL-1β, IL-6, and TNF-β IL-13, IL-22, TNF-β 









ICOS, IL-6, IL-21 IFN-γ, IL-2, IL-4, IL-10, 
IL-17, and IL-21  





IL-2 and TGF-β IL-10, TGF-β, IL-35 
NKT iTCR Prevention of 
autoimmunity and 
infection, involved 
in allergic reactions 
Glycolipids presented 
by CD1d 
IFN-γ , IL-2, IL-4, TNF-α 
γδ γδ-TCR Pathogen response Non-MHC I/II-bound 
antigens, IL-2 
IFN- γ, IL-17, TNF 
CD8+ CD8 General infection 
and immunity 
IFN-γ, IL-2 Granzyme B, IFNγ, 
Perforin, XCL1 
Table 1.4: T Cell Subsets 
 
While Th1, Th2, and cytotoxic CD8+ T cells have a recognized role in allergic disease and 
chemical sensitization, the roles of the remaining T cell subsets are largely unexplored.  Th17 cells 
have been implicated in the pathogenesis of autoimmune diseases and the clearance of extracellular 




acute and chronic inflammation (115).  Recently, these cells have also been associated with allergic 
diseases such as contact dermatitis and allergy.  Increased IL-17 levels and neutrophils have been 
found in the lungs of patients with asthma and murine models suggest that Th17 cells can act in 
concert with Th2 cells to promote allergic responses and airway hyperresponsiveness (115).  
Additionally, IL-17 appears to be important in the recruitment of neutrophils to the mouse airway 
and overall pathogenesis following TDI exposure (116, 117).  Th17 cells may also play a significant 
role in the pathogenesis of allergic contact dermatitis.  IL-17 was first associated with skin allergy 
in 1999 in a report utilizing Ni2+-specific T cells isolated from patients with allergic contact 
dermatitis (118).  Both human-derived Ni2+-specific T cells and keratinocytes were able to express 
IL-17 and il17r, respectively.  This study suggested that IL-17 was involved in T cell-mediated 
allergic responses in the skin.  Several years later, IL-17-deficient mice were utilized in several 
allergic disease models in an effort to define the role of Th17 cells in these conditions (119).  
Chemical-induced contact hypersensitivity and an ovalbumin (OVA) -specific airway 
hypersensitivity model were reduced in magnitude in the absence of IL-17 and this was attributed to 
impaired antigen-specific T cell activation, further implicating Th17 cells and IL-17 as major players 
in allergic disease.  The requirement of TGF-β in Th17 cell differentiation is notable, especially 
considering it is also important for Treg differentiation and signaling.  True to their name, Tregs are a 
subset of T cells that are involved in the maintenance of immune tolerance and homeostasis.  Tregs 
have been implicated as key players in allergic disease as well as potential therapeutic targets in a 
variety of disease states and will be discussed in more detail in Chapters 3 and 5.   
Th9 cells are characterized based on their production of IL-9, a cytokine that is recognized 
for the promotion of allergic responses.  Th9 induction has been shown to be dependent on TGF-β 




development, respectively.  In a murine model of ovalbumin-induced airway inflammation IL-9 
neutralization resulted in reduced allergic symptoms and inflammation (121).  Atopic human patients 
exhibit increased Th9 cell numbers compared to non-atopic patients, correlating with increased IgE 
levels (122).  In the same study, a murine model of house dust mite allergic airway inflammation 
was established and revealed rapid Th9 expansion (quicker than Th2 cells) resulting in mast cell 
recruitment and activation.  This concept has been demonstrated experimentally, with IL-9 
enhancing the survival of mast cells, stimulating the production of mast cell proteases, and generally 
priming the mast cells response in an allergic environment (120).  Th9 cells can be identified in the 
peripheral blood of allergic patients and in healthy and inflamed skin (123).  The stability of Th9 
cells in vivo is a contested matter; however, the recent development of an IL-9 fluorescent reporter 
mouse will aid in studies designed to address this issue.  There is still much to be learned about Th9 
cells, both in general and in the context of allergic disease.  Further characterization of this subset 
and increased knowledge of its role in allergic disease is important to our understanding of the 
mechanisms involved in allergic disease and chemical sensitization.   
Another newly characterized T cell subset thought to play a role in allergic disease is the 
Th22 subset.  Th22 cells are identified by production of IL-22 and their differentiation and activation 
depends on engagement of the aryl hydrocarbon receptor (AHR), leading to an increase in IL-22 
production and Th22 expansion (124).  Along with allergic disease, Th22 cells have been implicated 
in arthritis, autoimmunity, cancer, and infection.  IL-22 levels are increased in the skin of patients 
with atopic dermatitis, allergic contact dermatitis, and allergic asthma (124).  In a murine model of 
ovalbumin-induced allergic asthma, the external addition of IL-22 results in decreased asthmatic 
symptoms, implicating this cytokine as a protective factor in asthma which may be mediated through 




regarding the role of Th22 cells in allergic disease, including the overall role of this cell type, the 
specific effector mechanisms involved in modulating allergic disease, and the potential interaction 
with additional cell types with recognized involvement in allergic disease.   
Humoral immunity plays an important part in many immune responses, including multiple 
types of allergic disease.  While B cells and antibody production are the main effector molecules 
involved in this type of immune reaction, T cells are known to be a prerequisite for the development 
of humoral immunity in many situations.  TFH cells are a recently characterized T cell subset that are 
named based on their presence in germinal centers within B cell follicles of secondary lymphoid 
organs, where they exert their effector function of aiding the development of B cell antibody 
responses.  TFH cells are considered imperative for the generation of almost all isotype switched and 
affinity matured antibodies, demonstrating their significant role in a variety of immune responses 
including allergy, autoimmunity, vaccine-induced immunity, and protective responses against 
pathogens (125).  Regarding allergy, TFH cells have been loosely implicated in the pathogenesis of 
allergic protein-induced asthma, highlighted in a recent work illustrating the role of TFH cells in the 
process of IL-4 and IL-13 production and eosinophil recruitment, contributing to the overall 
pathogenesis of house dust mite antigen-induced asthma (126).  Further emphasizing the integral 
role for TFH cells in the development of allergic asthma, TFH depletion during the sensitization phase 
of the response prevented Th2-mediated responses in a house dust mite allergy model (assessed via 
Th2 allergic cytokine expression) (126).  This study demonstrates the important role of TFH cells in 
the development of Th2 responses during sensitization to protein allergens and in the overall 
pathogenesis of allergic asthma.  The role of this subset should be further investigated in additional 




also help to elucidate the role of B cells and antibody in chemical sensitization, which is currently 
contested for sensitizers such as TDI.   
Lastly, NKT cells are a unique subset of T cells that exhibit features of both T cells and 
natural killer cells.  NKT cells express the αβ T cell receptor and can be single positive or double 
negative for CD4 and/or CD8 (127).  These cells also express an invariant TCR (iTCR) and 
recognize glycolipid antigens via CD1d on APCs, bypassing the traditional MHC-mediated antigen 
presentation strategy utilized by other T cell subsets (127).  iTCR activation results in rapid and 
large-scale production of cytokines like IFN-γ and IL-4 (127), allowing these cells to participate in 
innate immune responses and help initiate adaptive responses.  NKT cells have been shown to play 
a part in a variety of disease states, including allergic disease, autoimmunity, infection responses, 
systemic lupus erythematosus, and transplant tolerance (127).  In the context of allergy, NKT cells 
have been implicated as key players most likely due to their ability to rapidly secrete large amounts 
of effector cytokines.  Specifically, studies have solidified their pathogenic role in animal models of 
airway hyperreactivity and human patients with asthma, even demonstrating that NKT cells alone 
are sufficient to induce airway hyperreactivity following a glycolipid challenge in a murine model 
(127).  Chemical-induced delayed type hypersensitivity skin reactions are partially mediated by NKT 
cells, which stimulate B-1 cells to produce IgM, leading to T cell recruitment to participate in the 
hypersensitivity response (128).  Further research on natural ligands of the iTCR, therapeutic 
targeting of NKT cells, and methods of NKT activation and effector mechanisms are necessary in 
order to fully understand the mechanisms responsible for NKT cell involvement in allergic diseases.    
NKT cells represent a class of cells that primarily exert their effector mechanism during the 
innate phase of the immune response, leading to the development of an adaptive response.  Innate 




the innate response and helping to initiate the adaptive one.  ILCs are non-T, non-B cells that do not 
possess rearranged antigen-specific receptors; they participate in innate reactions in response to a 
large range of innate signals (129).  ILCs are classified based on their phenotype and effector 
functions, and the current classification scheme is reflective of the CD4+ Th paradigm in the context 
of Th1, Th2, Th17, and Th22 cells.  The commonalities between ILCs and CD4+ Th cells are 
fascinating and illustrate the worlds of innate and adaptive immunity, which coexist both uniquely 
and synergistically, influencing each other yet performing separate functions via unique 
mechanisms.  Current ILC subclasses include natural killer (NK) cells, ILC1s, ILC2s, and ILC3s.  
NK cells produce IFN-γ, express tbet, and exhibit cytolytic activity (129).  Based on these functional 
attributes, NK cells have been implicated in innate viral defense, tumor surveillance, and both organ 
and hematopoietic stem cell transplantation (130).  ILC1s are related to NK cells, which is evident 
based on their production of IFN-γ and expression of tbet, but are distinct as they do not express 
granzyme B, killer-cell immunoglobulin-like receptors, nor perforin, and they respond to IL-7 rather 
than IL-15 (129).  ILC1s are involved in inflammatory responses, including pathogen defense.  
ILC2s have been called nuocytes or natural helper cells, required rorα and gata3 transcription factors 
for their expression, they produce IL-5, IL-9, and IL-13 (129), explaining their involvement in 
helminth infection and allergy.  ILC3s require rorγt and gata3 transcription factors for their 
development and are divided into several subtypes.  Overall, ILC3s can produce IL-17 and IL-22 
and may be involved in lymphoid organogenesis, host defense at mucosal sites, and inflammatory 
and allergic diseases (129).  
ILC2s are the ILC subtype most commonly associated with allergic disease.  Initially this 
subset was described fairly rudimentarily, as a non-T not B cell subset associated with a Th2 




IL-2 receptor α), CD90 (Thy1), CD117 (c-kit), CD127 (IL-7 receptor α), CD278 (Inducible T-cell 
costimulator (ICOS)), ST2 (IL-33 receptor), and IL-17 receptor β and to produce IL-5 and IL-13 in 
response to IL-25 and IL-33 (129).  ILC2s increase during helminth infections, inflammatory lung 
disease, and allergic conditions, and proliferate in response to pathogenic insults.  In a murine model 
of OVA-induced allergic asthma, ILC2-derived IL-33 was found to be important for maintenance of 
allergic cytokine secretion, inflammatory, and airway hyperreactivity, although not as important as 
Th2 responses (129).  Ultimately, ILC2s have been shown to be present and involved in models of 
allergic lung disease as well as in human patients; however, it remains to be seen whether these cells 
are absolutely required for the development and maintenance of these conditions.  ILC1 and ILC3s 
may also have specific roles in allergic disease; however, they have not been studied extensively in 
this context.  Further study of all subtypes of ILCs in the realm of allergic disease and chemical 
sensitization will greatly contribute to our understanding of the mechanisms responsible for these 
conditions and potential therapeutic strategies for allergic diseases.  The scarcity of research 
regarding the role of ILCs in chemical-induced allergy is striking and as more experimental tools are 
available to facilitate the study of these cells they should be characterized in relevant models of 
chemical-induced asthma and skin disease, as they likely play important roles in these conditions.  
Epigenetic mechanisms are commonly defined as alterations in gene expression due to 
changes in DNA binding elements (which can be influenced by environmental factors) as opposed 
to changes in the basic DNA sequence (131).  These mechanisms include DNA methylation, histone 
modification, and noncoding RNA regulation.  Yang and Schwartz suggest that epigenetic changes 
may be at least partially responsible for the recent increasing prevalence of asthma.  In a related 
murine study, Th2 cytokine genes (such as IL-4, -5, and -13) and the pathogenesis of allergic asthma 




and DNA methylation (132).  Numerous studies have demonstrated the link between histone 
modification and DNA methylation and allergic asthma in animal models.  There have also been 
demonstrations of the link between miRNAs and allergic asthma, which will be discussed below.  In 
human studies, the statistical association between epigenetic elements including DNA methylation, 
histone modification, and noncoding RNAs and asthma has been demonstrated (131); however, there 
remains much ground to be covered in the investigation of these components of allergic disease and 
the study of epigenetics itself is complicated by many factors such as diet, environmental influences, 
in utero exposures, aging, and comorbidities. 
Noncoding RNA elements such as microRNAs (miRNA), transfer RNAs, small interfering 
RNAs, ribosomal RNAs, and long noncoding RNAs (lncRNA) are molecules that have exhibited 
great regulatory potential in a variety of conditions and models.  Many of these noncoding RNA 
structures have been shown to exhibit particular functions, contributing to homeostasis, regulatory 
processes, and a variety of disease states.  Recently the perspective on eukaryotic noncoding RNAs 
has shifted from that of performing generic cellular functions (for example: ribosomal and transfer 
RNA involved in mRNA translation, small nuclear RNAs involved in RNA splicing, and small 
nucleolar RNAs involved in ribosomal RNA modification) to performing diverse regulatory and 
biological functions normally reserved for proteins (133).  These RNA molecules are not translated 
into protein like messenger RNA (mRNA) typically would be.  Noncoding RNAs can exert 
functional effects by regulation of gene expression during chromatin remodeling, transcription, RNA 
splicing, editing, translation, and turnover (133).  Specifically, regulatory RNA molecules function 
by base paring with complementary sequences on other RNAs or DNAs to form complexes that are 
recognized by RNA-induced silencing complexes (RISCs) or RNA-editing enzymes (133).  The role 




of the role of miR-126 in a model of house dust mite allergy and miR-145 in eosinophilic 
inflammation, mucus production, and Th2 cytokine production. The functional role of noncoding 
RNA molecules in chemical sensitization and allergy has not been investigated.  Anderson et al. 
investigated the global dLN miRNA expression profile in a murine model of dermal TDI 
sensitization (134); however, the specific roles for these differentially expressed miRNAs were not 
identified.  Pertinent functional investigations are carried out in Chapter 4.  
 
1.5. CONCLUSIONS 
The burden of occupational allergic disease is widespread.  Occupational allergic conditions 
are multifactorial and are the result of complicated immunologic events.  As illustrated in Section 
1.1, a plethora of allergic diseases can be caused by workplace exposures to both protein and 
chemical allergens.  Although Gell and Coombs hypersensitivity classification is helpful in the 
description of the mechanisms of many allergic reactions, this system is not fully inclusive.  Many 
allergic reactions, especially those precipitated by drug and chemical exposures cannot be 
comprehensively defined within the constraints of this classification system.  This illustrates the need 
for increased research pertaining to the mechanisms behind sensitization and allergic disease as well 
as the development of updated hypersensitivity classifications.   
Chemical sensitizers are utilized in virtually every industry worldwide.  Typically these 
compounds are LMW molecules that are known as dermal or respiratory sensitizers, depending on 
the route of sensitization.  Although this classification typically predicts the type of allergic response 
induced (Th1 vs Th2, respectively), this paradigm is not always valid.  Many chemical sensitizers 
can induce sensitization via dermal and respiratory routes and/or induce a mixed Th1/Th2 response.  




perennial question of “what makes a chemical an allergen” is persistently asked and may be 
answered with diligent and focused mechanistic research.  This inquiry is given greater weight due 
to the current focus on developing in vitro assays for the identification of chemical sensitizers.  The 
identification of novel mechanisms of allergic disease is paramount to the objective of answering the 
questions of what makes a chemical and allergen and what are the immunologic events that 
differentiate contact and respiratory allergens.  Furthermore, the investigation of innate events 
preceding full sensitization such as danger signals, cytokine and chemokine signaling, and  APC 
phenotype and function is also necessary to answer this question. 
As exemplified above, the discovery of novel mechanisms of allergic disease, specifically 
relating to chemical sensitization, is necessary to further the development of preventative and 
therapeutic strategies to combat allergic disease.  Having a more complete view of the immunologic 
events taking place during both sensitization and elicitation will be achieved by investigating novel 
cellular subsets and players potentially involved in these events.  There are numerous “suspects” in 
this regard as mentioned above; however, many of these have not been investigated in chemical 
allergy.  The role of Tregs and miRNAs are explored in this work yet these represent only a fraction 
of the immunological players involved.  Optimistically, the discovery of novel players will broaden 
the general classification schemes and views of chemical allergy as a whole.  This could represent a 
paradigm shift that may greatly improve allergy research and understanding by clinicians, 
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CHAPTER 2  















Isocyanates are a group of chemicals that contain at least one isocyanate group (-N=C=O).  
These chemicals are utilized in a variety of industries due to their high reactivity.  This characteristic 
is attributed primarily to their isocyanate side chains, which are capable of reacting with active 
hydrogen atoms, readily forming crosslinks (1).  Common reactions of the isocyanate group 
encompass interactions with hydroxyls resulting in the formation of urethanes, with amines resulting 
in urea derivatives, and with water forming carbon dioxide and the corresponding amine (2).  
Isocyanates are primarily utilized in the manufacture of polyurethane and associated products and 
workers may be exposed in a variety of jobs, including: painting, polyurethane manufacture 
(factory/chemical plant) and foam application.  Many isocyanates can cause allergic disease and 
some may also be carcinogenic (3).  Commonly used diisocyanates include hexamethylene 
diisocyanate (HDI), methyl diphenyl diisocyanate (MDI), and toleuene diisocyanate (TDI).  For the 
purposes of the work reported in this dissertation, TDI will be the primary focus due to its 
establishment in animal models of allergic disease, occupational relevance, and correlation with 
human allergic illness.  
TDI is a low molecular weight diisocyanate utilized in the automobile industry and in the 
manufacture of polyurethane foams, paints, elastomers, and coatings.  The two most common 
isomers of TDI are 2,4 and 2,6 which vary in the location of their isocyanate side groups; typically 
a mix of these isomers are utilized in a workplace setting.  At room temperature TDI is a clear liquid 
with a pungent odor.  Pure TDI will decompose in water but is very soluble in acetone and benzene 
and is miscible with additional chemicals (4).  TDI is widely used throughout the United States and 
around the globe; the U.S. Environmental Protection Agency reports that U.S. production and 




allergen and irritant; dermal and inhalation exposure can lead to a variety of allergic diseases 
including asthma, hypersensitivity pneumonitis, rhinitis, and contact dermatitis (1, 5).  These 
diseases can be disabling and extremely severe, potentially resulting in lifelong illness and/or death 
(6).  TDI is generally classified as primarily a respiratory (IgE/Th2)-mediated sensitizer with a  Th1-
mediated component (7), yet the pathogenic mechanisms of sensitization are not fully understood 
(8).   
 
2.2. OCCUPATIONAL EXPOSURE TO TDI 
As a result of its widespread industrial use and potent sensitizing capability, TDI is a major 
causative agent of occupational asthma (1, 9).  Although exact worker exposure numbers are 
currently unknown, NIOSH has estimated that 280,000 US workers are potentially exposed to 
isocyanates (10) and this estimate has likely increased due to the recent increased industrial use of 
isocyanates (5).  Both the respiratory tract and skin are documented sites of diisocyanate exposure, 
which can occur in aerosol, liquid, or vapor forms (11).  Recently, the potential for dermal 
diisocyanate exposure leading to the elicitation of diisocyanate-induced asthma has been noted and 
there has been an increasing amount of data being released regarding this concept (5).  This will be 
further addressed in Section 2.4.  Due to its high volatility, TDI exposure may occur in all stages of 
manufacture and use; workers may be exposed to TDI during production, handling, and processing 
of TDI or during the production of products made with TDI such as foams and coated fabrics (4).  
Worker exposure has been confirmed via TDI adducts in the plasma and urine; toluene diamine, a 
hydrolysis product of TDI, has been measured in the plasma of exposed workers after acid hydrolysis 
as an alternate marker of exposure (4).  It is difficult to monitor and control occupational TDI 




well-defined exposure data (11).  Despite gaps in the literature regarding TDI exposure it is clear 
that reduced exposure levels lead to lower cases of TDI-induced asthma.   
Limiting the development and incidence of occupational allergic disease is key to 
maintaining the health, safety, and vitality of workers.   One strategy utilized in the pursuit of this 
goal is the establishment of occupational exposure limits (OEL).  The current TDI OEL set by the 
Occupational Safety and Health Administration (OSHA) is 0.02 ppm (approximately 140 µg/m3) 
and 2.5 ppm is considered Immediately Dangerous to Life and Health (IDLH).  Workplace air 
concentrations can range from < 1 to > 1,000 µg/m3, based on various reports (4).  Typically these 
limits are set by risk assessors based on experimental data and human health studies (covering effects 
and exposures) encompassing carcinogenesis, portal of entry irritation, and systemic effects (12).  
Frequently OELs are not adequate for protecting workers from chemical-induced allergy due to 
limited human data and the complexity of the sensitization response.  Several of the key challenges 
associated with setting OELs for chemical allergens are: selection of sensitization or elicitation to 
serve as the basis of the OEL, temporal factors involved in the allergic response, individual 
susceptibility and reaction to sensitization, and examination of the relevant routes of exposure (12).   
Furthermore, once sensitization has occurred, exposure to very low levels of TDI (below the 
accepted OELs) may elicit symptoms, making regulation extremely difficult (11).  Asthmatic 
responses have been demonstrated in sensitized workers following inhalation challenge of ≤1-5 parts 
per billion (ppb) TDI, which is at or below the current American Conference of Governmental 
Industrial Hygienists (ACGIH) threshold limit value time weighted average of 5 ppb (12).  Clearly, 
prevention of sensitization is the ideal outcome of regulation; however, if this isn’t feasible early 





2.3. TDI SENSITIZATION 
The TDI sensitization response is characterized by a tightly regulated and coordinated 
immune response involving a variety of cellular subsets and signaling molecules (13); however, 
much is still unknown regarding the immunologic events that take place following TDI exposure 
and during sensitization.  Both dermal and respiratory sensitization are capable of priming the body 
for TDI asthma, highlighting the systemic nature of sensitization (14, 15).  The realization that 
dermal sensitization may result in respiratory allergic disease has significant implications for risk 
management and preventative measures in the workplace, as skin protection may be just as, or more 
important than respiratory protection, which is discussed in further detail in Section 2.4.   
In a typical T-cell mediated response involving dermal or respiratory exposure to a protein 
allergen, following access to the epithelium, allergen fragments are taken up by APCs.  It is believed 
that LMW chemicals like TDI pass through the stratum corneum then form complexes with self-
proteins, acquiring immunogenicity that is similar to that intrinsically exhibited by peptide fragments 
of protein allergens.  Following APC-antigen uptake these specialized cells migrate to the 
lymphatics, particularly the dLNs, where the allergen fragments are presented to T cells via MHC-
mediated antigen presentation.  This is thought to be the case for protein and chemical allergens.  
APC activation and mobilization are important events that may play an important part in the 
development of sensitization.  These events are modulated primarily via increased local cytokine 
and chemokine expression such as caspase-1, IL-1β, IL-18, and TNF-α along with danger signaling 
following chemical exposure in the case of sensitization precluding contact dermatitis in both 
humans and mice (14, 16).  In mouse skin, three major types of dendritic cells are thought to be 
important APCs involved in chemical sensitization: Langerhans cells (Langerin+CD103+), and two 




to proliferate and differentiate into a number of different CD4+ T-helper (Th) and CD8+ effector 
subsets including Th1, Th2, Th17, Treg, and cytotoxic T cells.  In a chemical-induced contact 
dermatitis, preferential expansion of Th1, Treg, and cytotoxic CD8+ cells is observed (16).  These 
activated T cells can migrate through the lymphatics, blood, and local tissues; orchestrating an 
adaptive immune response against the allergen.  This process characterizes the sensitization response 
and repeated exposures can cause the sensitized T cells to produce specific cytokines capable of 
skewing the immune response to a Th1/cytotoxic (contact dermatitis-dermal sensitizer) or Th2 
(asthma-respiratory sensitizer) –mediated pathway.  Th1 cells are characterized by production and 
secretion of interferon-у (IFN-у), IL-2, and tumor necrosis factor α (TNF-α), while Th2 cells are 
characterized by production and secretion of IL-4, IL-5, IL-6, IL-10, and IL-13 (17).  A mixed 
Th1/Th2 response is observed in both animal models and humans exposed to diisocyanates like TDI 
(18).  Diisocyanate-specific T cells and Th1 and Th2 cytokines have been observed in the respiratory 
mucosa of diisocyanate-exposed workers and this concept has been ratified in animal models of TDI 
sensitization and asthma, furthering the importance of Th1 and Th2 cells and associated cytokines.  
Activated T-cells and an allergic microenvironment may also stimulate B cells to become plasma 
cells and secrete antibody.   
Once the elicitation phase begins, a coordinated cellular response occurs and the allergic 
response ensues.  This response involves re-exposure to the haptenated complex as an antigen, 
causing crosslinking of the antigen with antibody, binding to mast cells and basophils, leading to 
degranulation, the production of additional antigen-specific allergic antibody, and the proliferation 
of antigen-specific T cells and the involvement of memory T cells.  The elicitation response is 
responsible for the symptoms of allergic disease such as asthma, which may involve airway 




asthma is not fully understood; however, observational data has been collected describing the 
physiological features of individuals suffering this condition.  Following an initial period of 
sensitization and latency which may last for months to years following initial TDI exposure, 
asthmatic symptoms typically begin to appear.  Overall, the clinical presentation of TDI-induced 
asthma is variable, which often complicates diagnosis and treatment (11).  Early symptoms include 
chest tightness, cough, shortness of breath, and wheezing and may appear anywhere from <1 hour 
to 2-4 hours following workplace TDI exposure (11).  Clinical features of TDI-induced asthma are 
similar to those of atopic asthma and include bronchial hyperreactivity and inflammatory infiltrate, 
goblet cell hyperplasia, increased airway mucus production, and subepithelial fibrosis (11).  An ideal 
animal model of TDI asthma would recapitulate airway narrowing and bronchial inflammation along 
with hyperreactivity following sensitization and airway-based challenge (19).  TDI-induced asthma 
can be fatal; in one case, an autopsy of a patient with TDI-induced asthma revealed symptoms similar 
to those found in status asthmaticus (2).  These findings included excessive mucus production, 
overinflated lungs, epithelial desquamation, bronchial wall thickening, and lymphocyte infiltration 
in the lamina propria.   Allergic rhinitis has also been reported as a comorbidity and sometimes a 
preceding condition in patients with TDI asthma and rhinitis may cost more in terms of lost 
productivity and time at work compared to asthma (18).  Due to the similarities between the upper 
and lower respiratory tracts in regards to fundamental allergic susceptibility many of the factors 
involved in TDI sensitization and asthma are thought to play a role in TDI rhinitis.     
Additional factors have been implicated as risk factors for human TDI sensitization including 
cigarette smoking and polymorphisms in the glutathione S-transferase, N-acetyltransferase, and 
MHC class II genes (14), shedding light on potential mechanisms and pathways involved in this 




The lack of association between IgE production and TDI sensitization and asthma is intriguing 
considering the well-established link between atopy and other chemical allergens, including acid 
anhydrides, platinum salts, and dyes (14).   
 
2.4. DERMAL TDI SENSITIZATION 
The epithelium plays a significant role in the early stages of sensitization, acting as a physical 
barrier to allergens and a site of immune surveillance (20).  The skin, in particular, serves as a 
protective layer for our bodies from the outside environment.  As the largest organ in the body, the 
skin is an extremely important player in relation to allergic disease.  The skin is made up of the 
epidermis and the dermis.  The epidermis represents the outermost portion of the skin and is 
comprised of cornified lipids and proteins such as keratin and filaggrin (21), forming a protective 
barrier for the rest of the body.  The inner layer, or dermis, is comprised of lymphatic vessels, hair 
follicles, sebaceous glands, nerve fibers, connective tissue, and blood vessels (21), effectively 
cellularly connecting the skin to the rest of the body.  The presence of multiple innate immune factors 
present in the skin including leukocytes, complement factors, antimicrobial peptides, and pattern 
recognition receptors (22) allow the skin to be a site of immune surveillance and tolerance yet these 
factors may also contribute to the development of allergic disease.  Not only is the skin involved in 
the development of dermal sensitization, it has recently been implicated in the development of 
systemic sensitization leading to elicitation at various sites in the body, including the respiratory tract 
(5).  This has been demonstrated in animal studies involving both protein and chemical allergens.  
Ovalbumin and isocyanates are perhaps the most well-studied models exhibiting skin sensitization 
leading to asthma (21, 23) but this has been demonstrated in a rat model of TMA sensitization as 
well (24).  In humans, several studies have linked isocyanate skin exposure to asthma risk and 




exposure quantitation, timing of sample collection, the diverse nature of dermal exposures and 
chemical composition (including mixed exposures), influence of personal protective equipment 
(PPE), and risk assessment challenges (21).  Regarding isocyanates specifically, the reliance upon 
free unreacted isocyanate groups for sampling methods further complicates the accurate 
documentation of isocyanate skin exposure (26).  
Due to occupational activities, the epithelium may be compromised and workers may be 
exposed to a variety of potential allergens, leading to increased risk of an allergic reaction to these 
substances.  Loss of barrier function has been identified as an important factor in the development 
of various allergic diseases including asthma, atopic dermatitis, and sensitization (21).  This concept 
has been elegantly demonstrated with animal and human-based studies involving filaggrin, a protein 
involved in the formation of the epidermis (27-29).  Genetic variability in barrier protein genes, 
solvent and soap exposure, excessive hand washing, existing skin conditions, humidity, temperature, 
physical trauma, and glove use are all factors that can influence skin barrier function, which is a 
known factor in the development of allergic disease (21).  Barrier disruption and dysfunction 
followed by allergen exposure may allow the perturbing agent to activate the epithelium, leading to 
the production of cytokines such as IL-33 and thymic stromal lymphopoetin (TSLP), which are 
directly involved in the stimulation of Th2 responses (30, 31).  Barrier dysfunction also allows 
dermal dendritic cells and Langerhans cells to come into contact with allergens and become 
activated, also potentially impacting the development of Th2 responses.         
Dermal isocyanate exposure has been a fairly recent topic of concern in relation to the 
historical perception that respiratory exposure primarily leads to asthma.  Several cases of skin 
sensitization leading to asthma have been surmised in humans and this concept has been 




isocyanates may be high, further supporting the idea that dermal exposures may lead to respiratory 
allergic disease.  In addition to their probability of occurrence in the workplace, isocyanate skin 
exposures also have the potential for high dose-delivery in comparison to inhalation exposures (5).  
From a regulatory perspective, there are few standards for skin isocyanate exposure in comparison 
to respiratory guidelines (5).  Although skin exposure as a route of sensitization has been noted and 
is a generally accepted concept among experts, there are no dermal exposure limits for di- or poly-
isocyanates including TDI.      
Chemical potency in relation to sensitization potential may also be affected by the route of 
exposure.  The studies described in this dissertation utilize a single exposure TDI sensitization model.  
This model was developed on the basis of extensive experimental sensitization confirmation as well 
as historical literature suggesting that single isocyanate exposure is sufficient to lead to sensitization 
in mouse models (5, 21).  Several murine studies have demonstrated the ability of a single dermal 
exposure of TDI (1% and 0.3%) to induce respiratory allergic symptoms such as lung associated 
lymph node cytokine secretion, serum IgE, and airway inflammation and hyperreactivity after 
subsequent respiratory challenge (32, 33).  Similar results have been ascertained utilizing HDI (34) 
and MDI (35), two related diisocyanates.  As our studies and others’ have demonstrated, doses 
ranging from 1-100 µmol isocyanate in the form of 1-10% solution are sufficient to induce 
sensitization in a murine model and are representative of a realistic occupational exposure of a few 
droplets of diluted diisocyanate solution (5).  These realistic exposure scenarios are compounded by 
human case reports suggesting development of diisocyanate asthma in occupational settings with 
very low or undetectable air isocyanate levels, implicating dermal sensitization in these workers (5).  
In addition to animal models and human case reports, several epidemiologic studies have linked skin 




sensitization causing a systemic immune response that can lead to asthma and other Th2-mediated 
allergic diseases.  This data emphasizes the need for more focused research in order to elucidate 
mechanisms involved in this phenomenon.  The lack of suitable workplace exposure limits for 
respiratory sensitizers that may sensitize dermally as well is a problem that needs to be addressed in 
order to limit unsafe exposures.  Clearly, the study of skin exposure-respiratory elicitation 
relationships has revealed interesting data yet there is still much to be researched in order to properly 
protect workers utilizing chemical and protein sensitizers.   
 
2.4.1. Animal models of Dermal TDI sensitization  
Karol, et al first demonstrated that TDI skin sensitization is capable of priming the immune 
system for subsequent respiratory asthmatic responses in guinea pigs (15).  Following this study, 
other investigators have demonstrated skin exposure to TDI leading to sensitization, followed by 
inhalation challenge, resulting in an asthmatic response (19, 32, 36, 37).  Vanoirbeek, et al. proposed 
a model of dermal TDI sensitization (ear; three consecutive days of dosing with 0.3% or 3% TDI or 
one single dose of 1% TDI) followed by a dermal “boost” at day 7 (same concentration as initial 
dosing) and intranasal challenge at day 10 (0.1% TDI or vehicle) (19).  These dosing regimens were 
followed by whole body plesthysmography (40 min following intranasal challenge) and 
methacholine challenge (24 hours later).  Terminal endpoints were bronchoalveolar lavage (BAL) 
and histology.  All mice that were dermally sensitized with TDI exhibited elevated enhanced pause 
(PenH) following intranasal TDI and/or methacholine challenge.  This alteration in ventilatory 
function was paired with increased neutrophil inflammation with the exception of mice dermally 
sensitized with 3% TDI (high dose) and given the day 7 dermal “boost”.  This observation led the 




response following intranasal challenge in this group, introducing an important concentration-
dependent response relationship between TDI and allergic reactions, as has been noted for protein 
allergens.  The efficacy of dermal sensitization has also been demonstrated for other chemicals such 
as trimellitic anhydride and protein allergens such as ovalbumin that can cause respiratory allergic 
disease (5, 24, 38).  Another notable study was performed by Matheson, et al. that involved repeat 
subcutaneous TDI sensitization followed by repeat inhalation challenge (39).  This model revealed 
increased methacholine airway reactivity and nasal and tracheal inflammation in wild-type mice 
sensitized with TDI, exhibiting the effective sensitizing potential of the subcutaneous route.   
Some important considerations regarding murine models of dermal TDI sensitization include 
potential differences in skin permeability between mice and humans and the relevance of exposure 
site and dose compared to real world exposures.  While the ability of TDI to penetrate both mouse 
and human skin is not in question, potential variability in skin permeability between the two 
organisms are important to remember when translating the value of these studies.  In a manuscript 
examining dermal penetration of perfluorooctanoic acid in mouse and human epidermal membranes 
Anderson, et al. observed slight variations in chemical penetration in mouse (39%) and human (24%) 
skin following perfluorooctanoic acid (PFOA) application (40).  Additionally, the total absorbable 
amount was 50% in mouse skin and 69% in human skin.  These findings illustrate potential 
discrepancies between mouse and human skin permeability and chemical uptake, which are 
important to consider when choosing doses for experimental studies and extrapolating murine results 
to human data.  The route of exposure and site of exposure should also be kept in consideration when 
interpreting murine studies.  Many dermal TDI sensitization models are carried out using ear pinnae 
exposures, which are experimentally sound and necessitated yet may not accurately represent real-




Additionally, subcutaneous injection models are a departure from most realistic exposure scenarios 
but may mimic exposure in the presence of skin abrasions and epidermal lesions.  Regardless of the 
site and route of exposure, dermal TDI sensitization models are valuable tools utilized for the 
investigation of this immune response.  Dose selection is also an important aspect of murine TDI 
sensitization models.  For many studies, the aim of dose selection is to induce a significant state of 
sensitization, while others seek to mimic real-world exposures.  We should be careful in interpreting 
exact doses from murine to human exposures due to the factors mentioned above including dermal 
penetration variability and route/site of exposure in mice and humans.       
Skin sensitization has been proposed to be an extremely effective route of allergic 
sensitization, in some cases it has been suggested to be more effective than respiratory sensitization 
regarding the downstream elicitation of asthma.  In a study evaluating four different models of MDI-
induced respiratory sensitization in guinea pigs, epicutaneous and intradermal MDI exposure were 
reported to be more effective at sensitizing the respiratory tract than inhalation MDI exposure (41), 
indicating that skin sensitization is a relevant and powerful route of exposure in relation to respiratory 
chemical sensitization.  More recent studies have bolstered this concept, including a TDI 
sensitization study that focused on a variety of sensitization exposure scenarios (epicutaneous, 
subcutaneous, and intradermal) followed by respiratory challenge in mice, revealing that epicutanous 
sensitization resulted in the most clinically relevant pathophysiological response in the lungs while 
inhalation sensitization was, in comparison, not an effective route of sensitization (32).  Observations 
with formaldehyde suggested that dermal sensitization was far more effective than respiratory 
sensitization, which did not occur following comparable formaldehyde exposures yielding similar 
irritation responses (42).  Similar investigations were completed utilizing the potent respiratory 




sensitization, despite an irritant response in both tissues (42).  The authors hypothesized that the 
hydrophilic and highly reactive glutaraldehyde dissolves in the mucus of the airways where it reacts 
with the dissolved lysine-rich proteins in this fluid, preventing immunologic activation by APCs 
which are required to induce sensitization (42).  This observation may be unique to aldehydes; other 
LMW sensitizers may be less reactive and more lipophilic and in turn less affected by the mucus 
layer in terms of sensitization potential (42).  In contrast, the skin does not contain a mucus layer, 
allowing LMW chemicals to more readily access APCs and initiate sensitization.  Interestingly, it 
has been reported that thiol-rich proteins in the stratum corneum may act as a barrier against 
dinitrothiocyanobenzene (DNTB) which contains highly reactive –SCN groups (42).  It appears that 
the unique environments of the skin and the respiratory tract are important factors in the development 
of LMW chemical-induced sensitization and these tissues exhibit unique characteristics that may 
impact the sensitization potential of chemicals depending on a number of factors.   
 
2.5. IMMUNOLOGIC FACTORS INVOLVED IN TDI-INDUCED 
ALLERGIC DISEASE 
          TDI-induced sensitization and asthma are complex and multi-factorial conditions.  TDI 
sensitization is characterized by repeated exposures leading to the establishment of the allergic 
threshold.  Typically, these exposures are cumulative and may occur for weeks to years, allowing 
the sensitization response to develop.  Once the elicitation threshold has been met, exposure to 
minute amounts of TDI can lead to severe asthmatic responses.  Although pathologically similar to 
atopic asthma, several key discrepancies have been identified in clinical studies, including a mixed 
Th1/Th2 response, low association with atopy and specific IgE antibodies, and high numbers of 




been fully elucidated for TDI-induced allergic disease, there are a number of immune mediators that 
have been suggested to play a role in these processes.  
 
2.5.1. Antigenicity and APCs  
TDI-induced asthma differs in the process of antigenicity compared to protein allergens, 
presumably by forming haptens with self-proteins such as albumins and keratins.  The high cross-
linking potential of diisocyanates like TDI contribute to their industrial utility but also to their 
immunotoxicity.  The electrophilic nature of TDI allows this chemical’s isocyanate side chains to 
react with hydroxyl, amino, and thiol groups on proteins, forming covalent bonds with self-proteins 
(11); in a process known as haptenation.  This event likely alters the mechanism of sensitization 
compared to that of protein allergens.  TDI is thought to bind to actin, albumin, glutathione, 
hemoglobin, keratin, laminin and tubulin in vivo based on numerous studies (11, 43, 44).  This 
binding may result in cellular damage and immune cell recognition of TDI-protein conjugates, fully 
initiating the TDI sensitization immune response.  The isocyanate groups in TDI can react with 
amine groups to form ureas, hydroxyl groups to form urethanes, and/or thiol groups to from thioureas 
(43).  The antigenic portion of TDI-hapten complexes are poorly understood along with the overall 
process in vivo.  This is a challenging subject as TDI and reactive diisocyanates can self-polymerize 
and haptenate proteins at single or multiple locations, creating a complex chemical environment (43).  
A greater understanding of this process will likely aid in the understanding of the immunologic basis 
for TDI sensitization and that of LMW chemicals in general.    
It has been demonstrated that TDI-protein complexes interact with Langerhans cells in the 
skin (specifically, in the hair follicles) and dendritic cells in the dLN in a murine model of 




adaptive immune response, antigen presenting cell-antigen interaction.  In an elegant study 
conducted to analyze binding of the hapten-major histocompatibility complex class II (MHC II) 
complexes to antigen-specific T cells, Kohler, et al. demonstrated that hapten-peptide complexes of 
trinitrophenyl (TNP) bound to a variety of proteins (both mouse self-proteins such as albumins as 
well as non-mouse proteins) accounted for the majority of epitopes recognized by TNP-specific 
CD4+ T cells (46).  This landmark study demonstrated the role of the chemical-peptide hapten 
complex in the induction of sensitization.  Following APC uptake of the hapten complex, these cells 
may migrate to the lymphatics and interact with T cells, initiating an adaptive response.  Uncertainty 
regarding the exact structure and identity of TDI hapten complexes that are relevant in vivo have 
posed challenges for diagnosis and understanding of the mechanisms driving TDI-induced 
sensitization and asthma. 
 
2.5.2. The Role of IgE in Respiratory Chemical Sensitization and Asthma 
Unlike atopic asthma induced by protein allergens, IgE has not been definitively implicated 
as an integral immune mediator in all cases of chemical-induced asthma, even though clinical 
symptoms are similar for both types of asthma (47).  For example, the consistent  expression of IgE 
in murine models of TDI allergy (48) is not reflected in human studies, as many individuals with 
diagnosed TDI-induced asthma do not have increased levels of TDI-albumin conjugate-specific IgE 
in their blood (49).  As few as 5-30% of symptomatic workers have detectable levels of diisocyanate-
specific IgE (11).  Levels of diisocyanate-specific antibodies typically do not correlate with 
development of reactive airway disease (50) and atopy has not been identified as a risk factor for 
diisocyanate-induced asthma (11).  Additionally, during the elicitation phase of diisocyanate-




less prevalent than that observed in protein induced asthma (11) (although they have been reported) 
suggesting that diisocyanate induced asthma is not solely IgE-mediated, as this response alone would 
be immediate.  As IgE is a hallmark of the humoral response induced by Th2 responses (51), this 
data suggests that either TDI-specific IgE is not capable of being properly detected or an IgE-
independent allergic mechanism is involved in human TDI sensitization.  The hypothesis regarding 
limited TDI detection is an interesting concept, given the uncertainty regarding the specific 
identification of the TDI-hapten complex responsible for antigenicity. Several components of 
antibody composition, including appropriate selection of hapten-protein conjugates and the molar 
substitution ratio, along with the time of blood collection in relation to chemical exposure are 
important in the detection of IgE in chemical allergy (14).  The temporal component of IgE detection 
also seems to play an important role in this process, in serum radioallergosorbent tests (RAST) from 
patients with documented diisocyante-induced asthma specific IgE measures were more likely to be 
detected if the samples had been collected within 30 days of the last exposure to diisocyanate (52).  
The requirement of a Th2 response for respiratory chemical sensitization and allergy, which has been 
well demonstrated in animal models and humans, suggests that IgE-independent mechanisms could 
be at play.  Further complicating this concept, a strong association between IgE and chemical-
induced asthma has been made for several chemicals, including methyltetrahydrophthalic anhydride 
(53).  The relationship between IgE and TDI sensitization is complicated and is not fully understood.  
There remains doubt as to the efficiency of hapten-specific IgE detection as well as the true role of 
IgE in TDI sensitization and allergic disease.  Further insight into this concept will be valuable for 
toxicological evaluation, prediction, and risk assessment.   
 




A hallmark of isocyanate-induced allergic disease in both humans and mice is an active Th2 
adaptive immune response.  This response also involves a Th1 component, but this is generally 
thought to be less dominant.  Increased levels of a variety of cytokines (IL-1β, IL-4, IL-5, IL-6, IL-
15, and TNF-α) and immune cell subsets (CD4+ and CD8+ T cells) have been documented in the 
BAL and sputum of patients with diisocyanate-induced asthma (2).  These data illustrate the mixed 
Th1/Th2 response that takes place in this response.  In a murine model of inhalation sensitization (6 
weeks, 5 days/week, 4 hours/day) and challenge (following a 14 day rest period, 1 hour), adaptive 
immune components of TDI asthma were examined (7).  Following TDI sensitization and challenge 
CD4- and CD8-deficient mice displayed significant reductions in PenH, an indirect measure of 
airway hyperreactivity, following a nonspecific methacholine challenge.  CD4 knockout mice 
exhibited reduced serum total IgE and undetectable total IgG levels following TDI sensitization and 
challenge compared to increased levels of both antibodies in TDI sensitized and challenged control 
animals.  CD8 knockout mice displayed similar reductions in IgE but did not show any significant 
decrease in total IgG levels nor any changes in specific IgG isotypes.  CD4 and CD8 knockout mice 
sensitized and challenged with TDI also experienced reduced levels of lung histopathological 
changes that were seen in TDI sensitized and challenged control mice; these changes include goblet 
metaplasia, epithelial damage, and cellular infiltration.  Th1 and Th2 cytokine mRNA expression 
was not elevated in CD4 and CD8 knockout mice following TDI sensitization and challenge, while 
control mice undergoing TDI sensitization and challenge exhibited increased levels of both Th1 and 
Th2 cytokine mRNA.  The authors also utilized mice deficient in IFNу, IL-4, IL-13, and IL-4+IL-
13 in their TDI sensitization and challenge model in an effort to establish the importance of these 
signaling molecules in the pathogenesis of TDI-induced asthma.  Following TDI sensitization and 




nonspecific methacholine challenge compared to control mice.  Total IgE antibodies were 
significantly decreased in the serum of IFNу, IL-4, and IL-4+IL-13 knockout mice following TDI 
sensitization and challenge, while all knockout groups exhibited lower IgG levels.  The 
histopathologic changes seen in cytokine knockout groups were less pronounced than that of the 
control TDI sensitized and challenged control mice.  A decrease in BAL eosinophilia was noted in 
CD4, CD8, IL-4, IL-13, and IL-4+IL-13 knockout mice following TDI sensitization and challenge, 
indicating that both CD4 and CD8-mediated mechanisms may play a role in TDI-induced asthma 
pathogenesis.  In summary, this seminal study emphasizes the importance of the T cell response in 
the pathogenesis of TDI-induced sensitization and asthma.  Specifically, this work demonstrated the 
requirement of the CD4+ Th2-mediated response and the less critical but still significant role of CD4+ 
Th1 cells and CD8+ T cells in this response.  The synergistic role of Th1 and Th2 cells in asthma 
pathogenesis has been proposed in models of protein allergy and appears to be a component of this 
study.   
Additionally, the role of B cells in TDI-induced asthma is a relevant topic, considering the 
controversial role of IgE in this condition.  In a recent work by De Vooght, et al., a dermal, murine 
TDI sensitization model was utilized to exhibit the importance of B cells in the allergic response 
following TDI challenge (54).  Adoptive transfer of B cells from TDI-sensitized mice into naïve, B-
cell knockout, and severe combined immunodeficiency (SCID) mice resulted in asthmatic symptoms 
following oropharyngeal TDI challenge; these observations suggest a T cell-independent capability 
of B cells to induce allergic outcomes.  Between this data and the questionable role of IgE in 
diisocyanate-induced asthma, B cells should be further investigated in chemical-induced allergic 
disease, specifically in human patients or human-like animal models in order to recapitulate the 




TNF-α is a Th1-associated cytokine that is pleiotropic and is a central regulator of 
inflammatory responses.  This cytokine has been implicated as a significant player in TDI-induced 
asthma due to its inflammatory nature and its potential effects on dendritic cells.  In a murine model 
of subcutaneous TDI sensitization and inhalation challenge TNF-α neutralization (via TNF-targeting 
antibody or TNFR1/2 knockout) reduced airway dendritic cell migration, inflammation, pathology, 
and hyperreactivity (following a methacholine challenge) (55).  Interestingly, serum TDI-specific 
IgG and total IgE levels were not affected by TNF-α neutralization, suggesting a role for this cytokine 
in the early inflammatory phase of the allergic response.  This data along with additional studies 
demonstrate  essential role for Th1 cells in the progression of TDI-induced asthma.  Although there 
has been limited investigation regarding the potential role of other T cell subsets in TDI sensitization 
and allergic disease, upregulation of Treg and Th17-associated cytokines (IL-10 and IL-17, 
respectively) were observed in the auricular lymph nodes of dermally sensitized mice receiving a 
single oropharyngeal aspiration challenge of TDI (56).  This data suggests a potential role for 
additional T cell subsets in TDI allergic disease and prompts investigation of these subsets in both 
animal models and humans. 
Neutrophils, mast cells, and eosinophils are additional immune cell populations thought to 
play a role in TDI-induced sensitization and asthma pathogenesis.  Clinical human studies support 
this concept, finding increased neutrophil activation and IL-8 levels in sputum samples (8), elevated 
eosinophil levels in the bronchial mucosa (47), and elevated mast cell numbers in the airway mucosa 
of TDI asthmatics (57).  Neutrophil involvement marks a key difference in TDI-induced and protein-
induced asthma; several studies have demonstrated the presence of airway neutrophilia during TDI 
asthma in both mice and humans (11), suggesting that the pathogenic mechanisms differ between 




neutrophils prior to airway (oropharyngeal aspiration) TDI challenge using a variety of strategies 
including chemical and antibody-mediated depletion (58).  Neutrophil depletion ameliorated airway 
hyperreactivity, suggesting that this cellular compartment is involved in the pathogenesis of TDI-
induced asthma.         
A loss of functional airway epithelium is also observed in isocyanate asthma.  An in vitro 
study demonstrated disintegration of tight junctions between human bronchial epithelium cells, 
cytotoxicity, and increased mucus secretion following exposure to TDI.  This study also found 
damage to cilia and impairment of their function at increasing concentrations of TDI, explained by 
an interaction between the isocyanate groups of TDI and structural filaments like tubulin (59).  
Another factor that may contribute to airway epithelium damage is isocyanate-glutathione binding 
(2).  This action may lead to the loss of glutathione-mediated protection against oxidative stress.  
Interestingly, several studies have demonstrated a connection between polymorphisms in glutathione 
S-transferase supergene family genes (GSTM1, GSTP1) and the risk for developing diisocyanate-
induced asthma (2).  These enzymes are responsible for catalyzing the conjugation of glutathione to 
electrophilic substances like TDI (60), indicating that glutathione may play a protective role in the 
pathogenesis of TDI-induced asthma.  The extracellular matrix (ECM) of the lungs can be disturbed 
during asthma, characterized by bronchial remodeling.  Matrix metalloproteinases (MMPs) are 
proteases whose primary function is to break down the ECM (61); MMPs and their inhibitors are 
important players in the homeostasis of the ECM under normal and perturbed conditions.  MMP-9 
is known to cause bronchial remodeling in allergic asthma and it also induces the movement of 
granulocytes across basement membranes (62).  Due to the known roles of MMPs in allergic asthma, 
the role of these enzymes in a murine model of TDI-induced asthma was investigated by Lee, et al. 




three weeks of rest, mice were further sensitized for 5 more days.  A week after the second 
sensitization exposure regimen mice were challenged via inhalation.  After establishing their model 
of TDI asthma, the authors observed increased levels of MMPs (including MMP-9) in BAL of TDI-
exposed mice.  After treating mice with a MMP-9 inhibitor three times at one day intervals beginning 
30 minutes before TDI challenge the lung inflammatory cell infiltrate was decreased (total cells, 
neutrophils, and eosinophils) and mice displayed reduced airway hyperreactivity following a 
nonspecific methacholine challenge compared to mice exposed to TDI and not receiving MMP-9 
inhibitor.  This data demonstrates a role for MMPs, specifically MMP-9, in the pathogenesis of TDI-
induced asthma.  Based on known mechanistic data, the authors postulate that MMP-9 activity alters 
the ECM, allowing the migration of inflammatory cells into the airways (62).    
Oxidative stress is known to play a pathogenic role in a variety of conditions, including 
respiratory illnesses such as contact dermatitis, asthma, and chronic obstructive pulmonary disease 
(63, 64).  The anti-oxidant defenses in the body exist to protect various tissues such as the lungs and 
the skin from oxidant insults such as cigarette smoke, UV radiation, combustion products, and 
homeostatic cellular processes.  These defenses include glutathione, vitamins A and E, catalase, 
superoxide dismutase, transferrin, haem oxygenase-1, and redox proteins (63, 65).  Elevated 
transferrin and decreased ferritin levels were observed in the serum of TDI asthmatics compared to 
asymptomatic exposed control subjects and non-exposed control subjects (63, 66).  Ferritin’s role in 
detoxifying inflammatory-induced oxidative stress and transferrin’s antioxidant capabilities suggest 
altered oxidative defense capabilities during TDI asthma.  Following further investigation, 
expression of ferritin light chain and the antioxidant protein heme oxidase-1 was inhibited in human 
airway epithelial cells in culture following TDI exposure (63).  This was demonstrated to take place 




(63).  These TDI-induced signaling alterations may result in a significantly impaired anti-oxidant 
defense repertoire due to the inability of Nrf2 to translocate to the nucleus, bind to anti-oxidant 
response elements, and induce transcription of numerous genes important to cellular defense against 
oxidative stress (67).  Importantly, cellular treatment with a PPAR-γ agonist, activating another 
important antioxidant signaling molecule, was able to rescue the expression of heme oxygenase-1 
and ferritin light chain which was formerly inhibited by TDI (63).  Additional studies investigating 
the therapeutic potential of epigallocatechin-3-gallate, a compound found in tea that has exhibited 
anti-allergic properties, revealed that this compound reduced murine TDI-induced asthma severity 
via regulation of inflammatory cell migration (68).  This may be mediated via suppression of MMP-
9 and reactive oxygen species (ROS) (68), two key mediators of ECM injury and oxidative stress 
which are known to play a role in TDI asthma (62).  These studies reveal the therapeutic potential of 
targeting antioxidant mechanisms in the treatment of TDI-induced asthma.   
In contrast to TDI elicitation, little is known regarding the role of oxidative stress during TDI 
sensitization. Oxidative stress is known to cause apoptosis, specifically in Tregs, which have been 
shown to be critically involved in a murine model of epicutaneous TDI sensitization (69).  
Additionally, oxidative stress induced by food contaminants and environmental chemicals contribute 
to the adjuvant effect of these molecules during the sensitization phase of OVA-induced allergic 
airway inflammation (70).  Both in vitro and in vivo studies reveal that exposure to these 
contaminants promote Th2 differentiation and induce Th1 and Treg apoptosis via induction of 
oxidative stress (specifically by glutathione depletion), ultimately promoting Th2-mediated allergic 
inflammation (70).  Interestingly, in vivo studies involved oral exposure to these contaminants, 
leading to oxidative stress in secondary lymphoid organs (70).  The effects of these compounds on 




disease, suggesting a potential role for these antioxidant defense supplementation during 
sensitization not elicitation. 
AMP-activated protein kinase (AMPK) is a widely expressed molecule involved in a variety 
of cellular processes including ATP depletion, apoptosis, proliferation, and protein synthesis (71).  
AMPK can influence inflammatory signaling by suppressing proinflammatory responses, promoting 
anti-inflammatory macrophage polarization, and inhibiting production of ROS in neutrophils (71).  
AMPK can be activated by 5-aminoimidazole-4-carboxamide-1-β-D-ribofunanoside (AICAR), 
which enters cells, is converted to the equivalent monophosphorylated nucleotide, ZMP, which 
mimics AMP and activates AMPK without changing levels of ATP, ADP, or AMP (71).  AMPK 
activation via AICAR administration has been shown to reduce inflammation and tissue injury in a 
number of experimental models including experimental autoimmune encephalomyelitis and LPS- 
and viral-induced lung inflammation.  Another signaling pathway thought to be involved in 
inflammation, hyperresponsiveness, and remodeling, specifically in the airway, is mediated by 
vascular endothelial growth factor A (VEGFA) (71).  VEGFA is produced by human airway smooth 
muscle cells in response to a variety of Th2-related cytokines and has been implicated as a major 
component of TDI-induced asthma in a murine model (71).  Using a murine model of TDI-induced 
asthma to investigate the role of AMPK and VEGFA on airway inflammation and other asthma-
related symptoms, the authors found that activation of AMPK via AICAR resulted in decreased TDI-
induced airway inflammation and hyperresponsiveness and increased levels of VEGFA (71).  These 
data indicate that AMPK activation has a negative effect on airway inflammation during TDI-
induced asthma and this is mediated by the VEGFA pathway, primarily by reducing vascular 
permeability and ROS production.  This study reveals a potential therapeutic avenue for the treatment 




Several genetic factors have been investigated as sources of susceptibility to isocyanate-
induced allergic disease.  Because of the known role of APCs in the uptake and presentation of TDI-
protein complexes (45) the influence of human leukocyte antigen (HLA) genes, which encode the 
major histocompatibility complex (MHC) in humans, have been investigated in the context of 
susceptibility to diisocyanate asthma.  One study carried out by Mapp, et al. involving TDI-exposed 
workers demonstrated that the HLA class II genotypes DQA1*0104 and DQB1*0503 were 
overrepresented in asthmatic workers compared to asymptomatic workers (72).  An earlier study by 
the same group demonstrated a positive association of DQB1*0503 with TDI asthmatics compared 
to individuals in control groups who had been exposed to TDI but were asymptomatic or had never 
been exposed to TDI and were asymptomatic (73).  This study utilized a different cohort of workers 
and contributed to the hypothesis that HLA-DQB1*0503 is involved in conferring susceptibility to 
TDI-induced asthma.  Additionally, the authors discovered that residue 57 of the DQB1 allele may 
play a particularly important role in this process.  These studies, among others, have demonstrated 
the involvement of HLA variability in TDI-induced asthma susceptibility.  TCR expression of Vβ 
gene repertoires was investigated in a cohort of diisocyanate asthmatics in an effort to investigate 
the hypothesis that diisocyanate asthma-susceptible workers process antigen differently than 
nonsymptomatic workers due to differences in TCR Vβ gene repertoires (74, 75).  Following 
coincubation with diisocyanate-conjugated proteins, mRNA was isolated from peripheral blood-
derived lymphocytes from diisocyanate asthmatics, asymptomatic diisocyanate-exposed workers, 
subjects without occupational asthma, and unexposed subjects free of symptoms.  Polymerase chain 
reaction (PCR) was performed before and after diisocyanate stimulation in order to profile each TCR 
on the basis of Vβ gene segment expression.  Before in vitro diisocyanate stimulation lymphocytes 




control groups; however, following stimulation these cells exhibited selective increases in Vβ1 and 
Vβ5 expression compared to controls.  These studies suggest that antigen-specific T cells may 
express varying TCR Vβ gene expression in response to diisocyanate exposure.   
Additional genetic risk factors that have been identified for diisocyanate-induced asthma are 
mannose-binding lectin (MBL) polymorphisms (76).  MBL is a component of the complement 
pathway, serving as the initiation step of the innate lectin complement cascade that follows the 
opsonization of a pathogen-derived carbohydrate structure.  Increased levels of MBL have been 
found in the BAL fluid of children with airway infections and this compound appears to be protective 
in inflammatory environments, reducing inflammation induced by oxidative stress (76).  MBL2 
polymorphisms have been linked to altered MBL serum levels and were shown to be associated with 
increased risk for severe airway hyperresponsiveness in diisocyanate asthmatics.  Additionally, there 
was an increased frequency of haplotype 2 expression among diisocyanate asthmatics compared to 
asymptomatic exposed controls (76).  This data sheds an important light on the influence of genetic 




TDI is a potent allergic sensitizer widely used in the manufacture of a variety of polyurethane 
products.  Workplace exposures result in a high number of occupational allergic disease cases each 
year.  The impact of isocyanate-induced allergic disease is geographically broad; exposures occur 
worldwide in a variety of industries and occupations.  The high reactivity of isocyanate groups on 
TDI molecules allows this chemical to bind to self-proteins following dermal or respiratory 




leading to respiratory elicitation is an important one.  This has been proven in animal models and 
human epidemiological data supports this concept.  The lack of exposure limits relevant to skin 
exposure and the limited understanding of the immunologic mechanisms involved in this process 
necessitate further investigation into this concept in both animal models and observational human 
studies.    
In rodents and humans TDI is considered to be a “mixed” Th1/Th2 sensitizer, exhibiting 
increased Th1 and Th2 T cell polarization, cytokine secretion, and effector mechanisms leading to 
conditions like asthma.  This mixed response is fairly unique among allergic sensitizers and is not 
currently encompassed by any formal hypersensitivity classification, which is a confounding 
variable in the study and treatment of TDI-induced allergic disease.  Additionally, the problem of 
not knowing the true TDI-hapten “antigen” structure contributes to the limited understanding of the 
mechanisms of sensitization of TDI and chemical allergens in general.  Although monoclonal 
antibodies against TDI-self-protein antigens have been produced and albumin is thought to be a 
primary soluble protein isocyanate target (77), the comprehensive in vivo TDI-hapten antigen 
landscape has not been fully elucidated and remains hampered by several factors including variation 
in murine and human TDI sensitization responses and limited isocyanate-specific reagent 
availability.  Another contentious concept in the TDI community is the IgE conundrum; this refers 
to the lack of consistent TDI-specific IgE in TDI asthmatics regardless of the proven importance of 
this isotype in murine models of TDI sensitization and asthma.  Whether this antibody is not able to 
be detected due to reagent limitations, testing is done at times when IgE levels are not detectibly 
above baseline, or there is truly no TDI-specific IgE increase in this condition, the IgE conundrum 
remains unsolved.  Consistent increases in IgG suggest that this isotype may be a main effector 




exposure.  This may be reflective of the influence of the Th1 component of the immune response.  
The role of IgE in TDI sensitization and allergic disease needs to be investigated further in order to 
fully elucidate the immunologic mechanisms of this condition.        
The lack of knowledge regarding the complete immunologic mechanisms of TDI 
sensitization and elicitation paired with the lack of validated hazard identification assays for 
respiratory sensitizers like TDI illustrate the need for the investigation of novel immune mediators 
of TDI-induced allergic disease.  As discussed in Chapter 1, there are a plethora of potential novel 
mediators of allergic disease that may be involved in TDI-induced conditions.  While some of these 
players such as Th1 and Th2 cells have been thoroughly investigated and others like miRNAs (78) 
and Tregs (69) have been explored (preliminarily, much work remains to be done), many others such 
at TFH and ILCs have not been investigated in TDI sensitization.  Work involving these novel 
molecules should be supported and pursued as it may lead to the further understanding of factors 
involved in TDI-induced allergic disease.  This, in turn, may aid in the development of hazard 
identification strategies for respiratory sensitizers, preventative, and therapeutic strategies for 
sensitizers like TDI.  Despite the many unresolved issues relevant to the study of isocyanate-induced 
allergic disease much progress has been made in the investigation of this condition both due to the 
use of animal models and observations in human patients.    
As previously stated, the pathologic features of TDI-induced asthma are typically similar to 
those found in atopic asthma.  TDI asthmatics typically express high numbers of inflammatory cells 
in the airway mucosa, increased eosinophils, mast cells, and leukocytes in the epithelium, and mast 
cell degranulation (79).  To reiterate, several key differences between TDI-induced and atopic 
asthma should be noted, including: low association with atopy and IgE, a mixed Th1/Th2 response, 




comprehensive knowledge of the pathogenic mechanisms of TDI-induced asthma warrant further 
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Toluene diisocyanate (TDI) is a leading cause of chemical-induced occupational asthma 
which impacts workers in a variety of industries worldwide.   Recently, the robust regulatory 
potential of regulatory T cells (Tregs) has become apparent, including their functional role in the 
regulation of allergic disease; however, their function in TDI-induced sensitization has not been 
explored.  To elucidate the kinetics, phenotype, and function of Tregs during TDI sensitization, 
BALB/c mice were dermally exposed (on each ear) to a single application of TDI (0.5-4% v/v) or 
acetone vehicle and endpoints were evaluated via RT-PCR and flow cytometry.  The draining lymph 
node (dLN) Treg population expanded significantly 4, 7, and 9 days after single 4% TDI exposure.  
This population was identified using a variety of surface and intracellular markers and was found to 
be phenotypically heterogeneous based on increased expression of markers including CD103, 
CCR6, CTLA4, ICOS, and Neuropilin-1 during TDI sensitization.  Tregs isolated from TDI-sensitized 
mice were significantly more suppressive compared to their control counterparts, further supporting 
a functional role for Tregs during TDI sensitization.  Lastly, Tregs were depleted prior to TDI 
sensitization and an intensified sensitization response was observed.  Collectively, these data indicate 
that Tregs exhibit a functional role during TDI sensitization.  Because the role of Tregs in TDI 
sensitization has not been previously elucidated, these data contribute to the understanding of the 
immunologic mechanisms of chemical induced allergic disease. 
 
 







Toluene diisocyanate (TDI) is a low molecular weight, highly reactive chemical utilized in 
the automobile industry and in the manufacture of polyurethane, foams, paints, and coatings. The 
U.S. Environmental Protection Agency reports that domestic production and importation of 2,4- and 
2,6- TDI isomers rose above 1 billion pounds in 2006 (1). TDI is a potent sensitizer and irritant; 
repeat dermal and/or inhalation exposure can lead to a variety of allergic diseases including asthma, 
hypersensitivity pneumonitis, rhinitis, and contact dermatitis (2-4)  These diseases can be disabling 
and extremely severe, potentially resulting in lifelong illness and/or death (5).   TDI is generally 
classified as primarily a respiratory, Th2-mediated sensitizer with a Th1 component (6).  Although 
the murine local lymph node assay (LLNA) is validated for the identification of chemicals that 
preferentially elicit dermal allergic disease, it is not validated for chemicals that preferentially elicit 
respiratory disease (7).  In light of this challenge, further mechanistic insight into the role of 
immunologically relevant cellular subsets (in addition to Th1 and Th2), involved in respiratory 
sensitization may ultimately contribute to the development of improved predictive models based on 
cellular phenotype, secreted cytokine expression, or other related parameters. Recent immunological 
developments such as the discovery of novel T cell subsets including Th17, T follicular helper, Th22, 
Th9, and Treg, cells support the potential for the utilization of novel mediators of allergic disease  (8). 
Classical Tregs (CD4+CD25+) were initially identified based on their suppressive capabilities 
which contributed to the maintenance of immune tolerance in mice (9).  Following this discovery, a 
transcription factor known as forkhead box p3 (Foxp3) was identified as the master transcription 
factor of Tregs, allowing for their identification and functional manipulation (10).  Both naturally 
occurring Tregs (nTregs) that develop in the thymus and inducible Tregs (iTregs) that develop in the 




demonstrated a critical role in the development of immune tolerance and can serve as effectors 
helping to prevent overzealous adaptive responses to foreign antigens and allergens (11, 12).  This 
suppressive function is mediated by a variety of mechanisms including, but not limited to, the control 
of conventional T cell proliferation through the inhibition of co-stimulation via cytotoxic T-
lymphocyte associated protein 4 (CTLA4) expression and/or IL-2 consumption, immunosuppressive 
cytokine secretion (IL-10 and TGF-β), metabolic interference, and disruption of dendritic cell 
function (12-14). 
  Although a functional role for Tregs has been suggested in models of chemical-induced 
contact hypersensitivity (15), this cellular subset has not been investigated in TDI sensitization.  
Vanoirbeek and colleagues observed suspected immune tolerance induced by high dose (3% TDI in 
acetone-olive oil) dermal sensitization followed by intranasal challenge resulting in the absence of 
airway hyperreactivity, contrasted with low dose (0.3% TDI in acetone-olive oil) dermal 
sensitization resulting in airway hyperreactivity following intranasal challenge (16).  Although not 
explicitly stated in the manuscript, this seminal study suggested a role for Tregs in TDI sensitization.  
The collection of data regarding Tregs and chemical allergy is growing but remains limited.  In order 
to elucidate the immunologic mechanisms involved in TDI sensitization, the biological functions of 
pertinent immune cell subsets need to be delineated. It is important to note that although a variety of 
regulatory T cells may be involved in chemical sensitization, this study focuses on classical Tregs 
(CD3+CD4+CD25+Foxp3+) due to their well-documented regulatory potential in a variety of disease 
states, including allergy and asthma (17), and to the lack of data regarding these cells in models of 
low molecular weight chemical allergy.  Here, we utilize a murine model of dermal TDI sensitization 
in order to elucidate the expression kinetics, phenotype, and functional role of Tregs during chemical 




3.2. MATERIALS AND METHODS 
 
3.2.1. Mice 
Female BALB/c mice (6-8 weeks of age) purchased from Taconic (Germantown, NY) were 
acclimated for 5 days and then randomly assigned to treatment group.  Homogenous weight 
distribution was insured across treatment groups.  BALB/c mice were selected on the basis of their 
Th2 bias, robust IgE production, and the historical use of these mice in the laboratory to investigate 
chemical sensitization (18).  Mice were housed in ventilated plastic shoebox cages with hardwood 
chip bedding at a maximum of five animals per cage.  A NIH-31 modified 6% irradiated rodent diet 
(Harlan Teklad) and tap water were administered ad libitum.  Housing facilities were maintained at 
68-72˚F and 36-57% relative humidity, and a 12 hour light-dark cycle was maintained.  All animal 
experiments were performed in the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) accredited National Institute for Occupational Safety and Health (NIOSH) 
animal facility in accordance with an Institutional Animal Care and Use Committee-approved 
protocol. 
 
3.2.2. TDI Sensitization Model 
             Toluene 2,4-diisocyanate (TDI, CAS# 584-84-9) was purchased from Sigma-Aldrich 
Chemical Company (Milwaukee, WI).  Animals (n=4-5) were exposed to a single dose of 0.5-4% 
TDI (v/v) on the dorsal surface of each ear (25 µL per ear).  The highest concentration (4% v/v; the 
maximum sensitizing concentration with minimal toxicity) and dosing regimen was previously 
shown to induce sensitization (19) and sensitization was confirmed in the lower dose based on total 




was selected as the vehicle control to minimize chemical reactivity as diisocyanates react with OH 
groups which are present in other potential vehicles such as olive oil.  Ear thickness was measured 
4 days following TDI exposure using a modified engineer’s micrometer (Mitutoyo Corporation, 
Japan) and measurements were collected in millimeters (mm).  Average ear swelling was calculated 
as previously described (20). Mice were euthanized via CO2 asphyxiation at time points ranging 
from 1 – 11 days post chemical exposure.    
 
3.2.3. Euthanasia, Tissue Collection, and Processing 
             Animals were weighed, euthanized via CO2 asphyxiation, and examined for gross pathology 
at the designated time point. Left and right superficial parotid draining lymph nodes (dLNs; drain 
site of chemical application (21)) were collected in sterile phosphate-buffered saline (pH 7.4) and 
manually dissociated using the frosted ends of two microscope slides.  dLN cellularity was 
determined using a Cellometer (Nexcelom Bioscience, Lawrence, Massachusetts) with size 
exclusion parameters (3.5 to 36 µm) and a combined Acridine Orange/Propidium Iodide (AO/PI) 
solution to identify viable cells.  Blood was collected via cardiac puncture, placed into serum 
collection tubes, centrifuged, and serum was removed and stored at -80˚C for subsequent total IgE 
analysis via ELISA.  Ears were collected in 1 mL RNALater (Ambion, Pittsburgh, PA), stored at -
80˚C for subsequent gene expression analysis or processed for flow cytometric analysis.  For flow 
cytometric analysis of the skin (Figure 5.4 and Appendix 5.1), ear cell suspensions were prepared 
by splitting ears into ventral and dorsal halves, mincing into 1cmx1cm pieces followed by an 
enzymatic digestion for 90 min at 37°C with 0.25mg/ml Liberase-TL Research grade (Roche) in 




strainer to make a single cell solution, washed with RPMI + 10% FBS, then live cells were counted 
on a Cellometer (Nexcelom) using AO/PI. 
 
3.2.4. RNA Isolation and Reverse Transcription 
Ears were processed for RNA isolation using a Tissue Lyser II in Qiagen lysis buffer.  Total 
RNA was isolated from the ears and dLN using the Qiagen RNeasy and miRNeasy kits respectively.  
A QiaCube (Qiagen, Hilden, Germany) automated RNA isolation machine was utilized in 
conjunction with the specified RNA isolation kits.  A DNase treatment was performed for removal 
of residual DNA.  The concentration and purity of the RNA was determined using a ND-1000 
spectrophotometer (Thermo Scientific Nanodrop, Wilmington, DE).  First strand cDNA synthesis 
was performed using a High-Capacity cDNA Synthesis Kit (Applied Biosystems, Carlsbad, 
California) according to manufacturer recommendations.  Ultimately, the cDNA was analyzed for 
mRNA expression as described in the real-time PCR methods section below. 
 
3.2.5. Real Time PCR (RT-PCR) 
For analysis of mRNA expression, TaqMan Universal Fast master mix (Applied Biosystems, 
Calsbad, California), cDNA, and mouse-specific mRNA primers (TaqMan Custom PCR Arrays, 
Carlsbad, California) were combined and PCR was performed according to manufacturer protocol.  
Primers used include: il-1β, il-6, and tnf-α.  Master mix, primers, and cDNA were added to a 
MicroAmp Fast Optical 96-well reaction plate and analyzed on an Applied Biosystems 7500 Fast 
Real Time PCR system using cycling conditions as specified by the manufacturer.  β-actin was used 
as the endogenous reference control gene as expression was determined to be stable following 




change over vehicle control, calculated by the following formula: 2−ΔΔCt = ΔCtSample − ΔCtControl.  
ΔCt = CtTarget − Ctβ-ACTIN, where Ct = cycle threshold.   
 
3.2.6. Flow Cytometric Analysis 
Single cell suspensions were prepared from tissues and a minimum of 150,000 dLN and 
1,000,000 ear skin cells were aliquoted into 96-well U-bottom plates and washed in FACS staining 
buffer (PBS + 1% bovine serum albumin + 0.1% sodium azide).  Cells were resuspended in staining 
buffer containing anti-mouse CD16/32 antibody (clone 2.4G2; BD Biosciences, San Jose, CA) for 
blocking of Fc receptors to minimize nonspecific binding.  Cells were resuspended in staining buffer 
containing a cocktail of fluorochrome-conjugated antibodies specific for cell surface antigens 
including: CCR6 (clone: 29-2L17, fluorophore: BV605, BioLegend), CD3 (500A2, V500, BD), 
CD4 (RM4-5, AF700, BD), CD8a (53-6.7, AF488, BioLegend), CD25 (PC61, APC Cy7, 
BioLegend), CD45 (30-F11, PE, BD), CD103 (2E7, PerCP Cy5.5, BioLegend), ICOS (C938.4A, 
PE Cy7, eBioscience), Neu-1 (3E12, PE, BioLegend), and Ter-119 (TER-119, FITC, eBioscience).  
Following surface staining, cells were washed in staining buffer and fixed using the Foxp3 fixation 
buffer set (eBioscience, San Diego, CA).  After overnight incubation in staining buffer, cells were 
permeablilized using the Foxp3 fixation buffer set (eBioscience, San Diego, CA) and re-suspended 
in permeabilization buffer containing a cocktail of fluorochrome-conjugated antibodies specific for 
intracellular antigens including: CTLA4 (UC10-4B9, BV421, BioLegend), Foxp3 (FLK-16s, eF450 
and APC, eBioscience), Gata3 (TWAJ, eF660, eBioscience), Rorγt (Q31-378, PerCP Cy5.5, 
eBioscience), and Tbet (4B10, PE Cy7, eBioscience).  Following staining, cells were re-suspended 
in staining buffer and analyzed on an LSR II flow cytometer using FacsDiva software (BD 




A minimum of 10,000 events were captured for each sample.  Leukocytes were first identified by 
their expression of CD45.  The Treg subset was further identified as CD3+CD4+CD8-CD25+Foxp3+.  
Numerical population values were calculated by applying subset frequencies to the initial cell count 
obtained following lymph node homogenization.  Compensation controls were performed using 
single stained cellular suspensions and OneComp beads (eBioscience, San Diego, CA) and 
fluorescence minus one (FMO) staining controls were included to help set gating boundaries. 
 
3.2.7. Treg Suppression Assay 
The suppressive ability of Tregs was analyzed using an ex vivo Treg suppression assay as 
described by Kruisbeek, et al (22) and Marshall, et al (23) with some modifications.  This assay 
evaluates the ability of naïve, conventional dLN-derived T cells (Tcons) to proliferate in the presence 
of varying numbers of Tregs isolated from acetone- or TDI-exposed mice.  Mice were exposed to 
acetone (n=7-11) or TDI (4%) (n=4-5) as previously described and following sacrifice at 4 and 7 
days post TDI (peak of the expansion) exposure the dLN and spleens were removed.  Tregs 
(CD4+CD25+) and Tcons (CD4+CD25-) were isolated from the lymph nodes and CD4- accessory cells 
were isolated from naïve spleens using CD4 negative and CD25 positive selection-based magnetic 
separation kits (Stemcell, Vancouver, BC).  Average Treg purity is as follows for 4 days: Acetone-
70.65% of CD3+CD4+ cells and 4% TDI-63.05% of CD3+CD4+ cells and 7 days: Acetone-91.35% 
of CD3+CD4+ cells and 4% TDI-82.8% of CD3+CD4+ cells post 4% TDI exposure.  Following 
isolation from naïve mouse dLNs, Tcons were labeled with 2 µM carboxyfluorescein succinimidyl 
ester (CFSE).   Tcons and Tregs were cultured in a 96-well U-bottom plate with anti-CD3 (0.2 µg/mL; 
BD Biosciences) and accessory cells at a variety of Tcon:Treg ratios (1:1, 2:1, 4:1, and 8:1).  Naïve 




accessory cells.  Additional controls included stimulated Tcons only to assess baseline proliferation, 
Tregs only, accessory cells only, and Tcons only with no stimulation nor accessory cells.  Cells from 
each treatment group were pooled and added to triplicate wells of the culture plate.  72 hours 
following plating, cells were stained with anti-CD4 and Live/Dead Violet (Life Technologies, 
Carlsbad, CA).  Tcons were defined as CD4+ CFSE+ cells and suppression was measured based on 
changes in the frequency of dividing CFSE+ cells based on the dilution of CFSE.  Tregs were analyzed 
for purity based on their expression of CD3, CD4, and Foxp3 as determined by flow cytometric 
analysis as previously described.   
 
3.2.8. In vivo Anti-CD25 Antibody Treatment 
In order to deplete Tregs before and during TDI sensitization, InvivoMAb anti m CD25 
(BioXCell, PC-61.5.3) was administered in vivo.  The use of this antibody as a Treg depletion strategy 
is validated in vivo (24, 25).  InVivoMAb Rat IgG1  (Bioxcell, HRPN) was utilized as a negative, 
isotype control.  Treatment groups for this study (n=5 mice) are as follows: isotype/acetone, 
isotype/0.5% TDI, isotype/2% TDI, anti-CD25/acetone, anti-CD25/0.5% TDI, and anti-CD25/2% 
TDI.  200 µg of the respective antibody in USP grade saline was administered intraperitoneally at 
days -11 and -8 during the depletion study (see Figure 6A for study timeline).  Animal weights were 
recorded throughout the duration of the experiment to monitor potential toxicity.  In order to confirm 
the effectiveness of the antibody, blood was collected from the lateral tail vein at days -2 and 7, and 
Tregs were measured by flow cytometry as previously described.  Baseline blood Treg levels were 
assayed at day -12 to ensure equal pre-treatment frequencies across all groups.  Mice were exposed 
to a single dermal application of 0.5% or 2% TDI on day 0.  The high dose of 2% TDI was selected 




maximum sensitization response.  Mice were euthanized 7 days following dermal chemical 
exposure.  Specific measures of sensitization were evaluated, including examination of the Th2 
population by flow cytometry (CD3+CD4+Gata3+), IL-4 dLN mRNA levels by RT-PCR, and total 
IgE levels in the serum.  Total serum IgE was quantified following serum separation from whole 
blood (centrifugation) and analysis using a Mouse IgE Ready-SET-Go! Kit (Affymetrix 
eBioscience, San Diego, CA) according to the manufacturer’s protocol.  Absorbance was determined 
using a Spectramax Vmax plate reader (Molecular Devices, Sunnyvale, California) at 450 and 650 
nm.  Data analysis was performed using the IBM Softmax Pro 3.1 program (Molecular Devices, 
Sunnyvale, California) and the IgE concentrations for each sample were interpolated from a standard 
curve derived from multipoint analysis. 
 
3.2.9. Statistical Analysis 
Statistical analyses were generated using SAS/STAT software, version 9.3 (SAS Institute, 
Cary, NC) and GraphPad Prism version 5.0 (San Diego, CA).  For irritancy and inflammatory gene 
expression analysis (Figure 1), a one way analysis of variance (ANOVA) was conducted.  If the 
ANOVA showed significance at p < 0.05 or less, the Dunnett’s Multiple Comparison Test was used 
to compare values from groups of mice treated with varying concentrations of TDI to the acetone 
control group.  Figures 2-6 and Table 2 were analyzed by analysis of variance using PROC MIXED. 
In some cases, data were transformed using the natural log to meet the assumptions of the analysis. 
Significant interactions were explored utilizing the “slice” option in PROC MIXED and pairwise 
differences were assessed using a Fishers Least Significant Difference Test.  Supplemental data was 




were considered significant at p < 0.05; representative significance symbols varied by figure, as 




3.3.1. Examination of Sensitization and Skin Irritancy Potential of TDI  
To confirm that a single dose exposure to TDI (0.5 and 4%) would sensitize animals, total 
serum IgE was evaluated following TDI exposure.  Although not initially statistically significant, 
IgE levels appeared to increase in a dose-dependent manner, reaching significance following 4% 
exposure (Figure 3.1 A).  Because TDI is a known irritant (26), the selected doses of TDI (0.5-4% 
v/v) were assayed for dermal irritancy potential via ear swelling measurements and ear inflammatory 
cytokine mRNA production quantified via RT-PCR.  Average ear swelling was significantly 
increased four days following 2 and 4% TDI exposure (Figure 3.1 B); however, neither 0.5 nor 1% 
TDI exposure induced significant increases in ear swelling (Figure 3.1 B).  Inflammatory cytokine 
(IL-1β, IL-6, and TNF-α) mRNA levels were significantly increased in the ear four days following 
4% TDI exposure (Figure 3.1 C-E).  These data suggest that 2 and 4% TDI exposure induce a 
significant irritation response in the ear compared to 0.5 and 1% TDI exposure.  Based on this data, 
0.5 and 4% TDI were selected as the exposure concentrations in subsequent studies to represent 
sensitizing concentrations that encompassed both a low dose exhibiting a lack of irritation (0.5%) 












































































































































































Figure 3.1: Confirmation of Sensitization and Evaluation of Skin Irritancy Following Dermal TDI 
Exposure 
ELISA analysis of total serum IgE levels 11 days following single TDI exposure at the indicated 
concentration (A).  Percent change in ear thickness as determined 4 days following TDI exposure 
(B).  Ear mRNA expression of the inflammatory cytokines Il-1β (C), il-6 (D), and tnf-α (E) as 
determined 4 days following TDI exposure via RT-PCR.  Bars represent mean (± SE) of 4-5 mice 




3.3.2. dLN Treg Expression Kinetics Reveal an Expansion of this Population During TDI 
Sensitization  
In order to profile the expression kinetics of the Treg subset during TDI sensitization we 
examined dLN cell populations at 1, 2, 4, 7, and 9 days post TDI exposure (See Table 3.1 for markers 
utilized).  Tregs were identified as CD3+CD4+CD25+Foxp3+ cells by flow cytometry (Figure 3.2 A).  
The frequency of Tregs was unchanged compared to control cells from acetone-treated mice during 
0.5% TDI sensitization; however, Treg frequency increased significantly at 4, 7, and 9 days post 4% 
TDI exposure (Figure 3.2 B).  Tregs also significantly increased in number at all time points analyzed 
during 0.5 and 4% TDI sensitization (Figure 3.2 C).  The peak numbers of Tregs in the dLN appeared 
to occur at day 4 post TDI exposure for both concentrations (mean ± SEM; 1.17 x 106 cells ± 0.08 
(0.5%) and 1.7 x 106 cells ± 0.08 (4%)) compared to the acetone control (0.18 x 106 cells ± 0.02).  
The Treg population remained elevated compared to the acetone control, but began to retract at days 
7 (0.5% TDI- 0.88 x 106 ± 0.09, and 4% TDI- 1.39 x 106 ± 0.1) and 9 (0.5% TDI- 0.37 x 106 ± 0.06, 
and 4% TDI- 0.79 x 106 ± 0.05) following TDI exposure relative to their peak at day 4. 
In order to better elucidate the origin of the Tregs involved in the TDI sensitization response, 
natural Tregs (nTregs) were identified based on their expression of neuropilin-1 (27).  Interestingly, the 
frequency of the nTreg subset as a percentage of total Tregs significantly decreased at 7 and 9 days 
during 0.5% and 4% TDI sensitization (Figure 3.2a C).  Although the frequency of this subset 
decreased in relation to the acetone control group, the numbers of nTregs in the dLN increased during 
0.5 and 4% TDI sensitization (Figure 3.2a D).  This increase was significant for 4-9 days during 
0.5% TDI sensitization and at all time points measured during 4% TDI sensitization.  It is important 
to note that both the nTreg and the neuropilin-1neg Treg population (presumably induced Tregs (iTregs)) 




Marker Abbreviation Surface or 
Intracellular 
Detection 





CD3 S Pan T cell marker All T cells 
Cluster of 
Differentiation 4 




CD25 S High affinity IL-2 
receptor α, T and B cell 
growth factor (via IL-2 
binding) (28, 29) 
Tregs, some 








Motif) Receptor 6 
CCR6 S Lymphocyte 
chemoattractant CCL20 
is its ligand (30) 
Migratory Effector 
Tregs (31, 32) and 




CD103 S Integrin involved in 
epithelial T cell migration 
and retention (34) 
Migratory Effector 
Tregs (35) and tissue 






CTLA4/CD152 IC Member of the CD28 
family that is a potent 
inhibitor of T cell 
costimulation (37) 
Tregs and activated 
T cells (non-Tregs) 
Inducible T-Cell 
Costimulator 
ICOS/CD278 S Member of the CD28 
family that has 
costimulatory 
functionality during T cell 
activation (38) 
Migratory Effector 
Tregs (39-41) and 
activated T cells 
(41) 
Neuropilin-1 Neuropilin-1 S Receptor for vascular 
endothelial growth 
factors and semaphorins 
(42) 
nTregs (11, 43), TFH 
cells (44), and 
CD8+ T cells (45)  
Table 3.1 Treg Flow Cytometry Phenotyping Marker Guide 
 
dLN Treg subsets were further phenotyped by flow cytometry (Table 1).  The phenotyping 
analysis revealed a number of Treg subpopulations that exhibited the potential to be functionally 
diverse in relation to their mechanism(s) of suppression (Table 1 and A3.1).  An expansion in the 
frequency and number of the CTLA-4+ Treg population was observed at all measured time points 




expression of both frequency (Figure 3.2a A) and number (Figure 3.2a B) at day 4 post TDI exposure.  
The emergence of the CTLA4+ Treg population during TDI sensitization suggests the engagement of 
CTLA-4, a negative costimulatory molecule, as a potential suppressive mechanism during this 
response (46).  As expected, presumably due to compensatory mechanisms during T cell activation, 
there was also an increase in CTLA4 expression in CD4+ non-Tregs; however, at the peak of 
expression (4 days) the mean frequency of expression among all CD4+ cells was 0.54% ± 0.024 for 
acetone, 4.6% ± 0.24 for 0.5% TDI, and 7.85% ± 0.66 for 4% TDI groups.  Compared to the Tregs 
expressing CTLA4 at the same time point, these numbers reveal a sizably smaller frequency of non-
Tregs expressing this marker, emphasizing the specificity of this marker to the Treg population during 
this response.   
In addition to the CTLA4+ Tregs and nTregs, cells expressing the homing molecules CD103, 
CCR6, and ICOS were analyzed during TDI sensitization.  Treg expression of CD103, CCR6, and 
ICOS increased in both frequency and number throughout 0.5 and 4% TDI sensitization (Table 3.2).  
The CCR6+ population’s expression frequency was highest at 7 days post TDI exposure, while the 
CD103+ and ICOS+ populations’ frequency peaked at 4 days post exposure.  It is important to note 
that while there are significant changes in these subsets, they represent a small portion of the total 
CD4+ population, as their expression is presented on Tregs, which themselves constitute a minority of 
the total CD4+ population.  Although there was robust Treg expression of CD103, CCR6, and ICOS 
as single markers, there was a significant population of dLN Tregs that co-expressed these molecules 
(Figure 3.2b A and B) with kinetics were similar to those exhibited by each single marker.  This 
population likely represents a migratory subset of effector Tregs that have been activated during TDI 
sensitization.  This co-expressing population expanded in the dLN in both number and percent during 




Tregs during 0.5% TDI sensitization and 20.7% ± 1.8 of Tregs during 4% TDI sensitization at 7 days 
post exposure (peak expression).  Ear-derived Tregs were also examined by flow cytometric analysis 




























































Figure 3.2 Treg Subset Expands During Dermal TDI Sensitization 
Flow cytometric analysis of Tregs following dermal TDI sensitization (A) Tregs were first gated on 
their expression of CD3 and CD4, then were further identified by CD25 and Foxp3 expression at 
indicated time points.  dLN Treg frequency (B) and number (C) were determined based on flow 




mean (± SE) of 5 mice per group.  P values are represented by ^ (0.5% TDI) and asterisks (4% TDI) 
(P<0.05).  Significance is indicated as follows: P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 
(****) for 4% TDI or P ≤ .05 (^), P ≤ .01 (^^), P ≤ .001 (^^^), and P ≤ .0001 (^^^^) for 0.5% TDI.  
Dermal treatment groups are indicated by the following symbols: circle- acetone, square- 0.5% TDI, 











































































































































Figure 3.2a Expansion of CTLA4+ and nTreg Populations During TDI Sensitization  
Flow cytometric analysis of dLN CTLA4+ Treg frequency (A) and number (B) and nTreg (Neuropilin-
1+) frequency (C) and number (D) following TDI sensitization.  Bars represent mean (± SE) of 5 
mice per group.  P values are represented by ^ (0.5% TDI) and asterisks (4% TDI) (P<0.05).  
Significance is indicated as follows: P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****) 
for 4% TDI or P ≤ .05 (^), P ≤ .01 (^^), P ≤ .001 (^^^), and P ≤ .0001 (^^^^) for 0.5% TDI.  Dermal 
treatment groups are indicated by the following symbols: circle- acetone, square- 0.5% TDI, and 





CCR6+ %  
(of Tregs) 
1 day 2 day 4 day 7 day 9 day 
Acetone 11.14 ± 0.7 12.72 ± 1.03 10.86 ± 0.55 18.22 ± 1.36 9.23 ± 0.8 
0.5% TDI 10.22 ± 0.68 17.7 ± 1.64** 20.58 ± 0.84**** 26.54 ± 
0.68**** 
14.82 ± 0.99** 




CCR6+ #  
(x 105 cells) 
     
Acetone 0.2 ± 0.05 0.14 ± 0.04 0.19 ± 0.02 0.24 ± 0.04 0.16 ± 0.03 
0.5% TDI 0.34 ± 0.06* 0.61 ± 0.12**** 2.41 ± 0.19**** 2.35 ± 0.28**** 0.57 ± 0.13**** 
4% TDI 0.533 ± 
0.05**** 
0.3 ± 0.07** 5.25 ± 0.48**** 5.59 ± 0.41**** 1.99 ± 0.2**** 
CD103+ % 
(of Tregs) 
1 day 2 day 4 day 7 day 9 day 
Acetone 22.86 ± 0.75 18.88 ± 4.24 20.82 ± 0.94 28.44 ± 2 21.18 ± 0.92 
0.5% TDI 18.38 ± 0.84 24.44 ± 2.99* 35.88 ± 0.84**** 38.8 ± 1.1*** 32.72 ± 
2.23**** 




CD103+ #  
(x 105 cells) 
     
Acetone 0.41 ± 0.09 0.16 ± 0.03 0.37 ± 0.04 0.38 ± 0.07 0.36 ± 0.06 
0.5% TDI 0.59 ± 0.1 0.83 ± 0.15**** 4.21 ± 0.33**** 3.47 ± 0.45**** 1.22 ± 0.23**** 






1 day 2 day 4 day 7 day 9 day 
Acetone 13.38 ± 0.36 15.92 ± 1.21 13.56 ± 0.41 18.7 ± 1.22 15.98 ± 1.24 
0.5% TDI 14.06 ± 1.03 36.42 ± 
2.16**** 
47.8 ± 1.15**** 38.38 ± 
1.72**** 
33.36 ± 2**** 
4% TDI 16.68 ± 1.45 33.18 ± 
1.27**** 





(x 105 cells) 
     
Acetone 0.23 ± 0.05 0.17 ± 0.04 0.24 ± 0.02 0.25 ± 0.04 0.28 ± 0.5 
0.5% TDI 0.46 ± 0.09** 1.31 ± 0.27**** 5.61 ± 0.45**** 3.42 ± 0.45**** 1.27 ± 0.26**** 
4% TDI 0.88 ± 0.09**** 0.94 ± 0.18**** 10.68 ± 0.62**** 7.62 ± 0.62**** 3.62 ± 0.29**** 
Table 3.2 dLN Migratory Effector Treg Population Expands During TDI Sensitization 
Data represents mean frequency and number of each Treg population 1-9 days following chemical 
exposure.  Significance is indicated as follows: P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 
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Figure 3.2b dLN Migratory Effector Treg Population Expands During TDI Sensitization (Co-
Expression) 
dLN CCR6+ CD103+ ICOS+ Treg frequency (A) and number (B) were determined based on flow 
cytometry analysis and extrapolation of this data with total dLN cellularity.  Bars represent mean (± 
SE) of 5 mice per group.  P values are represented by ̂  (0.5% TDI) and asterisks (4% TDI) (P<0.05).  
Significance is indicated as follows: P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****) 
for 4% TDI or P ≤ .05 (^), P ≤ .01 (^^), P ≤ .001 (^^^), and P ≤ .0001 (^^^^) for 0.5% TDI.  Dermal 
treatment groups are indicated by the following symbols: circle- acetone, square- 0.5% TDI, and 










3.3.3. Tregs Exhibit Potent Suppressive Ability During TDI Sensitization 
Because the Treg population expanded during TDI sensitization, the functional role of Tregs 
was further examined by performing a CFSE-based Treg suppression assay with Tregs isolated from 
acetone or TDI-treated mice (Figure 3.3 A).  Tregs from acetone-treated mice were significantly 
suppressive at all Tcon:Treg ratios tested when isolated at 4 (Figure 3.3 B) and 7 days (Figure 3.3 C) 
post exposure.  Acetone Treg-induced suppression was found to be equivalent to naïve-derived Treg-
induced suppression (data not shown).  Tregs from TDI-exposed mice exhibited increased suppressive 
ability compared to the acetone controls when isolated at both 4 (Figure 3.3 B) and 7 days (Figure 
3.3 C) at all Tcon:Treg ratios tested.  The heightened suppressive ability of Tregs was surprising, given 
the progression of sensitization at the selected concentrations of TDI.  This data suggested a 
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Figure 3.3 Treg Suppression Assay Reveals Increased Suppressive Ability of Tregs During TDI 
Sensitization 
A CFSE-based Treg suppression assay was performed and percent dividing CFSE+ cells were 
quantified as illustrated in (A).  The zero peak represents the cell population that retained all original 




mice 4 (B) and 7 (C) days following TDI exposure at a variety of Tcon:Treg ratios.  For (B) and (C) 3 
plate replicates were utilized from groups of 4-11 mice, as described in the materials and method’s 
section.  Significance is indicated as follows: P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 
(****).  P values are represented by asterisks (comparison of each treatment group to Tcon only from 
the same chemical treatment group) or horizontal bars with asterisks above (comparison of identical 
ratios between different chemical treatment groups).   
 
 
3.3.4. Depletion of Tregs Before and During TDI Sensitization Augments the T cell-mediated 
Allergic Response 
In order to analyze the functional potential of Tregs in vivo during TDI sensitization, this 
subset was depleted by injecting mice with anti-CD25 antibody days -11 and -8 prior to TDI 
exposure (Figure 3.4 A).  The high dose of 2% TDI was selected in an effort to allow for a measurable 
increase in the sensitization response, as 4% TDI elicits a maximum sensitization response.  The 
basal levels of Tregs in the blood of mice were determined to be comparable among all groups prior 
to dosing (A3.2 A) and depletion was confirmed in the blood (A3.2 A) at days -2 and 7 and in the 
dLN (A3.2 B) at day 7.  Mice dosed with 2% TDI that received anti-CD25 lost significantly more 
body weight (grams; mean decrease 5.33% ± 3.9) than mice exposed to 2% TDI and isotype control 
antibody (mean increase 1.01% ± 4.3), suggesting enhanced toxicity following Treg depletion and 
high-dose TDI administration.  Because local irritation is thought to influence allergic sensitization 
(47) and TDI is a known irritant (48), we analyzed the dermal irritation response at the site of TDI 
exposure by ear swelling measurements following Treg depletion.  As expected, there was a dose-




the isotype control and anti-CD25 groups (Figure 3.4 B).  Although not statistically significant, ears 
from animals treated with anti-CD25 and either concentration of TDI exhibited increased swelling 
(12.4% ± 3.7 for 0.5%; 54.4 % ± 10.7 for 2% TDI) compared to their isotype-treated counterparts 
(1.4% ± 6.6 for 0.5%; 35.6% ± 8.9 for 2% TDI).  Compared to values at day -11, total body weight 
decreased significantly in both groups treated with 2% TDI; however, the anti-CD25-treated group 
exhibited weight loss that was significant beyond that of the isotype control (A3.3 A).  At day 7, 
dLN cellularity increased dose-responsively (Linear trend test p < 0.05) for both the isotype control 
and anti-CD25-treated groups during TDI sensitization (Figure 3.4 C).  For both the 0.5% and 2% 
TDI-treated groups statistically significant increases in the dLN cellularity with anti-CD25 treatment 
compared to isotype were observed.  Another effector CD4+ T cell subset, Th2, which play an 
important role in allergic responses, was identified by GATA-3 expression and was found to dose-
responsively expand in number during 0.5% and 2% TDI sensitization for both the isotype and anti-
CD25-treated groups (Figure 3.4 D; Linear trend test p < 0.01).  When comparisons were made 
between the isotype control and anti-CD25 treated groups this population appeared to further expand 
during TDI sensitization, although these perceived trends were not statistically significant.  Similar 
observations were made for the Th2 population’s frequency (A3.3 B).  Interestingly, the Gata3 mean 
fluorescence intensity (MFI) was significantly augmented following anti-CD25 treatment in the 0.5 
and 2%-treated groups, indicating increased brightness on a cell-per-cell basis (A3.3 C).   IL-4 
mRNA expression levels increased dose-responsively in the dLN following 0.5% and 2% TDI 
exposure (Linear trend test p<0.05; isotype and anti-CD25 groups) and were significantly augmented 
in groups treated with anti-CD25 compared to isotype-treated controls (Figure 3.4 E).  Similarly, 
dose-responsive increases in total IgE levels in the blood appeared to occur at 7 days following 




only observed for the 2% TDI anti-CD25-treated group (Linear trend test p < 0.01; Figure 3.4 F).  
Statistically significant increases in serum IgE levels were observed after anti-CD25 treatment 
following exposure to 0.5 and 2% TDI.   
Other T cell-related dLN phenotyping was performed at day 7 including CD3, CD4, and 
CD8 expression, along with other effector CD4+ Th1 and Th17 populations based on their expression 
of Tbet and Rorγt, respectively (A3.4).  CD3+, CD3+CD4+, CD3+CD8+, Th1 and Th17 cells dose-
responsively expanded in number during 0.5% and 2% TDI sensitization and anti-CD25 depleted 
animals exhibited higher numbers of cells during TDI sensitization (A3.4 B, D, F, H, J).  dLN CD3+ 
cellular frequency decreased in isotype and anti-CD25-treated groups during 0.5% and 2% TDI 
sensitization compared to their respective acetone control (A3.4 A).  Interestingly, CD3+ cellular 
frequency was significantly increased in groups treated with anti-CD25 compared to isotype controls 
for acetone and 0.5% TDI, indicating that anti-CD25 treatment did not affect general T cell 
frequencies in the dLN.  CD4+ and CD8+ T cell frequency (as a percentage of CD3+ cells) remained 
stable during TDI sensitization; however, the CD4+ frequency decreased following anti-CD25 
treatment while the CD8+ frequency increased A3.4 C and E).  The Th1 dLN population 
significantly expanded in frequency during TDI sensitization (A3.4 C).  This subset further expanded 
in mice treated with anti-CD25 in frequency (2%) compared to the isotype control groups.  The Th17 
subset was also profiled and was not significantly altered in frequency during TDI sensitization in 
the isotype control treated groups; however, the frequency of Th17 cells was significantly increased 
above both the corresponding acetone and isotype-treated control groups during 2% TDI 
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Figure 3.4 The Severity of the Sensitization Response is Intensified in the Absence of Tregs During 
TDI Sensitization 
Tregs were depleted in mice prior to and during dermal TDI sensitization (A).  Evaluation of dermal 




serum total IgE (F) were evaluated following a single exposure of 0.5% or 2% TDI with isotype 
control or anti-CD25.  Bars represent mean (± SE) of 5 mice per group.  Significance is indicated as 
follows: P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).  P values are represented by 
asterisks (comparison of acetone to TDI-exposed group from the same antibody treatment regimen) 
or horizontal bars with asterisks above (comparison of antibody and isotype-treated groups receiving 
identical chemical treatment).   
 
3.4. DISCUSSION 
Occupational exposure to sensitizing chemicals that are capable of inducing allergic disease 
is increasing globally and is an important public health concern.  Although there continues to be 
progress made in the area of hazard identification, the limited knowledge of the immunologic 
mechanisms of sensitization induced by respiratory sensitizers such as TDI, continues to complicate 
the development of these assays.  Novel molecules and mechanisms involved in allergic disease need 
to be investigated in order to elucidate specific entities that can be utilized for the development of 
hazard identification assays for respiratory sensitizers.  Due to the recognized role of Tregs in related 
allergic disease states, we chose to investigate the expression kinetics, phenotype, and functional 
capability of Tregs in a murine model of dermal TDI sensitization.  To our knowledge, this is the first 
study that investigates the expression and functionality of Tregs in Th2-mediated chemical 
sensitization.   
Treg involvement has been suggested in the prevention of the development of allergic disease 
in both mouse and human models of allergy, specifically impacting Th2-related responses (49).  
Murine CD4+CD25+ T cells can prevent the transition of naïve CD4+ T cells to Th2 cells in vitro 




pathology and ex vivo-derived splenic IL-4 and IL-13 levels were observed following Treg adoptive 
transfer (51).  Additionally, Tregs have been implicated in in vivo-induced tolerance following inhaled 
ovalbumin exposure (52), highlighting the importance of these cells in the prevention of allergic 
disease.  Supporting human studies have demonstrated the expansion of Tregs in the nasal mucosa 
following allergen immunotherapy and noted their association with the efficacy of treatment, 
suggesting a role for Tregs in the development of antigen-specific tolerance in allergic humans (53).  
In addition to their direct actions on Th2 cells, Tregs have also demonstrated the ability to suppress 
allergic disease by influencing granulocytes, antibody-producing B cells, and resident tissue cells 
(54).  In addition, Tregs have demonstrated involvement in maintaining tolerance and controlling the 
allergic response during the sensitization phase of both ovalbumin-induced allergic airway 
inflammation (55) and hapten-induced CD8+ T cell-dependent contact hypersensitivity response 
(Christensen et al., 2015).   
In an effort to explore the role of Tregs in TDI sensitization, this population was profiled 
following epicutaneous TDI exposure.  Several basic Treg markers (CD3/CD4/CD25/Foxp3) were 
used to define the classical Treg population but it is important to note that some Treg subsets do not 
express CD25 and/or Foxp3 such as Tr1 (56) and Th3 (57) cells which typically exhibit TGF-β and 
IL-10-mediated suppression.   Due to the use of CD25 as a functional tool in these studies, we have 
chosen to focus on classical Tregs. The basic Treg population encompasses numerous subpopulations 
including, but not limited to, nTregs, iTregs, migratory and homing Tregs, and IL-10 secreting Tregs.  
Beyond the nTregs and iTregs, these subsets are not mutually exclusive, so while phenotyping markers 
may be presented alone, many of these populations are co-expressers of a variety of markers.  In 
general, the Treg populations (basic and specialized; Table 1) were identified to expand in both 




TDI exposure.  This retraction may be due to the early importance of this population in the dLN or 
may also be mediated by other compensatory or regulatory elements.  Interestingly, the general Treg 
population’s frequency did not significantly increase following 0.5% TDI exposure (Figure 3.2 B), 
potentially implicating a role for the irritant response in both the induction of Tregs and as a precursor 
to the initiation of sensitization.   
Further support for a role for Tregs in TDI sensitization was identified following in vivo 
administration of anti-CD25 treatment.  In this Treg depletion study, augmentations in traditional Th2 
allergic markers (dermal irritation, dLN cellularity, Th2 population, IL-4 mRNA expression, and 
serum total IgE production) were observed.  Dose-responsive increases in dLN cellularity, IL4, Th2 
cells, and IgE were also observed and were further augmented following anti-CD25 treatment 
indicating increased sensitization in the absence of Tregs.  dLN cellularity was measured as a gross 
marker of sensitization intensity, as this parameter is traditionally utilized in the standard 
sensitization assay known as the local lymph node assay (Anderson et al., 2011).  The dLN Th2 
cellular subset was examined as the main effector T cell subset traditionally thought to be involved 
in allergic responses, with the allergic cytokine IL-4 being primarily produced by this subset, 
influencing the development and homeostasis of the allergic microenvironment (58).  IgE expression 
indicates the development of an allergic humoral response.  While Treg depletion was identified to 
promote a Th2 response, the findings from the Treg suppression assay suggested that Tregs isolated 
from the TDI-sensitized animals were more suppressive compared to their acetone counterparts.  
These data suggest a significant role for Tregs in the regulation of chemical-induced allergy, implying 
that their presence may delay or reduce the intensity of sensitization.    
Typically, the development of allergic disease is thought to involve an imbalance between Th1 and 




is an important mediator of TDI sensitization, it is important to note that TDI sensitization and 
resultant allergic disease also contain Th1 and Th17 components (A 3.4 G-J) (8).  Tregs are capable 
of suppressing both Th1 (60, 61) and Th17 (62) –mediated responses, indicating that they may be 
influencing these components of the TDI sensitization response.  Selective suppression of the Th1 
response during TDI sensitization could further enhance the development of Th2-mediated 
sensitization based on the Th1/Th2 imbalance hypothesis.   
While Tregs isolated from TDI sensitized mice were identified to be more suppressive than 
acetone-derived Tregs, this was reported based as a combined function for all populations of Tregs.  
This is important to note because TDI-induced Tregs were identified to be phenotypically 
heterogeneous.  While the kinetics of the specialized Treg populations generally mimic that of the 
basic Treg population several discrepancies were identified that may provide insight into the 
mechanisms driving this response.  The CTLA4+ Treg population was identified to increase in number 
and frequency earlier than the general Treg population with significant increases identified one day 
post exposure (Fig 3.2a A and B).  The early expansion of this subset was intriguing, given the lack 
of any data implying a role for CTLA4-mediated suppression in chemical-induced allergy, although 
this population has been noted to play an immunosuppressive role in the sensitization phase of the 
ovalbumin-induced allergic response (63).  This population participates in contact-mediated 
suppression by binding to the B7 costimulatory complex expressed on APCs, thus inhibiting T cell 
activation in a highly suppressive manner (64).  Based on the early expansion of this subset, it is 
possible that these cells are interacting with APCs in the early phase of the sensitization response.  
nTregs are thymus-derived cells whose counterparts are inducible Tregs (iTregs) generated in the 
periphery; nTregs are identified by neuropilin-1 expression (11, 43).  Interestingly, the nTreg frequency 




population (Fig 3.2a C).  This decrease may be attributed to the efflux of cells from the dLN into 
peripheral tissues and/or the influx and expansion of iTregs in the dLN.  Because certain populations 
of Tregs are known to possess migratory capabilities, the Treg phenotyping panel included several 
markers associated with Treg migration and effector capabilities including CCR6, CD103, and ICOS.  
Tregs expressing any or all of these markers were defined as migratory effector Tregs due to the noted 
homing capabilities  and the effector functions (31, 32, 35, 39, 65).  The expansion of Tregs expressing 
CCR6, CD103, and/or ICOS (Table 3.2) may represent subsets that have acquired effector functions, 
such as IL-10 production, and possess migratory capabilities.  Taken together, these findings suggest 
that Tregs likely utilize a variety of suppressive mechanisms as indicated by their phenotypic diversity.  
This could be a potential explanation for why TDI sensitized Tregs were identified as more 
suppressive than their acetone control counterparts. 
These studies reveal an important role for Tregs in a murine model of TDI sensitization.  
Elucidation of the role of Tregs in this response will result in a better understanding of the 
immunologic mechanisms involved chemical sensitization.  Due to the complexity of mechanisms 
involved in chemical allergy, the investigation of novel cellular subsets and mediators of allergic 
disease is imperative for the greater understanding of these conditions and the development of hazard 
identification strategies for respiratory chemical sensitizers.  In conclusion, we have demonstrated 
that Tregs are a phenotypically heterogeneous population that expand, suppress, and play a part in 
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Toluene diisocyanate (TDI) is a potent low molecular weight chemical sensitizer and a 
leading cause of chemical-induced occupational asthma.  The regulatory potential of microRNAs 
(miRNAs) has been recognized in a variety of disease states, including allergic disease; however, 
the roles of miRNAs in chemical sensitization is unknown.  In a previous work, increased 
expression of multiple miRNAs during TDI sensitization was observed and several putative 
mRNA targets identified for these miRNAs were directly related to Treg differentiation and function 
including foxp3 and runx3.  In this work, we show that miR-210 expression is increased in the 
mouse dLN and Treg subsets during TDI sensitization.  Alterations in dLN mRNA and protein 
expression of Treg related genes/putative miR-210 targets (foxp3, runx3, ctla4, and cd25) were 
observed at multiple time points following TDI exposure and in ex vivo systems.  A Treg 
suppression assay, including a miR-210 mimic, was utilized to investigate the suppressive ability 
of Tregs.   TDI derived cells treated with miR-210 mimic had less expression of miR-210 compared 
to the acetone control suggesting other factors, such as additional miRNAs, might be involved in 
the regulation of the functional capabilities of these cells.  These novel findings indicate that miR-
210 may have an inhibitory role in Treg function during TDI sensitization.  Because the functional 
roles of miRNAs have not been previously elucidated in a model of chemical sensitization, these 
data contribute to the understanding of the immunologic mechanisms of chemical induced allergic 









Occupational allergic disease is a significant health burden.  A variety of diseases can be 
caused by workplace chemical exposures, including asthma, conjunctivitis, dermatitis, rhinitis, and 
urticaria (1).  Diisocyanates are a group of highly reactive chemicals characterized by the presence 
of double isocyanate functional groups; many of these chemicals are potent sensitizers and major 
causative agents of occupational allergic disease (2-4).  Toluene diisocyanate (TDI) is frequently 
utilized in the automobile industry and in the manufacture of polyurethane foams, paints, and 
coatings (5-8).  TDI is widely used throughout the United States (U.S.) and around the globe; the 
U.S. Environmental Protection Agency reports that U.S. production and importation of 2-4 and 2-6 
TDI isomers rose above 1 billion pounds in 2006 (6).  The principal routes of human exposure to 
TDI are inhalation and dermal contact (6).  While TDI has generally been classified as a T-helper 
type 2 (Th2) sensitizer, the immune response following exposure is more accurately characterized 
as a mixed Th1/Th2 response in both rodents and humans (1, 2, 9).  Both respiratory and dermal 
sensitization have been documented (7, 10) and can lead to allergic disease once the elicitation 
threshold has been reached.  Skin sensitization is thought to be sufficient for subsequent allergic 
disease of the respiratory tract (7), illustrating the systemic nature of TDI sensitization.  Although 
TDI-induced asthma is an extremely relevant occupational health concern, the pathogenic 
mechanisms of diisocyanate-induced asthma are not fully understood (5) and the identification of 
novel mediators of allergic disease may be necessary to obtain a full and complete understanding of 
the disease.  Because of the clinical significance of and lack of validated identification strategies for 
chemical respiratory sensitizers like TDI (4, 11), it is necessary to investigate and identify functional 
pathways and mechanisms that are involved in TDI sensitization.  Specific understanding of disease 




used in the selection of safe products, the identification of safer alternatives, and preclinical 
biomarker discovery.  
An emerging class of epigenetic regulatory elements that have been the subject of recent 
scientific focus are microRNAs (miRNAs).  These molecules are single stranded, noncoding RNA 
molecules that are approximately 19-23 nucleotides long (12).  They are processed by Drosha and 
Dicer nucleases preceding their mature form (13).  MiRNAs exhibit functional significance though 
posttranscriptional gene regulation due to their ability to bind to the target messenger RNA (mRNA) 
and destabilize and decrease protein translation when in complex with argonaute proteins and the 
RNA-induced silencing complex (RISC).  The seed sequence of a mature miRNA can interact with 
a portion of the target mRNA, typically within the 3’ untranslated region, nucleotide base paring can 
occur, and this may lead to the translational repression or degradation of the target mRNA, 
influencing gene expression.  Recently, it has been shown that miRNAs play a major role in a variety 
of immune responses (14-17).  These emerging regulatory factors have not been functionally 
investigated in the context of chemical sensitization, with the exception of recent work by our group 
that profiled the general expression kinetics of miRNAs involved in TDI sensitization (1) and 
research profiling miRNA expression in both human and murine diphenylcyclopropenone-induced 
dermatitis (18).        
  The identification of increased expression of several miRNAs in the draining lymph nodes 
(dLN) of mice during epicutaneous TDI sensitization prompted further investigation into the 
potential functional roles of these molecules in the allergic response.  Target analysis for these 
upregulated miRNAs revealed several putative and confirmed regulatory T cell (Treg)-related targets 
for miR-21, -22, -27b, -31, -155, -210, and -301a in murine and human genomes (1).  Several 




and CTLA4 are integral to Treg differentiation and function.  The expression of these molecules 
allows this subset to differentiate in response to allergens and exert immune regulatory functions, 
dampening inappropriate inflammatory and adaptive immune responses.  Additional miRNAs 
potentially involved in TDI sensitization have been implicated as regulators of Tregs in a variety of 
contexts including miR-31 and -155 (19, 20).  A role for Tregs has been suggested in models of 
chemical-induced contact hypersensitivity (21, 22) and in a recent manuscript, Long, et al. 
demonstrated the increased expression and functional capability of Tregs during TDI sensitization 
(22).  While the collection of data regarding Tregs and chemical allergy is growing, it is still limited.  
Similarly, data regarding the role of miRNAs in chemical allergy is very limited.  While our data 
suggests an important role for Tregs in dermal TDI sensitization, the interaction between these cells 
and selected miRNAs has not been investigated. While miR-210 is well characterized in the hypoxia 
response, its specific role in allergic disease has not yet been defined.  In the present study we utilized 
a murine model of epicutaneous TDI sensitization in order to elucidate the expression kinetics and 
role of miR-210 and its putative mRNA targets in a murine model of epicutaneous TDI sensitization, 
specifically in relation to the Treg subset.    
 
4.2. MATERIALS AND METHODS 
 
4.2.1. Mice 
Female BALB/c mice (6-8 weeks of age) obtained from Taconic (Germantown, NY), 
acclimated for 5 days, and then randomly assigned to treatment group; homogenous weight 
distribution was insured across treatment groups.  BALB/c mice were selected on the basis of their 




TDI sensitization (1, 23).  Mice were housed in ventilated plastic shoebox cages with hardwood chip 
bedding at a maximum of five animals per cage.  A NIH-31 modified 6% irradiated rodent diet 
(Harlan Teklad) and filtered tap water were administered ad libitum.  Housing facilities were 
maintained at 68-72˚F and 36-57% relative humidity, and a 12 hour light-dark cycle was maintained.  
All animal experiments were performed in the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) accredited National Institute for Occupational Safety and 
Health (NIOSH) animal facility in accordance with an Institutional Animal Care and Use 
Committee-approved protocol. 
 
4.2.2. TDI Sensitization Model 
Toluene 2,4-diisocyanate (TDI, CAS# 584-84-9) was obtained from Sigma-Aldrich 
(Milwaukee, WI).  Animals were exposed to a single dose of 0, 0.5, and 4% TDI (v/v) on the dorsal 
surface of each ear (25 µL per ear).  The chosen TDI concentrations (0.5 and 4% v/v) and dosing 
regimen was previously shown to induce sensitization (1, 22) and 4% TDI was previously reported 
as the minimum single dose concentration of TDI that could induce maximum sensitization in the 
absence of systemic toxicity (1).  Acetone was selected as the vehicle control and has been 
historically utilized in our laboratory to evaluate chemical sensitization (22-24).   
 
4.2.3. Euthanasia, Tissue Collection, and Processing 
Animals were weighed, euthanized via CO2 asphyxation at time points ranging from 1 to 11 
days post chemical exposure, and examined for gross pathology. Left and right auricular draining 
lymph nodes (dLNs; drain the site of chemical application) were collected in 4 mL sterile phosphate-




Cells were counted using a Cellometer (Nexcelom Bioscience, Lawrence, Massachusetts) and size 
exclusion parameters (3.5 to 36 µm) with a combined acridine orange/propidium iodide solution to 
identify viable cells.  For isolation of specific cellular subsets Stemcell magnetic isolation kits 
(Vancouver, BC) were utilized, including the Treg isolation kit (CD4 negative and CD25 positive 
selection).   
 
4.2.4. Ex vivo miRNA Transfection Assays 
Following dLN processing and counting miR-31, -155, and -210 mimics (25 pmol in 
Lipofectamine transfection reagent, ThermoFisher, Waltham, MA) were reverse transfected in flat-
bottom 24-well plates.  1.5 x 106 naïve or acetone-treated dLN cells/mL (in RPMI-1640 media) were 
added to plates followed by general T cell stimulation (2 µg/mL α-CD3, 1 µg/mL α-CD28).  Plates 
were incubated for 72 hours at 37◦C and 5% CO2.  Following a 72 hour incubation, cells were washed 
with RPMI-1640 and RNA was isolated as described in the following section.  RNA was assayed 
for intracellular miRNA expression to conform the intracellular uptake of miRNA mimics as well as 
Treg-related gene expression via RT-PCR.   
 
4.2.5. RNA Isolation, Reverse Transcription, and RT-PCR  
Total RNA was isolated from the ears and dLN using the Qiagen RNeasy and miRNeasy kits 
respectively according to the manufacturer’s directions.  A QiaCube (Qiagen, Hilden, Germany) 
automated RNA isolation machine was utilized in conjunction with the specified RNA isolation kits.  
A DNase treatment was included in the RNeasy protocol for the removal of residual DNA.  The 
concentration and purity of the RNA was determined using a ND-1000 spectrophotometer (Thermo 




strand cDNA synthesis was performed using a High-Capacity cDNA Synthesis Kit (Applied 
Biosystems, Carlsbad, California) according to manufacturer recommendations.  For mature miRNA 
reverse transcription TaqMan MicroRNA Assays (looped-primer RT-PCR; Applied Biosystems, 
Carlsbad, California) were utilized according to manufacturer recommendations (both multiplex and 
singleplex protocols were utilized).   
For analysis of mRNA and primary miRNA expression, TaqMan Universal Fast master mix 
(Life Technologies, Calsbad, California), cDNA, and mouse-specific mRNA primers (TaqMan 
Custom PCR Arrays, Carlsbad, California) were combined and PCR was performed according to 
manufacturer protocol (TaqMan Gene Expression Analysis).  For analysis of miRNA expression, 
TaqMan Universal 2x master mix, No AmpErase UNG (Life Technologies, Calsbad, California), 
cDNA, and mouse-specific miRNA primers (TaqMan Custom PCR Arrays, Carlsbad, California) 
were combined and PCR was performed according to manufacturer protocol (TaqMan miRNA 
Assays both Single- and Multi-Plex).    Primers used include: β-actin, cd25 (il2rα), ctla4, foxp3, 
mature miR-21, -22, -27b, -31, -126, -155, -210, and -301a, primary miR-210, runx3, and sno234.  
MicroAmp Fast Optical 96-well reaction plates were analyzed on an Applied Biosystems 7500 Fast 
Real Time PCR system using cycling conditions as specified by the manufacturer.  β-actin (mRNA 
and primary miRNA) and snoRNA234 (miRNA) were used as the endogenous reference control 
gene as expression was determined to be stable following chemical exposure (data not shown).  RT-
PCR data were collected and represented as relative fold change over vehicle control, calculated by 
the following formula: 2−ΔΔCt = ΔCtSample − ΔCtControl.  ΔCt = CtTarget − Ctβ-ACTIN, where Ct = cycle 






4.2.6. Flow Cytometric Analysis and Treg Phenotyping 
Single cell suspensions were prepared from tissues and a minimum of 150,000 dLN cells 
were aliquoted into 96-well U-bottom plates and washed in FACS staining buffer (PBS + 1% bovine 
serum albumin + 0.1% sodium azide).  Cells were resuspended in staining buffer containing anti-
mouse CD16/32 antibody (clone 2.4G2; BD Biosciences, San Jose, CA) for blocking of Fc receptors 
to minimize nonspecific binding.  Cells were resuspended in staining buffer containing a cocktail of 
fluorochrome-conjugated antibodies specific for cell surface antigens including: CD3 (500A2, 
V500, BD Biosciences, Franklin Lanes, NJ), CD4 (RM4-5, AF700, BD), CD8a (53-6.7, AF488, 
BioLegend, San Diego, CA), CD25 (PC61, APC Cy7, BioLegend), CD45 (30-F11, PE, BD).  
Following surface staining, cells were washed in staining buffer and fixed using the Foxp3 fixation 
buffer set (eBioscience, San Diego, CA).  After overnight incubation in staining buffer, cells were 
permeablilized using the Foxp3 fixation buffer set (eBioscience, San Diego, CA) and re-suspended 
in permeabilization buffer containing a cocktail of fluorochrome-conjugated antibodies specific for 
intracellular antigens including: RUNX3 (R3-5G4, PE, BD), Foxp3 (FLK-16s, eF450 and APC, 
eBioscience, San Diego, CA).  Following staining, cells were re-suspended in staining buffer and 
analyzed on an LSR II flow cytometer using FacsDiva software (BD Biosciences). Data analysis 
was performed with FlowJo 10.0 software (TreeStar Inc., Ashland, OR).  A minimum of 10,000 
events were captured for each sample.  Leukocytes were first identified by their expression of CD45.  
The Treg subset was further identified as CD3+CD4+CD8-CD25+Foxp3+.  Numerical population 
values were calculated by applying subset frequencies to the initial cell count obtained following 
lymph node homogenization.  Compensation controls were performed using single stained cellular 
suspensions and OneComp beads (eBioscience, San Diego, CA) and fluorescence minus one (FMO) 




4.2.7. Treg Suppression Assay 
The suppressive ability of Tregs was analyzed using an ex vivo Treg suppression assay as 
described by Long, et al. (22).  This assay evaluates the ability of naïve, conventional dLN-derived 
T cells (Tcons) to proliferate in the presence of varying numbers of Tregs isolated from acetone- or 
TDI-exposed mice.  Mice were exposed to acetone (n=7-11) or TDI (4%) (n=4-5) as previously 
described and following sacrifice at 7 days post TDI (peak of the expansion) exposure the dLN and 
spleens were removed.  Tregs (CD4+CD25+) and Tcons (CD4+CD25-) were isolated from the lymph 
nodes and CD4- accessory cells were isolated from naïve spleens using CD4 negative and CD25 
positive selection-based magnetic separation kits (Stemcell, Vancouver, BC).  Average Treg purity is 
as follows for 7 days: Acetone-96.5% ± 0.8 of CD3+CD4+ cells and 4% TDI-97.35% ± 0.25 of 
CD3+CD4+ cells.  Following isolation from naïve mouse dLNs, Tcons were labeled with 2 µM 
carboxyfluorescein succinimidyl ester (CFSE).  miR-210 mirVana mimic (2 pmol; ThermoFisher) 
in Lipofectamine RNAiMAX (ThermoFisher) or Lipofectamine only control (LO) were added to a 
96-well U-bottom plate in order to reverse transfect cells.  Tcons and Tregs were cultured in a 96-well 
U-bottom plate with anti-CD3 (0.2 µg/mL; BD Biosciences) and accessory cells (naïve CD4- 
splenocytes treated with Mitomycin C) at a variety of Tcon:Treg ratios (1:1, 2:1, 4:1, and 8:1).  
Additional controls included stimulated Tcons only to assess baseline proliferation, Tregs only, 
accessory cells only, and Tcons only with no stimulation nor accessory cells.  Cells from each 
treatment group were pooled and added to triplicate wells of the culture plate.  72 hours following 
plating, cells were stained with anti-CD4 and Live/Dead Violet (Life Technologies, Carlsbad, CA).  
Tcons were defined as CD4+ CFSE+ cells and suppression was measured based on changes in the 




based on their expression of CD3, CD4, and Foxp3 as determined by flow cytometric analysis as 
previously described.   
 
4.2.8. Statistical Analysis 
Statistical analyses were generated using GraphPad Prism version 5.0 (San Diego, CA).  Data 
was analyzed by a Student t-test comparing groups as indicated in the figure legends.  Figure 4.4 C 
was analyzed by analysis of variance using PROC MIXED. In some cases, data were transformed 
using the natural log to meet the assumptions of the analysis. Significant interactions were explored 
utilizing the “slice” option in PROC MIXED and pairwise differences were assessed using a Fishers 
Least Significant Difference Test. All differences were considered significant at p < 0.05; 




4.3.1. Examination of miR-210 Expression during TDI Sensitization 
The kinetics of mature miR-210 expression were investigated via RT-PCR in the dLN 
following 0.5% and 4% TDI exposure.  As previously reported (1), dLN miR-210 increased at 
various time points during 0.5 and 4% TDI sensitization, including 4 (4%), 7, and 9 (0.5 and 4%) 
days post single exposure, with expression appearing to peak at 4 days post 4% TDI exposure (Figure 
4.1A).  Primary miRNA (pri-miRNA) transcripts represent the early precursor stage of mature 
miRNA structure prior to modification and cleavage by Drosha and Dicer.  Pri-miR-210 levels were 
analyzed in the dLN 4 days post TDI exposure, which represents the relative peak of dLN miR-210 




were observed.  Alternatively, pri-miR-210 expression significantly decreased in the CD4+ subset 
during 4% TDI sensitization (Figure 4.1 B)     
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Figure 4.1 Mature miR-210 expression increases during TDI sensitization 
RT-PCR analysis of mature miR-210 expression in the dLN at various time points post TDI exposure 
(A).  Primary miR-210 expression in the whole dLN and dLN CD4+ subset 4 days post TDI exposure 
(B).  Cellular purity was assessed via flow cytometric staining for CD4+ Cells (% CD4+ of all cells; 
Acetone: 89.6% ± 2.2, 0.5% TDI: 91.5% ± 0.3, and 4% TDI: 90.4% ± 0.3).  Bars represent mean 
relative fold change (± SE) of 3-5 mice per group.  P values are represented by ^ (0.5% TDI) and * 
(4% TDI) (P<0.05).  Dermal treatment groups are indicated by the following symbols: circle- 








4.3.2. Ex vivo miR-210 Mimic Transfection Reveals Potential Inhibitory Effect of miR-210 on 
Treg-related Genes 
Due to the putative link between miR-210 and Treg-related targets in both human and mouse-
based studies and target algorithms (1), an ex vivo transfection and stimulation assay was set up to 
directly examine miR-210 and Treg-related gene expression.  Analysis of Treg-related gene expression 
induced by the addition of excess levels of miR-210 was examined.  Although not statistically 
significant, Figure 4.2 A reveals increased miR-210 expression in cells treated with miR-210 mimic 
(101 fold) as compared to lipofectamine only (LO) control (1.2 fold).  Analysis of Treg-related genes 
revealed decreased trends of expression of Treg-related genes following miR-210 mimic transfection 
compared to the LO control, including foxp3 (~ -2.0 fold compared to 0.6 fold) and cd25 ((~ -3.2 
fold compared to 0.2 fold) (Figure 4.2 B)).  No apparent changes in runx3 nor ctla4 were observed 
(data not shown).    
 



































































Figure 4.2 Ex vivo Data Reveals Potential Inhibitory Effect of miR-210 on Treg-related Genes  
 
Intracellular miR-210 (A) was quantified via RT-PCR in ex vivo stimulated samples 72 hours 




cd25 (il2rα) were investigated as potential miRNA targets via RT-PCR.  Bars represent mean 
relative fold change (± SE) of 3 replicates per group.  Data represents two independent 
experiments.   
 
 
4.3.3. In vivo dLN Target Expression Reveals Decreased Expression of Several Key Treg-related 
Genes 
The expression of potential miR-210 targets and key Treg genes potentially affected by miR-
210 was investigated in the whole dLN at various time points following 4% TDI exposure.  Similar 
to the findings of the ex vivo study and previously reported findings, dLN target/key player mRNA 
expression was significantly decreased at 4 (runx3), 7 (foxp3), and 9 (foxp3) days post 4% TDI 
exposure (Figure 4.3 A and B).  Foxp3 expression was decreased by approximately threefold in 
comparison to the acetone control at 7 and 9 days post TDI exposure (Figure 4.3 A). Early 
statistically significant increases in foxp3 (1day) and run3 (2 day) were also observed but only for a 
single time point and not determined to be of biological significance.  dLN ctla4 and cd25 expression 
significantly increased with peak expression at 4 and 2 days post 4% TDI exposure, respectively.  
However, these increases in expression were not maintained at later time points (Figure 4.3 C and 
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Figure 4.3 In vivo Target mRNA Expression 
RT-PCR analysis of foxp3 (A), runx3 (B), ctla4 (C), and cd25 (D) expression in the whole dLN at 
various time points post 0 and 4% TDI exposure.  Bars represent mean relative fold change of 5 mice 








4.3.4. Treg-Specific miRNA and Gene Expression  
Due to the suspected influence of miR-210 on Tregs the levels of this miRNA were examined 
in Tregs (CD4+CD25+) from the dLN of mice treated with 0, 0.5, and 4% TDI at 2 and 7 days post 
exposure.  These time points were selected to reflect early and peak miR-210 and Treg responses in 
the dLN (Figure 4.1 A and (1)).   While no statistically significant changes were observed following 
2 days of exposure, miR-210 levels were significantly increased in Tregs during 0.5 and 4% TDI 
sensitization in a dose responsive fashion at 7 days post exposure (Figure 4.4 A).  Expression of Treg-
related genes was also examined in isolated Tregs following TDI exposure.  Significant decreases in 
foxp3, ctla4, runx3, and cd25 were observed at both concentrations (except for ctla4 at 4%) at 2-
days post exposure.  Similarly, significant decreases in foxp3, ctla4, and cd25 mRNA were observed 
in Tregs from 4% TDI-exposed mice at 7 days post 4% TDI exposure (Figure 4.4 B), further indicating 
that these genes may be influenced by miRNA (Figure 4.1 A).  Treg-specific expression of Runx3 
was assayed in dLN Tregs during TDI sensitization.  In contrast to the mRNA levels, increases in 
frequency and numbers of Runx3+ Tregs at all time points were observed following 0.5 and 4% TDI 















































































    




























































































































































































Figure 4.4 Mature miRNA expression increases in Tregs during TDI sensitization 
RT-PCR analysis of -210 (A and B) and Treg–related gene (C and D) expression in the dLN Treg 
subset at 2 and 7 days post TDI exposure.  Tregs were isolated as CD4+CD25+  cells and cellular purity 
was assessed via flow cytometric staining for CD3+CD4+Foxp3+ events (2 days: % Tregs of all CD4+ 
events, mean, n=4-5 per group: Acetone: 83.8% ± 1.6, 0.5% TDI: 67.1% ± 4.2, and 4% TDI: 72.3% 
± 1.9; 7 days: % Tregs of all CD4+ events, one representative sample: Acetone: 91%, 0.5% TDI: 
88.4%, and 4% TDI: 86.7%).  Flow cytometric analysis of dLN Runx3+ Treg frequency and number 
(C) following TDI sensitization.  Bars represent mean relative fold change (± SE) of 4-5 mice per 
group.  For A and B, P values are represented by ^ (0.5% TDI) and asterisks (4% TDI) (P<0.05).  
For C, Significance is indicated as follows: P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 
(****) for 4% TDI or P ≤ .05 (^), P ≤ .01 (^^), P ≤ .001 (^^^), and P ≤ .0001 (^^^^) for 0.5% TDI.  
Dermal treatment groups are indicated by the following symbols: circle- acetone, square- 0.5% TDI, 
and triangle- 4% TDI.  
 
4.3.5. The Ex Vivo Suppressive Capability of Tregs is Influenced by miR-210 Levels 
In order to examine the suspected inhibitory role of miR-210 on Tregs during TDI 
sensitization, the functional capabilities of Tregs were tested in an ex vivo suppression assay.  miR-
210 mimic was transfected in selected wells utilizing a lipid-based transfection strategy and 
intracellular miR-210 mimic uptake was confirmed in these wells at the time of cellular harvest 
(Figure 4.5 A).   Interestingly, following addition of the miR-210 mimic, miRNA-210 levels were 
almost 10-fold higher in wells containing acetone Tregs compared to those with TDI Tregs (Figure 4.5 
A).  No differences were noted between miR-210 levels among the acetone and TDI groups treated 




Lipofectamine onle and acetone-derived Tregs as well as 4% TDI-derived Tregs (data not shown).  This 
was not altered significantly upon the addition of miR-210 mimic with the exception of the 1:1 ratio 
in wells with 4% TDI-derived Tregs (data not shown).  As previously evidenced (22), TDI-derived 
Tregs exhibited greater suppressive capability than acetone-derived Tregs in mimic-treated wells for the 
1:1, 2:1, 4:1, and 8:1 ratios (Figure 4.5 B).    This increased function was observed in the presence 
of lower miR-210 levels suggesting that TDI might induce additional factors that might influence 



























































































Figure 4.5 Increased Treg Suppression is Associated with Decreased miR-210 levels  
A CFSE-based Treg suppression assay was performed with Tregs from mice treated with acetone or 
TDI (7 days post exposure) and the addition of miR-210 mimic.  RT-PCR analysis of intracellular 
miR-210 expression (A) in pooled wells from each indicated group was performed (one replicate 
from each ratio was included for the 1:0, 1:1, 2:1, and 4:1 Tcon:Treg ratios.)  A CFSE-based Treg 
suppression assay with the addition of miR-210 mimic was performed and percent dividing CFSE+ 
cells were quantified (B).  For (B) 3 plate replicates were utilized from groups of 5-10 mice, as 
described in section 4.2.  P values are represented by asterisks (P<0.05; comparison of each 
treatment group to Tcon only from the same chemical treatment group) or horizontal bars with 
asterisks above (comparison of identical ratios between different LO/mimic treatment groups).  Bars 
represent mean relative fold change (± SE) of 3 replicates per group.  P values are represented by 
horizontal lines and asterisks (P<0.05).   
 
4.3.6. Further Investigation of miR-31 and -155 Suggest Additional Regulation of the TDI 
Sensitization Response, Potentially Impacting miR-210 and Tregs 
Evaluation of additional miRNAs was performed in an attempt to identify other potential 
factors that might influence miR-210 and Treg function.  MiR-31 and -155 were selected since they 
have been identified to significantly increase in dLN expression earlier in TDI sensitization 
compared to miRNA-210 (Figure 4.6 A and B).  Ex vivo target analysis was performed utilizing 
additional miRNA mimics including miR-31 and -155 in order to further pursue the potential 
regulation of the Treg subset by these miRNAs in addition to miR-210.  Significantly increased 
intracellular levels of -31 (Figure 4.6 C) and -155 (Figure 4.6 D) were confirmed 72 hours following 




expression were observed following miR-31 (Figure 4.6 E) and -155 (Figure 4.6 F) mimic 
transfection.  No changes in expression were observed for runx3, ctla4, or cd25 following mimic 
addition (data not shown).   
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Gene - Treatment  
Figure 4.6 In vivo dLN miR-31 and -155 Levels Increase During TDI Sensitization  
 
Whole dLN miR-31 (A) and -155 (B) levels were quantified via RT-PCR at various time points 
post TDI sensitization.  Intracellular miR-31 (C), -155 (D) was quantified via RT-PCR in ex vivo 
stimulated samples (with miR-31 or -155 mimic addition, respectively) after 72 hours.  In D-F 
foxp3 expression was investigated in cultures following miR-31 (D) and -155 (E) mimic 
treatment.  Bars represent mean relative fold change (± SE) of 3 replicates per group.  P values 
are represented by ^ (0.5% TDI) and * (4% TDI) (P<0.05).   
 
Treg-specific expression of miR-31 and miR-155 were also analyzed, revealing increased 
miR-31 levels 2 and 7 days post 0.5% TDI exposure (Figure 4.7 A) and increased miR-155 levels 7 
days post 4% TDI exposure (Figure 4.7 B).  Since miR-31 was identified to increase in expression 
earlier than miR-210 in the dLN and Tregs, miR-210 expression was evaluated in dLN cells treated 
with 31 and 155 mimics.  However no changes in expression were observed.  Similarly, expression 
of miR-31 and -155 was analyzed in cells treated with -210 mimic but no significant changes in 












































































































































































































Figure 4.7 Mature miR-31 and -155 expression increases in Tregs during TDI sensitization 
RT-PCR analysis of miR-31 (A) and -155 (B) expression in the dLN Treg subset at 2 and 7 days post 
TDI exposure.  Tregs were isolated as CD4+CD25+  cells and cellular purity was assessed via flow 
cytometric staining for CD3+CD4+Foxp3+ events (2 days: % Tregs of all CD4+ events, mean, n=4-5 
per group: Acetone: 83.8% ± 1.6, 0.5% TDI: 67.1% ± 4.2, and 4% TDI: 72.3% ± 1.9; 7 days: % Tregs 




86.7%).  Bars represent mean relative fold change (± SE) of 4-5 mice per group.  P values are 




The occupational use of sensitizing chemicals such as TDI remains a significant public health 
concern.  There are no validated hazard identification strategies for respiratory sensitizers like TDI 
and the complete immunologic mechanisms of sensitization have not been elucidated for these 
agents, hindering development of appropriate preventative assays.  This justifies research pertaining 
to the identification of novel cellular subsets and epigenetic regulatory mechanisms such as miRNAs 
that may be involved in the respiratory chemical sensitization process.  Following the identification 
of several upregulated dLN miRNAs during TDI sensitization, these molecules were investigated 
during this response, specifically in relation to Treg development and functionality.  To our 
knowledge, this is the first work that functionally investigates miRNAs in a model of Th2-mediated 
chemical sensitization. 
miRNAs are powerful regulatory molecules which have been implicated in a number of 
immunologic states and conditions, including allergic disease (25-27).  Specifically, miR-155 has 
demonstrated a critical role in the development of antibody responses and germinal center function 
(28), miR-326 has been shown to regulate Th17 differentiation, exhibiting critical involvement in 
multiple sclerosis pathogenesis (29), and in vivo miR-126 inhibition reduces a house dust mite-
induced asthmatic phenotype, demonstrating the importance of this miRNA in the regulation of Th2 
responses and allergic asthma (25).  Vennegaard, et al. described upregulation of several miRNAs, 
including miR-21, in skin biopsies from patients with allergic responses to diphenylcyclopropenone 




Additionally, previous work from our groups identified upregulation of several miRNAs, including 
miR-31, -155, and -210, in a murine model of epicutaneous TDI sensitization (1). These ubiquitous 
signaling molecules are well-established mediators of many of signaling pathways in a number of 
cell types; however, their role in chemical sensitization is not well understood.  For the work 
described in this manuscript, miR-210 was selected for additional investigation since it has been 
predicted and demonstrated to target Treg-related genes.  In addition, its role in chemical sensitization 
and Treg regulation has not yet been described. 
The expression of miR-210 was quantified in a variety of tissues and cellular subsets in a 
murine model of TDI sensitization.  Consistent with previous findings (1), increased expression of  
miR-210 in the dLN was also demonstrated in the present study during TDI sensitization (Figure 4.1 
A).  In addition, increased expression of miR-210 was also identified in Tregs during TDI sensitization 
(Figure 4.4 A).  Since miRNA can be transported to cells via mechanisms such as exosomal 
transport, experiments to determine if cells are actively producing miR-210 following TDI exposure 
were conducted. The expression of pri-miRNA indicates gene level expression, presumably within 
the cell type tested.  Pri-miR-210 was detected in the dLN and CD4+ subsets 4 days post TDI 
exposure (Figure 4.1 B), indicating that miR-210 is being expressed in this tissue by CD4+ T cells.  
Interestingly, although they were detectable, pri-miR-210 levels significantly decreased in CD4+ T 
cells 4 days post 4% TDI exposure compared to equivalent cells in acetone-exposed mice, potentially 
indicating that the majority of mature miR-210 in the dLN is being produced by another cell type, is 
being transported from another tissue, or is being transcriptionally downregulated at this point, the 
peak of mature miR-210 levels in the dLN.  While pri-miR-210 levels in Tregs were not investigated 
in the current study, previous studies have demonstrated miR-210 expression following the 




Since Tregs have been implicated as regulators of TDI sensitization (22) and miR-210 
expression has been shown to increase in Tregs following TDI sensitization (Figure 4.4 A), an ex vivo 
target analysis system was designed in order to directly examine the effects of miR-210 on Treg-
related genes.  Selected genes included foxp3, the master transcription factor of the Treg subset and 
runx3, a transcription factor that signals upstream of foxp3 by binding to this gene’s promoter (31) 
and identified as a potential direct target of miR-210.  Additionally, cd25 and ctla4 were investigated 
as important Treg-related genes as they are involved in IL-2 signaling and proliferation along with 
direct suppressive functions, respectively.  This setup revealed a potential role for miR-210 in the 
downregulation of Treg-associated genes (foxp3 and cd25; Figure 4.2 B) following the addition of 
miR-210 mimic.  In addition foxp3 and runx3 dLN expression decreased in the dLN at various time 
points following TDI exposure (Figure 4.3 A and B) which is consistent with our previously reported 
findings (22).  The earlier decrease in runx3 expression observed at 4 days post 4% TDI exposure 
may be reflective of the upstream signaling activity of this transcription factor in relation to foxp3 
(Figure 4.3 B).  While the findings for the ex vivo assay did not reach statistical significance, further 
support for Treg-associated genes as miRNA targets was provided by in vivo data. Interestingly whole 
dLN expression of ctla4 and cd25 increased at 1, 2, and 4 days post 4% TDI exposure (Figure 4.3 C 
and D) which is likely a reflection of the activation of both Tregs and conventional T cells as elevated 
protein expression of these molecules is observed in Tregs at these time points (22) and would likely 
be increased in conventional T cells involved in TDI sensitization as well.  In Tregs, decreases in 
foxp3, cd25 and ctla4 were observed at 2 and 7 days with runx3 only being decreased at the earlier 
time point post TDI exposure (Figure 4.4 B).  These early changes in Treg factors provide further 
support that additional factors might be involved in Treg regulation since peak increases in miR-210 




to the transcript, the expression kinetics of Runx3 increased following TDI exposure (Figure 4.4 C).  
This expression pattern was similar to other Treg proteins such as CD25 and Foxp3 (which are 
represented by the general Treg population) and Treg-specific CTLA4 expression which have 
previously been investigated during TDI sensitization (22).  The kinetics of Tregs bearing these 
molecules tended to peak at 4 days post TDI exposure with a relative decrease in both cellular 
frequency and number at 7 days post TDI exposure (22).  In relation to miR-210 expression kinetics, 
this data may suggest that miR-210 has a regulatory role on the Treg subset, as its expression wanes 
in concert with the general Treg population as well as CTLA4+ and Runx3+ Tregs.  Additionally, miR-
210 is a putative runx3 target, suggesting a potential direct effect on this gene (1).  Collectively, this 
data is suggestive of Treg regulation with visible effects on the expression of proteins beginning at 
day 7 post TDI exposure.  miR-210 expression remains elevated in the dLN throughout 9 days post 
0.5 and 4% TDI exposure (Figure 4.1 A) and in Tregs at 7 days post 0.5 and 4% TDI exposure (Figure 
4.4 A).   
Due to the potential link between miR-210 and Treg-related gene expression, the functional 
capabilities of Tregs (acetone and TDI -derived) were examined in the presence and absence of miR-
210 mimic.  Interestingly, it appeared that miR-210 levels were lower in wells containing Tregs from 
TDI-treated mice and miR-210 mimic compared to wells with acetone-derived Tregs and miR-210 
mimic (Figure 4.5 A).  The increased suppressive capability of TDI Tregs with miR-210 mimic 
(Figure 4.5 B) may be a reflection of reduced miR-210 levels, as we hypothesize that miR-210 is 
inhibiting Treg differentiation and/or function.  This finding suggested that other regulatory factors 
including other miRNAs might be involved in the regulation of Treg function.  Complex interactions 
and interplay have often been reported for other miRNAs (32), therefore this concept was evaluated 




complementary binding, resulting in the formation of duplexes (32).  Additionally, indirect miRNA-
miRNA interaction may occur via target gene interaction; e.g. if a miRNA targets a gene that induces 
a different miRNA, this miRNA is being regulated by its own species.  
miRNA-31 and-155 were further investigated for the potential to regulate the expression of 
miR-210 as they were identified to increase at early time points in TDI sensitization in the dLN 
(Figure 4.6 A (miR-31) and B (miR-155)) and Tregs (Figure 4.7 A (miR-31)).  Similarly to miR-
210, miR-31 and -155 were shown to potentially downregulate foxp3 expression in this assay (Figure 
4.6 E and F).  Although limitations in the assay sensitivities did not reflect significant changes, this 
may be reflective of a direct effect on foxp3 or an indirect effect on this gene via other signaling 
pathways such as miR-210.  These alterations are in accordance with recent findings pertaining to 
miRNA-mRNA interactions.  miR-31 may indirectly target foxp3, leading to suppressed iTreg 
development (20), accounting for the potential decreases in this gene evidenced following miR-31 
mimic transfection.  Also miR-31 increases earlier when more persistent decreases in foxp3 were 
observed.  Additionally, miR-155 expression appears to be controlled by foxp3 in Tregs via binding 
to the intron within the DNA sequence encoding Bic, the precursor transcript of miR-155; 
accordingly, Treg miR-155 levels have been shown to be highly responsive to foxp3 levels (33).  This 
regulation may be interrupted by abnormally high levels of miR-155 in the mimic transfection 
system, resulting in decreased foxp3 expression in these conditions via signaling feedback.  This 
data suggests that miR-31 and -155 may be influencing the expression of miR-210 and/or Tregs, 
possibly acting as early signaling mediators in the TDI sensitization response.    
The lack of significance associated with the ex vivo experiments conducted in this work could 
be a reflection of experimental variability associated with similar assays and temporal discrepancies 




utilization of the in vivo TDI sensitization model in the target investigation as well.  The Treg-related 
gene alterations that were observed as a consequence of miRNA mimic transfections in this system 
may indicate direct and/or indirect targeting by the miRNA.  We propose that for the majority of 
miRNA-mRNA interactions investigated in our model, regulation is indirect, as few, if any, putative 
binding sites were identified for many of the potential targets and the corresponding miRNA.  For 
example, miR-210 is predicted to target the 3’ UTR of runx3 (1) and although we did not observe 
significant alterations in runx3 expression following miR-210 mimic transfection in our ex vivo 
system, the in vivo expression kinetics of runx3 suggest potential regulation.  The ubiquitous nature 
of miRNAs and their involvement in various signaling processes accounts for their functional 
significance but can also cloud investigations into their mechanistic functions. 
It is important to note that the increases in miRNA expression were not dependent on the 
irritant response, as dLN miR-210 levels significantly increased (Figure 4.1 A) following the non-
irritating (22) 0.5% TDI exposure.  As 4% TDI exposure causes significant dermal irritation (22), 
ear miR-210 expression was analyzed at both non-irritant (0.5%) and irritant (1, 2, and 4%) TDI 
concentrations, revealing significant increases in dLN and ear expression at both non-irritant and 
irritant does (A 4.1 A).  In addition other miRNAs including miR-22, -31, and -301a were also shown 
to increase significantly in expression regardless of the irritant status of the TDI dose (data not 
shown).  This data prompts insight into the concept of the “two-signal” sensitization hypothesis 
which states that antigen delivery alone is insufficient for effective immunological priming but rather 
a second, innate signal is necessary to ensure the development of sensitization (34, 35).  As noted in 
previous studies, the irritant response appears to be a prerequisite for strong sensitization responses 
in the case of dermal TDI sensitization (22).  Regardless, the expression of multiple miRNAs in the 




irritant component of this response, which may be revealing as to their supposed functional roles in 
the sensitization response and may suggest potential utility as biomarkers of sensitization. 
These studies reveal a potential role for miR-210 in a murine model of dermal TDI 
sensitization.  Additionally, miR-31 and miR-155 were investigated for their regulatory potential in 
this response.  The investigation of novel mediators of chemical-induced allergic disease is important 
for the overall understanding of the mechanisms involved in these responses.  Therefore, this data 
may result in enhanced understanding of the mechanisms involved in chemical sensitization and 
could potentially aid in the development of hazard identification strategies for respiratory chemical 
sensitizers.  In conclusion, we have demonstrated that miR-210 may negatively influence the 
differentiation and/or function of Tregs via direct targeting of runx3 and/or indirect actions on other 
Treg-related genes. These findings suggest that these miRNAs may work in concert to affect the 
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5.1 Introduction  
Recent increases in the global burden of allergic disease have prompted study into the 
underlying immunologic mechanisms of these conditions.  Encompassing a wide variety of 
conditions, the umbrella of allergic disease may include asthma, contact dermatitis, eczema, 
folliculitis, hypersensitivity pneumonitis, rhinitis, and urticaria.  Although many factors may 
contribute to the development of allergic disease, including atopy, environmental exposures, 
epigenetics, genetics, and stress, occupational exposures are a major cause of allergic disease.  It is 
evident that exposure to a variety of substances via multiple routes of exposure can lead to allergic 
disease, illustrating the significant breadth of occupational allergic disease.   
While protein and metal allergens are important causative agents of allergic disease, this 
work focuses on TDI, an organic LMW chemical agent of allergic disease.  In general, LMW 
chemical allergens are diverse and encompass a wide variety of chemical structures and are utilized 
in a number of industries worldwide (Table 1.1).  While it may be easy to imagine significant 
chemical exposure as a factory worker in a chemical plant, these exposures may occur in virtually 
any industry.  Many disinfectants utilized in the healthcare and cosmetology industries are known to 
cause asthma and contact dermatitis (e.g. eugenol, glutaraldehyde, ortho-phthalaldehyde (OPA), 
quaternary ammonium compounds) or may augment existing allergies (e.g. triclosan).  Many of 
these chemicals are found in consumer products such as antimicrobial coatings and cleaning 
products, further illustrating the ubiquity of these products and potential for exposure.     
As eloquently summarized by TV Rajan, the term “allergy” was initially utilized to identify 
both immune responses that were protective and deleterious to the host; this concept was also initially 
applied to the term “hypersensitivity” which was used to indicate the [typically] protective response 




“hypersensitivity” as a host-deleterious response with an allergic component is illustrated in the Gell 
and Coomb’s hypersensitivity classification (Table 1.1).  In this context, the Gell and Coomb’s 
classification is largely accurate, yet non-inclusive for a wide variety of reactions, particularly those 
caused by chemicals, metals, and drugs.  In line with the origins of the term “hypersensitivity”, the 
four types of reactions classified by Gell and Coombs may be attributed to overarching mechanisms 
originating from those utilized by the immune system during pathogen defense (1).  This view, 
proposed by TV Rajan, is based on the idea that immune reactions likely arose for host-protective 
reasons rather than solely to cause harm to the host, as seems to be the case when allergy is viewed 
from a separate origin from pathogen defense strategies (1).  This understanding may aid in the 
interpretation of each reaction and appropriate revisions that could possibly be made to the 
classification, in light of the dramatically altered landscape of immunological knowledge.  
Essentially, the inappropriate activation and/or execution of these “protective” mechanisms may 
result in host-deleterious conditions.  Type I hypersensitivity is characterized by IgE and mast cell 
activation; this reaction may have initially developed as a parasite-defense mechanism, indicated by 
similar IgE-mediated mechanisms and expulsive strategies manifested in symptoms such as 
vasodilation and mucin production (1).  Type II hypersensitivity is characterized by complement 
activation (due to antibody-antigen recognition) and neutrophil invasion and these mechanisms are 
involved in extracellular pathogen clearance (1); antibody opsonization is a classic mechanism of 
pathogen clearance as is complement activation and neutrophil recruitment.  The main effector 
mechanisms of type III hypersensitivity reactions are the formation of antibody-antigen complexes, 
deposition of these complexes in tissue, and complement and neutrophil recruitment (1); these 
mechanisms are proposed to be based on viral clearance strategies.  Type IV hypersensitivity is 




destruction and conditions such as contact dermatitis and diabetes mellitus (1).  This reaction is 
thought to be an inappropriate manifestation of both viral and intracellular bacterial host clearance 
strategies, which commonly involve the same effector cellular subsets.  A strong epidemiological 
link has been noted between respiratory virus infection and asthma risk, suggesting that these 
conditions may share common risk factors and mechanisms (2).  The inverse is also true; atopy has 
also been associated with increased severity of respiratory viral infections and wheezing (2).  These 
associations emphasize both the common underlying mechanism of each condition as well as the 
potential common evolutionary origins of each disease state.    
While viewing hypersensitivity reactions in light of their proposed evolutionary origins is 
helpful for the understanding of the mechanisms involved, there remains uncertainty regarding the 
validity of Gell and Coomb’s classification in the context of new immunological insights into both 
allergic disease and pathogen defense.  For many conditions, the current parameters of Gell and 
Coombs do not provide an accurate classification.  These conditions include hypersensitivity 
pneumonitis and certain instances of chemical-induced asthma (3).  The pathogenesis of 
hypersensitivity pneumonitis is similar to “traditional” atopic asthma (which is typically considered 
a Type I hypersensitivity reaction) in many ways, yet several key differences exist.  Neutrophilia, 
alveolitis, Th1 involvement, and eventual fibrosis are all important components of hypersensitivity 
pneumonitis reactions that may not be present in conventional asthmatic responses (4).  The acute 
phase of hypersensitivity pneumonitis can be summarized as an inflammatory process characterized 
by non-atopic neutrophilic inflammation caused by small organic particles, generally, nonspecific 
airway hyperreactivity and mucus production are not observed during this reaction as is typically 
they case with atopic asthma (4).  The chronic symptoms associated with hypersensitivity 




granulomas along with fibrosis of the alveoli and bronchioles (4).  These pathological features differ 
from those associated with atopic asthma, clearly delineating these two conditions.  Hypersensitivity 
pneumonitis has been considered both a Type III and IV hypersensitivity reaction due to the 
formation of IgG-antigen complexes and the involvement of CD8+ and Th1 cells, respectively (4, 5).  
It is important to note that, while hypersensitivity pneumonitis exhibits features of multiples 
classifications of hypersensitivity, leading to potential misunderstanding of the underlying 
mechanisms of disease.  This condition may warrant its own subtype of hypersensitivity, due to its 
shared, yet unique characteristics.  In either case, it is important to note that this condition transcends 
the Gell and Coomb’s classification by encompassing multiple reactions at once.     
Many cases of chemical-induced asthma cannot be accurately classified utilizing the Gell 
and Coomb’s system.  Specifically, diisocyanate-induced asthma exhibits immunologic and clinical 
features that are not accurately summarized by any of the four types of hypersensitivity reactions 
individually.  While diisocyanate-induced asthma shares several commonalities with type I 
hypersensitivity reactions including eosinophilia, Th2-involvment, and clinical features of asthma, 
many other distinguishing characteristics do not fit within this classification.  Neutrophil 
involvement, a Th1 component, IgG involvement, and the contested role of IgE are all components 
of diisocyanate-induced asthma that contribute to hypersensitivity classification uncertainty.  
Diisocyanate-induced asthma also shares similar features with hypersensitivity pneumonitis such as 
neutrophilia, Th1, CD8+ T cell, and IgG involvement, yet clinical symptoms are significantly 
divergent.  LMW chemical-induced asthma seems to be related to both atopic asthma and 
hypersensitivity pneumonitis while remaining a unique entity.  It may be classified as a mixed type 
I and IV response; however, this does not account for the condition as a whole.  Additionally, as 




mechanisms of sensitization in perspective when setting classification guidelines for allergic 
reactions.  With the investigation of additional mediators of allergic disease such as novel T cell 
subsets, this predicament will likely be amplified.  This work identified the potential involvement of 
Tregs and Th17 cells in TDI sensitization, and although the functional roles of these cells need to be 
investigated further, particularly in the elicitation phase, these subsets are not addressed in the current 
classification.           
When evaluating Gell and Coomb’s classification in the context of modern immunologic 
knowledge, it is important to consider all significant aspects of each hypersensitivity reaction without 
getting “bogged down”.  All hypersensitivity reactions are unique in some way; therefore, emphasis 
of less functionally-relevant mechanisms may result in an overly complicated classification system, 
defeating the entire purpose of the system.  Gell and Coomb’s classification has withstood the test 
of time remarkably well, considering the massive influx of data and knowledge gained regarding 
hypersensitivity reactions.  With this in mind, I propose a reevaluation of the current classification 
system, potentially resulting in further sub-classification of current types of hypersensitivity along 
with novel types of hypersensitivity reactions.  The current sub classification of Type IV reactions 
is a poignant example of the potential diversity of reactions that fall in the same classification.  
Divided based on the cytokine milieu and effector cells present, four Type IV subclasses have been 
described (6) and these descriptive groupings aid in the understanding of each unique reaction.  
Following a basic survey of each of the four types of hypersensitivity reactions, the possible 
subcategorization of each type could be useful.  In light of the known role of relatively new mediators 
such as Th17 cells, this reevaluation would serve as an update to the current system, potentially 
aiding student and clinicians in the understanding of these conditions.  This also brings to light the 




of the underlying mechanisms of hypersensitivity reactions may result in the re-classification of 
certain poorly understood conditions or the formation of novel types of hypersensitivity.  Overall, 
the Gell and Coomb’s classification system remains valid for a number of conditions but others 
remain un-classifiable with the current system.  This should be taken into consideration by 
researchers and clinicians alike, as further investigation into the immune effectors of hypersensitivity 
reactions is needed and the current system should be interpreted with care.     
LMW chemical allergens are an occupationally relevant class of compounds that are 
responsible for a variety of allergic diseases, perhaps the most notable being asthma and contact 
dermatitis.  LMW chemical allergens are generally characterized as dermal (Th1) or respiratory 
(Th2) sensitizers, depending on the type of disease they elicit.  While this classification is technically 
valid for some sensitizers, it is confusing in many cases.  Certain LMW chemical sensitizers like 
TDI may elicit asthma following respiratory and/or dermal sensitization, yet this chemical is known 
as a respiratory sensitizer.  This is a misnomer because although TDI exposure primarily causes 
respiratory disease, sensitization may occur by the dermal route.  TDI may be more accurately 
classified as a systemic sensitizer and a respiratory allergen.  Furthermore, respiratory sensitizers are 
generally associated with a Th2-dominant response with contact sensitizers being linked to Th1-
dominant mechanisms.  TDI induces a mixed Th1/Th2 response in both animal models and humans, 
further emphasizing the ambiguous nature of the current nomenclature.  Nevertheless, there are no 
validated hazard identification strategies for LMW chemicals that are capable of causing respiratory 
allergic disease.  This suggests that further research is necessary to elucidate the mechanisms of 
LMW chemical-induced sensitization and elicitation in both animal models and humans. 
With recent expansions of immunology knowledge, specifically relating to novel mediators 




study.  Some novel mediators include ILCs, miRNAs, and additional Th subsets.  Currently, the 
general understanding of the mechanisms of chemical sensitization are sometimes defined by the 
Gell and Coombs classification; typically, dermal sensitizers are considered Type IV inducers and 
respiratory sensitizers are considered Type I inducers.  This may be appropriate for certain 
sensitizers; however, many LMW chemicals induce responses that do not fit within these categories.  
TDI is an example of this conundrum, as previously described.  This work identifies several novel 
immunoregulatory elements as being potentially involved in TDI sensitization.  The suppressive role 
of Tregs is demonstrated both ex vivo and in vivo, the increased presence of Th17 cells is documented, 
and a potential immunomodulatory role for miR-210 is identified in this work.  This data reveals the 
involvement of several T cell subsets along with epigenetic mechanisms that have been understudied 
in the context of chemical sensitization and allergy.  Additionally, our lab has investigated the 
phenotype of ILCs during TDI sensitization, revealing increased activation of dermal ILC2s at 1-9 
days post single TDI exposure (data not shown).   While the role of these cells remains to be 
elucidated during the elicitation phase of allergy, the identification of these mediators during the 
sensitization response provides valuable mechanistic insight into the key events that take place prior 
to the establishment of the allergic threshold.  Many additional innate and adaptive immune 
modulators need to be studied in models of chemical allergy including T cell subsets (e.g. Th9, Th22, 
and TFH cells), ILCs, and epigenetic factors.  Pertinent investigations will result in the expansion of 
current knowledge regarding immune mechanisms responsible for chemical allergy and may 
ultimately aid in the development of preventative and therapeutic strategies to combat disease caused 
by these agents.   
With the increasing immunologic perspective into the mechanisms of chemical sensitization, 




development of hazard ID strategies to differentiate respiratory and contact sensitizers.  Because the 
Gell and Coomb’s classification does not take into account the mixed responses that are observed 
during both types of sensitization, it is important to define common effector mechanisms and 
biomarkers of sensitization in order to utilize methods like T cell phenotyping and cytokine profiling 
along with the LLNA.  Although much remains to be investigated regarding these responses, the 
growing body of experimental data is adding to our knowledge of the mechanisms underlying 
chemical sensitization and this can only enhance efforts to develop predictive assays for chemical 
sensitizers.    
   
5.2 TDI Sensitization 
TDI sensitization may occur via the skin or respiratory tract and is due to the coordinated 
action of innate and adaptive immunological cells and mediators (7), some of which have, 
presumably, not yet been identified nor investigated.  TDI sensitization may be viewed as a systemic 
event, illustrated by the ability of dermal sensitization to lead to asthma following a single respiratory 
exposure post sensitization.  According to the most recent compilation of experimental data, the TDI 
sensitization response is initiated by penetration of TDI through the stratum corneum and other 
dermal structures (e.g. hair follicles and sebaceous glands) followed by the haptenation of self-
proteins with TDI molecules.  This event emphasizes the reactivity of the isocyanate groups on TDI 
molecules and serves as the mechanism responsible for the formation of a TDI-protein complex that 
can be recognized by APCs, initiating the adaptive immune response.  The unique formation of 
hapten complexes may be a critical determinant of the downstream immunological mechanisms 
involved in LMW chemical allergy; however, further investigation is needed regarding this subject.  




chemokine expression induced by danger signals and skin irritation.  In mice, three primary dendritic 
cell types are purported to be involved in chemical sensitization, including Langerhans cells 
(Langerin+CD103+), and two additional subsets of dermal dendritic cells (Langerin-CD103- and 
Langerin+CD103-).  Following APC-antigen uptake and lymphatic migration, APCs are thought to 
present fragments of the TDI-protein conjugates to T cells via MHC-mediated antigen presentation, 
although this mechanism has not been fully confirmed in models of TDI sensitization.  This action 
results in the proliferation of T cells into a number of effector subsets including CD4+ Th1, Th2, 
Th17, Treg, and cytotoxic T cells.  Data from our model of dermal TDI sensitization shows increased 
Th1, Th2, Th17, and Treg cell numbers in the dLN following exposure (Figures 3.2, 3.4 and A3.4).  
A mixed Th1/Th2 response (based on T cells and associated cytokines) is observed in both animal 
models and humans exposed to diisocyanates like TDI (8).  Additionally, the presence and 
importance of CD8+ T cells has been established in murine models of TDI sensitization (9).  These 
activated T cells can migrate through the lymphatics, blood, and local tissues; orchestrating an 
adaptive immune response specific to the TDI-protein antigen.  Activated T cells and the allergic 
microenvironment may serve as mediators of B cell activation.  Although the role of IgE is contested 
in a portion of TDI asthma, IgG is thought to play a role in the development and pathogenesis of this 
condition (10).  Both Th1 and Th2 cells are important mediators of antibody class switching due to 
cytokine production.  Another T cell subset intimately involved in germinal center B cell maturation 
is the TFH cell which remains uninvestigated in chemical allergy but may be heavily involved in the 
pathogenesis of this process.  Collectively, these processes allow the immune system to develop an 
“arsenal” of TDI-specific cells; subsequent exposures may further augment this process and will 
eventually lead to the elicitation phase, which is typically represented by asthma.  The immunologic 




of the response have not been fully proven such as TFH cells and ILCs; however, existing data from 
models of other types of allergy indicate that these cell types may play an important role in the TDI 
sensitization response.  
 
Figure 5.1 Overview of the Immune Mechanisms of TDI Sensitization 
Upon initiation of the elicitation phase, allergic symptoms begin to appear.  This response is 
thought to involve the TDI-protein complex and immune cell recognition (APCs, B cells, and T 
cells), potentially causing crosslinking of the TDI-protein antigen with antibody, leading to mast cell 
degranulation, the production of additional antigen-specific allergic antibody, the proliferation of 
antigen-specific T cells, and the involvement of memory T cells.  These processes likely contribute 
to the manifestation of diverse symptoms observed in human TDI asthmatics such as airway 
inflammation, bronchial thickening, epithelial alterations, hyperreactivity, lymphocyte, neutrophil, 
and eosinophil infiltration and excessive mucus secretion (11-13).  Following sensitization and a 




symptoms usually begin to appear.  Chest tightness, cough, shortness of breath, and wheezing are 
frequently described anywhere from <1 to 4 hours following TDI exposure (13).   
Unfortunately, TDI sensitization is a difficult response to fully characterize due to the 
difficulty of performing appropriate human studies and variation observed between human and 
mouse models.  Accordingly, the clinical pathogenesis of TDI-induced asthma is not fully 
understood, beyond observational data collected from patients with this condition.  The contested 
role of IgE in TDI sensitization and asthma is a poignant example of the lack of understanding of 
basic mechanisms involved in these conditions.  The consistent appearance of IgE in murine models 
of TDI allergy is contrasted by the inconsistent appearance of this antibody (both total and specific) 
in human patients.  The fact that IgE is associated with other chemical allergens and the pathogenesis 
of allergic asthma caused by these agents further complicates this question.  When present, TDI-
specific IgE serves as a predictive tool but this antibody is not detected in many TDI asthmatics who 
also frequently exhibit normal total IgE levels (14).  It is possible that IgE-independent mechanisms 
of sensitization and asthma such as those mediated by Th1, Th17, and IgG are integral in the 
pathogenesis of TDI allergy.  Regarding the IgE conundrum along with general mechanisms of 
disease, it is evident that additional understanding of the immunologic mechanisms of sensitization 
and elicitation will better enable the development of appropriate hazard identification strategies and 
therapeutic targets relevant to TDI sensitization and asthma.  
 
5.3 The role of Tregs in TDI sensitization 
Among the numerous regulatory strategies employed by the immune system, Tregs are one of 
the most functionally significant.  These cells act as both general and specific immunoregulators; 




The rocky history of Tregs began in the 1970s when Gershon and Kondo identified suppressor T cells 
which were capable of dampening immune responses (15).  In the 1980s, the study of suppressor T 
cells was shaken by scrutiny based on observations that the MHC gene did not encode the I-J region 
which was purported to be associated with the function of these cells (15).  This observation, paired 
with difficulties in the identification of reliable markers for suppressor T cells and uncertainty 
regarding specific mechanisms of suppression resulted in the decline of suppressor T cell study (15).  
The study of nTregs that arise naturally in the thymus, rather than experimentally-induced cells (15) 
aided in the “rebirth” of the suppressor T cell, now known as the Treg.  The identification of Foxp3 
as the “master transcription factor” responsible for the differentiation and function of Tregs was 
prompted by the investigation of the genetic mechanisms responsible for the symptoms seen in 
patients with immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) and 
in scurfy mice which are mediated by loss-of-function mutations in foxp3 (16, 17).   
Tregs can be derived from the thymus (nTreg) or induced in the periphery (iTregs) (18), 
acquiring suppressive capabilities that are mediated through a diverse repertoire of mechanisms.  
Tregs aid in the mediation of self-reactive or overzealous immunity utilizing a variety of mechanisms.  
Tregs have a known role in a plethora of diseases and conditions mediated by the immune system 
including allergy, asthma, autoimmune disorders, cancer, and infections (19).  Regarding allergic 
disease, impaired nTreg inhibition of allergen-specific Th2 responses during hay fever responses, 
decreased levels of Tregs in patients with allergic disease compared to healthy individuals, and a 
protective role for Tregs in grass, milk, and nickel allergy have been demonstrated (19), emphasizing 
the functional importance of these cells in the control of allergic responses.  Additionally, depletion 
of Tregs in a model of OVA atopic dermatitis lead to augmented lung responses (characterized by 




OVA challenge in a murine model (20).  The corresponding study found that Tregs are important in 
the regulation of both skin inflammation and allergen-specific immune responses, both of which are 
involved in TDI sensitization as well.  Several studies have explored the potential action of IL-10 
secretion by Tregs in a nickel allergy model and the presence of Tregs in murine models of urushiol 3-
pentadecylcatechol and TNCB sensitization (7).  Generally, Tregs are able to regulate immune 
response and their numbers and/or function appear to be impaired in various disease states.    
Chapter 3 described several experiments demonstrating the role of Tregs in TDI sensitization.  
This subset expands in the dLN (Figure 3.2) and ears (Figure 5.4), was phenotypically diverse, and 
likely contained a number of functionally significant subsets.  The expansion of the general Treg 
population in the dLN (Figure 3.2) was significant in number following both 0.5 and 4% TDI 
exposure; however, increases in frequency were only observed for the 4%-exposed mice (Figure 3.2; 
significant at days 4-9).  This may be indicative of Treg migration and proliferation in response to the 
strongest sensitizing concentration and may also be influenced by the irritant nature of this dose, as 
cytokine and chemokine signaling would be augmented in response to both of these factors.  This 
hypothesis is based on studies demonstrating IL-4 and IL-13-dependent iTreg differentiation (21), 
which is likely occurring in response to the Th2 component of TDI sensitization.   
Thymic nTregs are typically CD25hiCD62L+CCR7+ and migrate to secondary lymphoid 
tissues such as lymph nodes following the completion of their development (22).  Upon egress, a 
subset of these Treg emigrants acquire high CD44 expression; this confers non-lymphoid tissue access 
to these cells (22).  These CD44hi Tregs may be attributed to recognition of self-antigens in secondary 
lymphoid tissues (22).  Their phenotypic divergence represents the innate diversity in the Treg 




to proliferate more quickly than their counterparts and their presence in non-lymphoid environments 
may allow them to incorporate diverse suppressive strategies.   
Peripherally-induced iTregs typically exhibit a more diverse phenotypic profile due to their 
origin.  iTregs may be generated during an active immune response that is skewed towards a certain 
Th phenotype or that involves diverse antigen presenting cells, influencing Treg development.  iTregs 
are thought to be less stable than nTregs, further emphasizing their apparent plasticity and response-
specific nature.  Both nTregs and iTregs were found in the dLN of mice during TDI sensitization, with 
the frequency of nTregs actually decreasing at 7 and 9 days post 0.5 and 4% TDI exposure (Figure 
3.2a).  This may be a reflection of the reduced trafficking of these cells to the lymphatics at later time 
points post exposure or may simply be that these cells are “overshadowed” by the expanding iTreg 
population, as the number of nTregs is still significantly increased compared to the acetone control at 
these time points.  The presence and expansion of both nTregs and iTregs is reflective of the systemic 
nature of TDI sensitization as well as the migratory and proliferative potential of Tregs in response to 
an antigenic challenge.         
Recent data suggests the development of specialized Treg phenotypes which allow these cells 
to respond to individual Th subsets (18, 22).  In order to migrate to areas of Th action, Tregs have 
been shown to express transcription factors such as tbet (Th1), interferon regulatory factor-4 (Th17, 
Th2, and TFH), stat3 (Th17), and gata3 (Th2) while retaining immunosuppressive functions such as 
the secretion of IL-10 (18).  Steady-state Tregs have also been shown to dynamically express tbet and 
gata3 in order to maintain homeostasis (23).  This phenotypic diversity and plasticity is an important 
concept relevant to all types of T cells.  A phenotypically varied Treg population was observed in 
both tissues during TDI sensitization and this would be expected in terms of Th-specific transcription 




phenotyping of Tregs involved in TDI sensitization (in both the dLN and ears) may reveal diverse 
transcription factor expression; therefore, influencing Treg-Th dynamics and the suppressive capacity 
of these cells in relation to the diverse Th response involved in TDI sensitization.   
 
5.3.1. Tregs Suppressive Strategies 
Investigations into the suppressive mechanisms of Treg function during TDI sensitization are 
warranted based on the data in Chapter 3.  These mechanisms generally raise the T cell activation 
threshold and/or inhibit dendritic cell function, preventing the priming of self-reactive T cells and 
aberrant immune responses.  Cells that may be directly impacted by the suppressive actions of Tregs 
include B cells, CD4+ and CD8+ T cells, NK cells, and NKT cells (24).  Not only can Tregs suppress 
the activation and expansion of naïve T cells but they can inhibit previously activated T cells 
(including memory and effector T cells) (25).   Tregs may utilize a variety of mechanisms including 
secretion of immunosuppressive cytokines (IL-10, IL-35, and TGF-β), CTLA4 expression (via 
CD80/86 downregulation on dendritic cells), indolamine 2,3-dioxygenase (IDO) expression, IL-2 
consumption, and perforin-dependent cytolysis of dendritic cells (Summarized in Figure 5.2).  IL-
10 secretion and CTLA-4 expression have been proven as imperative for Treg function in Treg-specific 
selective depletion models exposing spontaneous colitis and augmented immune responses (IL-10 
depletion) and systemic multi-organ autoimmunity paired with dysregulated T cell activation 
profiles (CTLA-4 depletion) (22).  Cell-to-cell suppression has also been documented between Tregs 
and dendritic cells; in some cases this may be dependent on LFA-1 dependent formation of Treg-
immature dendritic cell aggregates leading to LFA-1 and CTLA4-mediated downregulation of 
CD80/86 on dendritic cells (26).  The type(s) of suppressive mechanism employed by Tregs may 




between Treg function and localization remains complex and merits further investigation in a variety 




Figure 5.2 Mechanisms of Treg Suppression 
 
Treg phenotyping data implied that Tregs may employ a number of functional strategies to 
suppress the TDI sensitization response, including CTLA4 expression.  The increased expression of 
CTLA4 was evident following 0.5 and 4% TDI exposure at all time points analyzed (Figure 3.2a A 
and B).  This data suggests that CTLA4 expression may be utilized by Tregs in order to dampen TDI 
sensitization responses in a cell-to-cell manner, which should be investigated further.   
The expression of CD103, ICOS, and chemokine receptors are also linked to effector 
functions of Tregs, as described in Chapter 3. The expression of both ICOS and CD103 increased 
among Tregs in the skin (Figure 5.4 F and G) and dLN (Table 3.2) during TDI sensitization.  More 
specifically, Tregs co-expressing both ICOS and CD103 were identified in the skin and dLN during 




specific differentiation stage of Tregs (27).  ICOS expression is likely connected to Treg – migratory 
dendritic cell interactions (27) and is associated with activated Tregs and suppressive activity.  As 
expected based on their lymph node specificity, the increase in frequency of ICOS+CD103+ Tregs was 
more pronounced in the dLN than in the ears (Figure 5.3 A and B).  Interestingly, ICOS+CD103+ 
Tregs also slightly increased in the ear during TDI sensitization, possibly indicative of a migrating 
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Figure 5.3 ICOS+CD103+ Treg Population in the Ear and dLN during TDI sensitization 
ICOS+CD103+ Tregs were identified in the ear (A) and dLN (B) of mice exposed to 0, 0.5, or 4% TDI 




of 5 mice per group.  P values are represented by ^ (0.5% TDI) and * (4% TDI) (P<0.05).  Dermal 
treatment groups are indicated by the following symbols: circle- acetone, square- 0.5% TDI, and 
triangle- 4% TDI. 
 
5.3.2. Skin Tregs and Dendritic Cells 
The epithelium is a barrier to allergens like TDI; specifically, the skin and its related 
structures, specifically, play an important role in the development of TDI sensitization.  The skin has 
been implicated in the development of both dermal and respiratory sensitization (via dermal 
exposure) in a variety of models of allergic disease, encompassing both protein allergens such as 
OVA (28) and chemical allergens such as TDI (29).  Occupational practices may compromise 
epithelial surfaces, further contributing to the development of allergic disease.  The innate immune 
system houses many cells and surveillance systems in the skin and related tissues, presumably as a 
“first line defense” against pathogens.  These cells include keratinocytes, T cells, dendritic cells, 
macrophages, monocytes, granulocytes, and innate lymphoid cells (30).  Innate factors may also 
contribute to the development of allergic disease by precipitating, augmenting, and/or initiating the 
adaptive immune response that is characteristic of disorders like TDI allergy.   
Skin Tregs were phenotyped (Gating strategy is shown in Appendix 5.1) during TDI 
sensitization in an effort to profile these cells and gauge their involvement in this response. Tregs 
increase in the skin in both frequency and number following 0.5 and 4% TDI exposure (Figure 5.4 
D).  These cells may be skin resident Tregs or they may be trafficked in from other tissues such as the 
dLN.  Tregs are capable of expressing an abundance of chemoattractant and surface adhesion 
receptors, allowing them to be present in nearly all tissues in the body (22).  Clearly, the presence of 




the inflammatory environment present in the impacted tissue.  During experimental autoimmune 
encephalomyelitis (EAE), Th17-mediated inflammation promotes epithelial expression of the 
chemokine CCL20, which is recognized by CCR6, leading to increased CCR6 expression on Tregs 
and recruitment to epithelial tissue (22).  Alpha E integrin, or CD103, is expressed by a high 
frequency of skin Tregs (Figure 5.4 F) due to its importance in the migration and retention of these 
cells in the skin (22).  Conversely, CCR7 is involved in Treg migration to dLN and overall Treg 
function as loss of this receptor results in loss of the ability of Tregs to migrate to the dLN and function 
in a murine model of colitis (22, 31).  Treg migration is highly coordinated by a number of signaling 
molecules and remains a highly temporal and site-specific process.  Compartmentalization and 
proper localization have been shown to be imperative for Treg function, with each unique subset 
working in concert in a “division of labor” to maintain tolerance and regulate immune responses 
(32).  In light of this, therapeutic targeting of Treg migration is not fully feasible and such efforts will 
require additional understanding into this process and the mechanisms involved.   
During TDI sensitization ear Tregs expand in frequency at 2 and 4 (4%) and 4 and 7 (0.5%) 
days post exposure (Figure 5.4 D).  They also expand in number during days 2-9 following exposure 
to both concentrations of TDI (Figure 5.4 D).  This expansion exhibited similar kinetics to the dLN 
Tregs during this response, with an apparent peak in Treg expression 4 days post TDI exposure.  This 
congruency between tissues was intriguing and may reveal the systemic nature of sensitization and 
Treg trafficking.  As previously mentioned, CCR7 expression is involved with Treg lymph node 
homing and the expression of this receptor was analyzed on Tregs during TDI sensitization (Figure 
5.4 E).  Treg CCR7 expression was decreased in frequency during 4% TDI sensitization (2-7 days 
post exposure) but due to the general expansion of Tregs CCR7+ cells increased in number during 0.5 




migratory markers in order to move to the ear, the site of chemical application and of a significant 
inflammatory response in the 4% TDI-exposed mice.  This hypothesis is supported by decreased 
expression of CD103, an epithelial Treg marker, in skin Tregs during 0.5% (4 days post exposure) and 
4% (1-9 days post exposure) TDI sensitization (Figure 5.4 F).  ICOS+ Tregs significantly increased in 
frequency and number during 0.5% and 4% TDI sensitization (Figure 5.4 G; 0.5%: 1-9 days post 
exposure and 4%: 2-9 days post exposure).  This population accounted for more than 70% of skin 
Tregs in acetone-treated control mice and nearly 100% of skin Tregs in TDI-exposed mice, revealing 
the dermal Treg population is probably capable of being functionally active and is at a high activation 
status as ICOS is a costimulatory molecule important to Treg function (33).  These data reveal an 
expansion of dermal Tregs at the site of TDI application during sensitization that is potentially 
functionally active and phenotypically diverse.   
In line with the general migratory capabilities of lympocytes (34), the Tregs identified in both 
the ear and dLN during TDI sensitization are potentially migratory, allowing for the regulation of 
the systemic sensitization response that develops in response to TDI.  Comparison of the dLN and 
skin Treg subsets lends important insight into the potential migration and action of Tregs during TDI 
sensitization.  While the general kinetics of Treg frequency appeared to be similar between dLN 
(Figure 3.2 B) and skin (Figure 5.4 D) Tregs, the overall percentages are very different for each tissue.  
Approximately 5-10% of CD4+ T cells in the dLN are Tregs and approximately 10-30% of CD4+ T 
cells in the ear are Tregs.  This may be a reflection of the greater percentage of naïve and/or effector 
T cells in the lymph node as a secondary lymphoid organ.  Treg numbers varied greatly between the 
dLN (Figure 3.2 C) and skin (Figure 5.4 D), revealing up to approximately 1.6 million Tregs in the 
dLN and 50,000 Tregs in the skin of TDI-treated mice.  This is likely a reflection of the status of the 




expression of CCR7 following 4% TDI exposure in the ear Tregs (Figure 5.4 E) indicated that dLN 
Tregs were migrating to the ears.  This was supported by increased dLN CCR6+ Treg frequency during 
0.5% (2-9 days post exposure) and 4% (4-9 days post exposure) TDI sensitization (Table 3.2).  CCR6 
is a lymphocyte chemotactic factor that causes T cell migration to inflammatory tissues (35) and its 
upregulation on dLN Tregs during TDI sensitization suggests that Tregs are moving from the dLN to 
the ear during TDI sensitization.  CD103 was expressed on approximately 80% of acetone-treated 
Tregs in the ear (Figure 5.4 F) compared with approximately 20% of their counterparts in the skin 
(Table 3.2).  This is in accordance with CD103’s skin homing role in Tregs described above.  CD103+ 
Tregs increased in frequency in dLN Tregs during 0.5% (2-9 days post exposure) and 4% (4-9 days 
post exposure) TDI sensitization (Table 3.2), while the frequency of this subset decreases in the ear 
following 0.5% (4 days post exposure) and 4% (1-9 days post exposure) TDI exposure (Figure 5.4 
F).  This increase in CD103+ Treg frequency in the dLN may indicate Treg migration to the skin as 
observed with CCR6 expression.  Decreases in CD103+ Treg frequency in the skin may be attributable 
to lymph node migration from the ear, particularly at later time points such as 4 days post exposure, 
where this population seems to be the most well represented during 4% TDI sensitization.  Lastly, 
the ICOS+ Treg subsets increased in both the dLN (Table 3.2; 2-9 days post exposure) and ear (Figure 
5.4 G; 0.5%: 1-9 days post exposure and 4%: 2-9 days post exposure), suggesting an activated state 
in these Tregs.  Overall, it appeared that more ear Tregs expressed ICOS (in both the basal and TDI-
treated states) than dLN Tregs in terms of frequency.  All ear Treg subsets increased in number during 
TDI sensitization (Figure 5.4 E-G) with similar kinetics, indicating that regardless of percentage 
alterations, increased Tregs expressing each marker analyzed expanded in the skin due to the overall 
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Figure 5.4 Ear Treg Phenotyping 
Flow cytometric analysis of dermal Tregs following dermal TDI sensitization. Tregs were first gated 
on their expression of CD45 (A), CD3 (B), and CD4 (C) then were further identified by CD25 and 
Foxp3 expression (Tregs) at indicated time points.  Treg frequency and number (D) were determined 
based on flow cytometry analysis and extrapolation of this data with total ear cellularity.  Tregs were 
also analyzed for CCR7 (E), CD103 (F), and ICOS (G) expression.  Graph symbols represent mean 
(± SE) of 5 mice per group.  P values are represented by ^ (0.5% TDI) and * (4% TDI) (P<0.05).  
Dermal treatment groups are indicated by the following symbols: circle- acetone, square- 0.5% TDI, 
and blue triangle- 4% TDI.   
 
The Treg phenotyping carried out in a murine model of TDI sensitization did not specifically 
characterize effector memory Tregs.  This is primarily due to the fact that this model utilizes a single 
exposure and may not induce high numbers of effector memory Tregs by the assayed time points; 
however, this subset is likely important in the elicitation phase of allergic disease and upon repeated 
allergen exposures.  While several of the migratory-related receptors may be expressed on these 
cells, complete phenotyping of effector memory Tregs would require the identification of CD127 (IL-




lower levels of CD25 and higher levels of CD127 compared to Tregs in the dLN and IL-2-/- and IL-
7Rα-blocking antibody studies indicate that murine skin memory Tregs require IL-7 but not IL-2 for 
their survival in this tissue (36).  The IL-7 requirement was not evidenced with respect to human 
memory Tregs in the skin (37).  Murine and human Tregs in the skin localize to hair follicles, in close 
proximity to the follicular epithelium while conventional T cells did not appear to preferentially 
localize to the hair follicle (37).  Interestingly, in our epicutaneous murine TDI sensitization model, 
TDI-hapten complexes localize to several sites in the skin, including the hair follicles; these TDI-
hapten complexes were shown to co-localize with CD11b+, Langerin+, and CD103+ cells in the hair 
follicles, presumably demonstrating APC-hapten interaction (38).  The presence of Tregs at sites like 
the hair follicles may be a protective mechanism due to the accessibility of these structures by 
allergens.  In order to compare the antigen-specificity of human skin memory Tregs and memory T 
cells deep sequencing of the TCR β chain was performed in each of these subsets and this analysis 
revealed that these two cell types likely recognize dissimilar antigens (37).  Another unique attribute 
of human skin memory Tregs is that they are largely nonmotile, compared to memory conventional T 
cells which tend to express CCR7, a lymphatic homing marker (37).  In a murine model of DNFB 
contact allergy, memory effector Tregs were found to be capable of circulating from the blood and 
skin, returning to the skin upon antigen exposure (39).  This data suggests that memory effector Tregs 
are likely present in both the skin and in the circulation in our model of TDI sensitization, migrating 
throughout the body but able to respond to TDI exposure both locally and distally.   
dLN and ear Treg comparisons reveal potential insights into the function of these cells.  
Presumably, each tissue holds a diverse array of Tregs whose origins and functions are as unique as 
their home.  Dendritic cell interactions play an important role in the differentiation and stimulation 




dendritic cell populations of the lymph nodes and skin are innately diverse yet contain many shared 
populations due to the normal migration of immune cells between barrier surfaces and dLNs.  
Typically, the murine lymph node dendritic cell population is made up of several main subsets 
including CD4+CD8-DCE-205-, CD4-CD8-DCE-205-, and CD4-CD8+DCE-205+ dendritic cells 
along with skin-derived dendritic cells which may originate as dermal dendritic cells or Langerhans 
cells (40).  Langerhans cells are the only dendritic cell subset present in the epidermis at a basal level 
and the dermis contains several dermal dendritic cell subtypes (41).  Homeostatic migration of skin-
derived dendritic cells is considered normal even in the absence of an active immune response (40).  
Additionally, skin Tregs may actively migrate to the lymph nodes and back, participating the 
maintenance of tolerance and in the regulation of immune responses such as TDI sensitization.  The 
ability of immune cells to access the lymphatic network from barrier sites such as the skin is 
imperative in normal functioning of the immune system and is also a major contributor to the 
development of systemic sensitization.  Dendritic cells are often regarded as the “bridge” between 
innate and adaptive immunity due to their antigen presentation abilities.  Although they are involved 
in the activation of reactive Th cells, dendritic cells play a crucial role in Treg induction.  IL-10, IL-
27, and TGF-β production and IOCSL signaling by dendritic cells promotes Tr1 differentiation and 
thymic dendritic cells produce thymic stromal lymphopoetin (TSLP) to promote nTreg 
differentiation, generally from self-reactive T cells (42).  iTreg differentiation can be influenced 
dendritic cell-derived IDO and tryptophan depletion metabolites 3-hydroxyanthranilate and 
kynurenine, dendritic cell TGF-β, retinoic acid, and RANKL signaling (42).   
The role of dendritic cells in relation to Tregs has been investigated in a murine model of 
DNTB contact hypersensitivity (41).  This work utilized a weak hapten model in an effort to 




DNFB).  DNTB cannot activate the inflammasome nor can it induce contact hypersensitivity 
following a single exposure in mice yet it generates similar self-peptide complexes upon skin contact 
as those associated with DNFB which behaves as a strong allergen (41).  As a weak hapten, DNTB 
appears to promote tolerance to DNFB sensitization and this effect is thought to be mediated by Treg 
induction (41).  Additionally, Langerhans cells are able to cause anergy and deletion of DNTB-
reactive CD8+ T cells and promote the expansion of ICOS+ Tregs in order to suppress allergic contact 
dermatitis (41).  In this model of DNFB allergy, Langerhans cells and dermal dendritic cells were 
able to present the hapten-protein complex within 24 hours of dermal exposure, emphasizing the 
quick response time of these cells and their important role in the allergic response (41).  The 
importance of Langerhans cells in the maintenance of tolerance in this “weak hapten” model is 
relevant to “strong haptens” like TDI; although different dendritic cell populations may be mediating 
this effect (possibly monocyte-derived skin dendritic cells and/or CD207+ dermal dendritic cells) 
(41), it is likely a part of the immune response involved in TDI allergy.  Based on the importance of 
both MHC I and II in the induction of dendritic cell-initiated tolerance in the DNTB model (41), in 
the case of TDI sensitization, it is likely that this mechanism of dendritic cell tolerance establishment 
is skewed, resulting in the massive expansion of antigen-reactive T cells.  The difference between 
tolerance established following “weak hapten” exposure and the allergic disease established 
following “strong hapten” exposure may be attributed to variant outcomes following dendritic cell 
antigen presentation in the lymph node.   
In our TDI sensitization model, tolerance may not be established due to skin irritation causing 
danger signal induction and antigen presentation by dendritic cells resulting in activation of antigen-
reactive T cells.  Although Tregs do expand and some antigen-reactive T cells may be deleted, these 




local cytokine environment is a very important factor involved in the maintenance of tolerance or 
the induction of an allergic response.  IL-35 has been shown to impact tolerance by promoting anti-
inflammatory pathways; this cytokine acts as a regulatory signaling molecule in a murine model of 
OVA-induced allergic airway inflammation (43).  IL-35 exerts these effects by a number of 
mechanisms, including the suppression of inflammatory dendritic cells at the site of inflammation 
as well as the dLNs (43).  Another anti-inflammatory cytokine, IL-10, is known to downregulate 
pro-inflammatory cytokine (IL-1β and IL-6) production if produced early in the innate immune 
response (44).  IL-10 may be produced by Tregs, macrophages, dendritic cells, neutrophils, and 
keratinocytes (20) and may play a role in regulating the TDI sensitization response as early as the 
initiation of dendritic cell function.  A study by Cumberbatch, et al. revealed dichotomous immune 
responses in the skin of mice exposed to contact (DNCB) and respiratory (TMA) allergens.  
Langerhans cell migration to the dLN was delayed in response to TMA compared to DNCB which 
was attributed to differential epidermal cytokine profiles, in particular altered IL-10 expression 
leading to reduced IL-1β levels (45).  This data reveals the importance of the cytokine environment 
in the development of allergic disease, as well as the potential importance of IL-10 in the 
development of Th2 sensitization.  The increased inflammatory response observed in our murine 
TDI sensitization model (Figure 3.1) may influence the phenotype and functional capabilities of skin 
dendritic cells, leading to the development of an adaptive response which we know as sensitization.  
Clearly the local cytokine and chemokine environment can guide the dendritic cell response, which 
is also a crucial component of the induction of allergic disease.  Further investigation into dendritic 
cell and Treg activity during TDI sensitization may reveal valuable information regarding the 
mechanisms involved in the orchestration of sensitization and the balance between allergic disease 




5.3.3. Therapeutic Potential of Tregs 
The therapeutic potential of Tregs is an exciting prospect, yet in many cases this concept 
remains in its infancy in functional terms.  General challenges regarding the development of Treg-
based therapeutics include Treg isolation and identification issues, plasticity, high cost, and 
unintended, “off-target” effects on pathogen clearance or tumor immunity (46).  Regardless, several 
Phase I clinical trials have been completed utilizing Tregs therapeutically in the context of graft versus 
host disease and type 1 diabetes (46).  These studies revealed generally safe responses to 
supplemental Treg therapy with immunosuppression being a major side effect (46).  Several Phase I 
and II clinical trials are currently recruiting and will investigate the use of Treg therapy in kidney and 
liver transplant, Crohn’s disease, and multiple sclerosis (46).  Although a Phase I trial for the use of 
autologous polyclonal Tregs in steroid-resistant asthma is purported to be initiated soon, this has not 
begun (46).  The subcutaneous and intradermal administration of insulin-like growth factor-1 helped 
to alleviate inflammation (ear swelling) in a murine model of DNFB contact hypersensitivity (47), 
demonstrating that Treg expansion is helpful in the control of allergic responses in the skin.  It seems 
that much remains to be learned about these cells before they may be used in the effective treatment 
of allergic disease.  In terms of TDI allergy, the role of Tregs in TDI elicitation is currently unknown 
and should be elucidated to fully characterize the importance of these cells in a complete model of 
TDI allergy, encompassing both sensitization and elicitation.  This would allow for a clear 
understanding of the temporal significance of Tregs during all phases of this response, which may 
have strong implications in regards to clinical uses of these cells.   
In models of OVA-induced allergy, Tregs were shown to have a protective role in the 
sensitization but not the elicitation phase of this response (48, 49).  The suppressive role of Tregs has 




hypersensitivity (50).  If Tregs play a role in TDI sensitization but not in elicitation, these cells may 
not have an immediately apparent therapeutic or preventative role.  Because sensitization is typically 
not accompanied by any clinical symptoms or “outward” signs, the interventional significance of 
Tregs at this time in the development of the response may be difficult to discern.  In line with the 
thoughts of Baru, et al. (49) the apparent lack of Treg importance during OVA-induced elicitation 
does not automatically discredit the idea that Tregs may be able to help lessen allergic inflammation 
and pathology if administered exogenously or induced at this phase of the response.  Exogenous Treg 
administration has been shown to ameliorate tissue damage, remodeling, and pathology in murine 
models of LPS-induced acute lung injury (51) and OVA-induced allergic airway inflammation (52, 
53).  Also, adoptive transfer of preactivated OVA-specific Tregs into OVA-sensitized mice resulted 
in a blunted Th2 response in the lung in response to OVA challenge (54).  Importantly, Treg 
supplementation following the establishment of allergic symptoms did not reverse airway 
hyperreactivity, regardless of the decreased airway inflammation and eosinophilia observed 
following treatment (52).  This data indicate that Tregs exhibit therapeutic potential in the regulation 
of allergic disease, even if administered once symptoms appear.  Clearly, further investigation into 
the mechanisms and temporal influence of Tregs during TDI sensitization and elicitation is necessary 
in order to fully realize the potential utility of these cells.  Ideally, therapeutic strategies involving 
Tregs such as vitamin D treatment leading to dexamethasone-induced IL-10 responsiveness (Treg 
mediated) in glucocortacoid-resistant asthmatics (55) may be effective for TDI asthmatics. 
 
5.4 The role of miRNAs in TDI sensitization 
Just as Tregs are important in the regulatory milieu of the immune system, miRNAs have 




estimated that approximately 30-92% of human genes are regulated by miRNAs (56).  The ability 
of multiple miRNAs to regulate multiple genes and simultaneously impact target protein translation 
demonstrates the ubiquitous regulatory power of these tiny structures.  These small RNA molecules 
originate from mRNA that is typically transcribed by RNA polymerase II or III, producing primary 
miRNA transcripts (56).  miRNAs can originate from the activation of independent promoters as 
polycistronic transcripts from the introns of protein-coding genes (57).  Primary RNA transcripts are 
then processed into pre-miRNA stem loops which contain approximately 60 nucleotides; this is 
mediated by the RNase III enzyme Drosha and DGCR8 (56).  The pre-miRNA stem loops are 
transported out of the nucleus into the cytoplasm by Exportin-5 and are processed into mature 
miRNA molecules by the cytoplasmic Rnase III ribonuclease Dicer (56).  This mature miRNA 
molecule can then form a complex with RNA-induced silencing complex (RISC) machinery and 
impact the translation of target gene by sequence-specific targeting of mRNA, typically within the 
3’ UTR where their binding is the most efficient (57, 58).  RISC-miRNAs bind through 
complementarity that may be partial (at least 6-8 nucleotides) or perfect, leading to repression of the 
target gene’s translation or mRNA degradation via initiation of deadenylation (57).  Mature miRNAs 
can be released from their cells of origin via exosomes, which are cell-membrane derived vesicles, 
by cellular degradation, or by complexing with proteins such as high-density lipoprotein and 
Argonaute (57).  These extracellular miRNAs may be taken up by recipient cells bearing scavenger 
receptors (HDL-bound miRNAs) or passively (57).  
miRNAs have integral functions in the development of the immune system, as conditional 
Dicer depletion in hematopoietic stem cells leads to dysfunction in the hematopoietic compartment 
and this setup in T or B cells causes lymphopenia and reduced functional capacity of these cells (58).  




Several miRNAs have been shown to be differentially expressed in the airways of asthmatic patients 
and in the lymphocytes of mice in models of allergic asthma (57).  miR-155 appears to be a major 
player in the development of Th2-mediated allergic disease as miR-155 deficient mice exhibit 
reduced eosinophilic inflammation and reduced Th2 cell numbers in a murine model of OVA-
induced asthma (57).  The upregulation of this miRNA during TDI sensitization (Figure 4.7 B) 
suggests that this miRNA may be involved in the development of TDI sensitization, which contains 
strong Th2 components.  The inhibition of several miRNAs (including miR-106a, -126, -145, and -
221) in murine models of allergic asthma has resulted in the reduction of pathogenic symptoms (57, 
59), suggesting important roles for additional miRNAs in the development of allergic asthma.  
Alternatively, miR-24 and -27 suppress Th2 differentiation via IL-4 downregulation in T cells, acting 
as negative regulators of OVA-induced allergic disease (60).  miR-21 is thought to target IL-12p35, 
leading to augmented Th2 responses in both murine and human models (57).  miR-155 has also been 
found to be overexpressed in skin samples from patients with atopic dermatitis and from skin 
challenged with diphenylcyclopropenone (57).  Additional miRNAs have been shown to be 
differentially expressed in models of allergic skin disease, including atopic dermatitis and allergic 
contact dermatitis (57).  There is likely a complex network of miRNAs involved in the regulation of 
allergic disease, both augmenting and decreasing the response. 
 
5.4.1. Overview of Selected miRNAs and their Relationship with Tregs 
Although miR-210 was the focus of the miRNA-based studies included in this work, miR-
31 and -155 were also investigated for their potential to induce miR-210 expression and to influence 
Treg differentiation and function.  Interestingly, miR-21, -155, and -301a made up a signature 
expression profile in stimulated splenic CD4+ T cells (both nonspecific and MOG35-55 peptide-




dLN of mice dermally sensitized to TDI (62).  Due to obvious differences in treatment and exposures 
in each of the models, the temporal kinetics of each miRNA were variable; however, for each 
response, these miRNAs were significantly elevated at time points encompassing immunologically 
significant events.  Collectively, this data emphasizes the importance of multiple miRNAs in 
immunologic processes and the conserved nature of these miRNAs in similar cell types and 
responses. 
Thymic Treg development is affected by miRNAs as conditional Dicer1 allele deletion at the 
double negative/double positive transition results in a significant decrease in Foxp3+ nTreg frequency 
in the LN, spleen, and thymus (63).  The authors also investigated iTregs in the context of Dicer 
depletion and upon stimulation and dicer-deficient, TGF-β stimulated CD4+CD25- T cells produced 
less Tregs (13.5%) than Dicer-competent T cells (48.5%).  In a recent work by Liston, et al. Treg-
specific miRNA depletion via Dicer caused a lethal autoimmune condition analogous to that 
observed in foxp3-deficient mice (64).  These data show the importance of miRNAs in the 
development of Tregs.  Murine nTregs and Tcons exhibit distinct miRNA expression profiles; nTregs 
exhibited increased expression of miR-21, -22, -27b, and -155 (among others) compared to Tcons 
(63).  The human cord blood-derived nTreg miRNA signature is similar with increased miR-21 and 
decreased miR-31 (65).  The same study revealed that in human cord blood-derived non-Tregs miR-
21 induces foxp3 expression while in nTregs miR-31 targets foxp3, antagonizing Treg development.  
The impact of miRNAs on Treg development is clearly significant, and may occur through positive 
or negative regulation.  In light of their potential roles in Treg differentiation and/or function, miR-
210, -31, and -155 will be discussed in the context of current knowledge from the literature as well 






miR-210 is upregulated in breast cancer, pancreatic tumors, and head and neck cancer (66).  
Functionally, this miRNA is known to be cytoprotective, increase angiogenesis, and inhibit apoptosis 
in hypoxic conditions, precluding its moniker, the “master hypoxamir” (66).  miR-210 has also been 
associated with breast cancer tumor proliferation (67), identified as a potential human serum 
biomarker for pancreatic cancer (68), and has been suggested as a therapy for the treatment of 
ischemic heart disease (69).  The relationship between miR-210 and Tregs is not well studied; 
however, most of the investigations into this concept have been carried out in humans.  In a study 
involving patients with psoriasis vulgaris, miR-210 levels were increased in peripheral blood 
mononuclear cells (PBMCs) from patients with psoriasis (66).  Foxp3 was identified as a miR-210 
target and this interaction was correlated with downregulated IL-10 and TGF-β secretion by Tregs.  
This study suggested that miR-210 negatively regulates foxp3, leading to immune dysfunction.  In 
Tregs isolated from healthy adult donor blood miR-210 was found to potentially target the 3’ UTR of 
foxp3 and ctla4 (70).  Additionally, foxp3 has been predicted to target runx3 (62), a transcription 
factor that acts upstream of foxp3 and is imperative for iTreg activation (71, 72).  Our investigations 
showed increased dLN and Treg-specific miR-210 expression and altered runx3 expression during 
TDI sensitization.  Collectively, this data suggests that miR-210 may be targeting Tregs during TDI 
sensitization.   
miR-210 may be induced by HIF-1α and may also target this gene (73).  Due to the hypoxic 
conditions in lymphoid tissues such as the lymph nodes and inflammatory sites such as TDI-exposed 
skin, it is logical to assume HIF-1α is inducing the expression of miR-210 during TDI sensitization.  
HIF-1α expression increases in allergic murine and human airways (74).  HIF-1α protein levels in 




factor is increasing miR-210 expression in the ear.  dLN levels of HIF-1α should be investigated as 
primary miR-210 expression was noted in this tissue, indicating that miR-210 was being produced 
locally.  Interestingly, the increased expression of miR-210 at non-irritant TDI concentrations in both 
the dLN (Figure 4.1) and ear (A4.1) suggests an alternative induction pathway for this miRNA.   
In hypoxic conditions, HIF-1α can induce foxp3 expression by binding to the hypoxia 
response elements found within the foxp3 promotor (75).  Dissimilarly, an earlier study reported the 
negative effect of HIF-1α on Treg development via targeting foxp3 for proteasomal degradation (76).  
This was elegantly refuted by studies utilizing foxp3-GFP transcriptional reporter mice which 
showed that the frequency of foxp3 mRNA-expressing cells (GFP+) was tightly correlated with the 
frequency of foxp3 protein-expressing cells in normoxic and hypoxic conditions (75).  HIF-1α has 
also been reported to affect Th17 cells by inducing transcription of rorγt, promoting the 
differentiation of this subtype (73), emphasizing the global and diverse effects of this signaling 
molecule on T cells.    If HIF-1α is inducing the expression of miR-210 during TDI sensitization, it 
is possible that this is a regulatory mechanism to prevent the over proliferation of Tregs (and maybe 
Th17 cells as well) in hypoxic conditions, assuming miR-210’s purported action on Tregs is valid.   
miR-210 has been investigated in the context of hif1α expression and T cell differentiation 
both at steady state conditions and in a model of experimental colitis (73).  These studies revealed 
increased miR-210 levels in activated T cells and that HIF-1α is both a target and important inducer 
of miR-210 (73). Additionally, miR-210 suppressed Th17 differentiation in specific oxygenation 
conditions and was able to reduce the severity of colitis, presumably due to targeting hif1α (73).  
Although this data does not directly address Tregs in relation to miR-210, the authors show increased 
miR-210 levels in this subset following in vitro polarization of naïve T cells (73).  Clearly regulatory 




immune response.  While miR-210 may be suppressing Th17 differentiation during TDI sensitization 
this remains to be investigated.  Overall, this data exposes the dynamic nature of miRNAs and their 
targets which may be variable among unique immune responses.    
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Figure 5.5 HIF-1α Protein Levels in Ear Lysates During TDI Sensitization 
HIF-1α levels were quantified in lysates from ear cells collected at various time points during TDI 
sensitization utilizing a DNA-binding ELISA (A).  Bars represent mean (± SE) of 4 mice per group.  
P values are represented by * (P<0.05).   
 
dLN and CD4 expression of primary miR-210 during TDI sensitization (Figure 4.1 B) 
indicates that this tissue and cell type are capable of producing miR-210 at the transcriptional level.  
Additionally, mature miR-210 levels are detected (and increase) in Tregs following ex vivo Treg 
polarization (73).  This data suggests that miR-210 is expressed by CD4+ T cells in the dLN during 
TDI sensitization.  Interestingly, although they were detectable, primary miR-210 levels significantly 




4% TDI exposure (Figure 4.1 B).  This data may suggest that CD4+ T cells are not the primary 
producers of miR-210 in the dLN, as mature miR-210 levels significantly increase at this time point 
in the dLN (Figure 4.1 A).  Because 4 days post TDI exposure appears to be the peak of mature miR-
210 expression, decreasing primary miR-210 levels at this time may indicate the beginning of 
transcriptional downregulation of miR-210, which could be reflected by relative decreases in mature 
miR-210 expression at later time points (Figure 4.1 A).  Another possibility is that miR-210 could 
be shuttled into the dLN via exosomes or other trafficking machinery which would result in increased 
mature miR-210 but not necessarily increased primary miR-210 levels.  Regardless of the method 
or site of induction, it is clear that mature miR-210 is likely responsible for a regulatory functions 





Figure 5.6 Potential sites of miR-210 action in Treg Biology 
*Indicates putative or confirmed targets of miR-210.  This may be occuring through direct or indirect 
means. 
miRNA 31 
Due to the reported miR-31 binding site on foxp3 mRNA, this miRNA has been investigated 
for its potential role in the development and/or function of Tregs.  In a murine model of EAE, increased 
miR-31 expression was observed in pathogenic CD4+ T cells along with stimulated CD4+ T cells 
from naïve mice, implicating TCR signaling as an inducer of this miRNA (77).  In an effort to 




Th17, and Treg subsets in vitro and each population’s miR-31 expression was measured.  miR-31 
levels increased in Th1 and Th17 cells but decreased in Tregs when compared to naïve T cells; the 
authors also discovered that foxp3 was significantly recruited to the putative miR-31 promoter (via 
chromatin immunoprecipitation assay), suggesting that foxp3 may bind to the miR-31 promoter and 
downregulate its expression when Tregs are present and/or expanding.  Gprc5a, or retinoic acid-
inducible protein 3, was identified as a target of miR-31, its knockdown leading to iTreg 
downregulation and increased EAE severity.  These data suggest that miR-31 is a negative regulator 
of iTreg generation via downregulation of Gprc5a expression.  
miRNA 155 
miR-155 is a very well-investigated molecule that was one of the initial miRNAs functionally 
identified in T cells and associated with TCR stimulation and inflammation (61, 78).  miR-155 can 
be induced by a number of innate immune signaling elements, including LPS, Poly (I:C), interferons, 
TNF-α, CpG, and PMA (78).  Autoimmune symptoms have been observed in miR-155-deficient 
mice and this has been attributed to a Th2 imbalance (61).  miR-155 deficient mice exhibit 
dysfunctional Th1 and Th17 differentiation and are highly resistant to EAE (57, 79).  The pro-
inflammatory and pro-allergic role of miR-155 has been linked to its action in macrophages, where 
it targets IL-13RA, SOCS1, and SHIP1; upon reduction of miR-155 levels, macrophages assume a 
M2 phenotype, suggesting that miR-155 promotes the inflammatory M1 phenotype (57).  miR-155 
has also been linked to dendritic cell Th2 priming, as miR-155-deficient dendritic cells exhibit 
limited Th2 priming function in vitro and failed to induce airway inflammation following 
intratracheal transfer in a murine model of ovalbumin-induced allergic airway disease (80).  These 
effects were shown to be mediated by miR-155 targeting of ATP-induced dendritic cell migration 




center B cell expansion, EAE pathogenesis, and dendritic cell function (56, 61), emphasizing the 
global importance and complexity of this miRNA.  MiR-155 expression increases in response to 
various inflammatory stimuli, potentially explaining its early increases in response to irritant 
concentrations of TDI (Figure 4.6 B).  These increases are typically attributed to TLR activation or 
inflammatory signaling mediated by cytokines such as tumor necrosis factors, interferons, and NF-
κB (58). 
The intron encoding miR-155 (precursor mRNA, Bic) can be bound by Foxp3 (81, 82), 
showing that miRNA expression can also be regulated by Treg-associated genes.  miR-155 expression 
was found to increase in Tregs and this was dependent on sustained foxp3 expression (81).  The 
authors also found that miR-155 had a positive effect on the numbers of Tregs and the proliferative 
potential of these cells; these effects were attributed to attenuated IL-2 signaling primarily due to 
elevated SOCS1 protein expression in miR-155-deficient Tregs as miR-155 was verified as a target of 
socs1 (83).  miR-155 was shown to target socs1, a negative regulator of IL-2R/STAT5 signaling, 
enhancing foxp3 expression (84).  This study demonstrated the critical role of miR-155 in Treg 
homeostasis in competitive IL-2 scenarios (but not in lymphopenic situations where IL-2 is 
dispensable) along with the crucial activity of foxp3 in the maintenance of miR-155 expression.  
Additionally, miR-155 deficient mice exhibit reduced thymic and peripheral Treg numbers (84).  
Generally, it seems that miR-155 affects the proliferation and differentiation of Tregs but not the 
suppressive capability nor specific markers expressed by these cells, although miR-155 was shown 
to be a direct target of ctla4, which would affect Treg function (84).  miR-155 can also suppress c-
Maf, leading to impaired IL-4 and Th2 responses and enhanced Foxp3 and Treg responses (84).  
Overall, miR-155 positively regulates tbet, foxp3, and rorγt while it negatively regulates gata3, 




miR-31, -155, and -210 are all valid experimental focuses in future studies evaluating TDI 
sensitization.  Their unique expression and functions hold much potential in terms of elucidating the 
underlying mechanisms of allergic disease as well as the identification of biomarkers for these 
conditions.  Before confirming the functional roles of these miRNAs, the functional availability of 
these structures should be confirmed, either by Luciferase binding assays to evaluate the ability of 
these miRNAs to bind targets or by Argonaute immunoprecipitation assays which identify mature 
miRNAs, the RISC, and their target mRNA in active complex.  Because the specific targets of these 
miRNAs have not been fully elucidated, these target-based mechanisms may not be feasible; 
however, it is important to consider miRNA degradation by nucleases (85) and natural circular RNA 
(86) in this context.  Generally mature miRNAs are stable and degradation should not interfere with 
functional roles. 
 
5.4.2. Therapeutic Potential of miRNAs 
The quantifiable expression of miRNAs in a variety of tissues and fluids in the body suggest 
their potential utility as biomarkers of disease.  Perhaps the most promising site of miRNA 
expression regarding the use of these molecules as biomarkers is the blood.  miRNAs can be 
expressed in additional bodily fluids such as lavage fluids, saliva, and urine; however, blood 
miRNAs have been proposed as suitable biomarkers for cancer, inflammatory disease, and tissue 
injury (57).  The blood miRNA profile of patients with chronic obstructive pulmonary disease, 
allergic rhinitis, and the BAL fluid miRNA profiles of patients with mild asymptomatic asthma have 
been shown to be unique and may have potential use as biomarkers of allergic disease (57, 87).  
When mice were dermally exposed to archetypal Th1 (DNCB and α-HCA) or Th2 (TDI and OPA) 




decreased in response to the Th1 sensitizers (data not shown).  This suggests the potential utilization 
of miRNA expression as a tool to determine if a chemical is a dermal or respiratory sensitizer.  
Furthermore, miR-210 expression was investigated in a variety of tissues during TDI sensitization 
and expression was significantly increased in the ear at various time points post 4% TDI exposure 
(A 4.1 A).  miR-210 expression in the ear was significantly increased 4 days post 0.5, 2, and 4% TDI 
exposure; however, expression following the strong irritant dose of 4% was much higher in relation 
to the less irritating doses, indicating that miR-210 expression in the ear is more dependent on dLN 
expression of miR-210 at the same doses (data not shown).  miR-210 expression was also examined 
at day 4 post 4% TDI exposure in the blood (A 4.1 B).  Blood miR-210 levels were not altered at 
this time point in response to TDI sensitization; this warrants further investigation at multiple time 
points post exposure in the study of miR-210 as a biomarker.        
MicroRNA-based therapies are in their infancy, with several currently undergoing Phase I 
and II clinical trials.  Regardless, these therapies exhibit great potential due to the ubiquitous 
functional power of miRNAs.  miRNA-based therapies can involve the inhibition or overexpression 
of individual or multiple miRNAs.  Miravirsen, the first miRNA-based therapeutic to undergo 
clinical trials, is a miR-122 inhibitor which inhibits Hepatitis C replication, acting as a potent anti-
viral agent in nonhuman primate studies (57).  Although no miRNA-based therapeutics are currently 
in clinical trials to combat allergic disease, intranasal inhalation of various miRNA inhibitors has 
been shown to reduce allergic airway inflammation in murine models (57), providing experimental 







5.5 Other Conclusions 
 
5.5.1. Irritancy and the Development of Allergic Disease 
Ni2+ allergy is an example of the importance of innate signaling pathways in the development 
of allergy.  Ni2+ is typically a false negative in the LLNA although it is an extremely common cause 
of allergic contact dermatitis in humans (88).  The explanation for this phenomenon are species-
specific variations in TLR4 histidine residues (positions 456 and 458 on human TLR4 but not on 
mouse TLR4) that allow Ni2+ to activate this receptor, if present (88).  This response illustrates the 
necessity of the innate “danger signaling” in the initiation and sustainability of an adaptive allergic 
response.  Local trauma, endotoxin, and additional adjuvants may serve as danger signals to allow 
for the initiation of adaptive responses that may have been suppressed in the absence of these signals; 
essentially, these events control the fine balance between tolerance and immunity.  It is assumed that 
many chemical allergens are capable of inducing irritation or inflammation, supporting the initiation 
of an adaptive response and sensitization (88-90).  As noted in section 5.1 regarding hypersensitivity 
classifications, innate mechanisms precluding allergy are remarkably similar to pathogen clearance 
responses.  These signals may originate from epidermal cells which may produce inflammatory 
cytokines such as IL-1β and IL-6 when activated (44).  This is summarized in the “two signal” 
hypothesis which states that antigen delivery alone is insufficient for effective immunological 
priming but rather a second, innate signal is necessary to ensure the development of sensitization 
(88, 90).  This concept is illustrated in the studies outlined in Chapter 3.  The contrasting biological 
effects of 0.5 and 4% TDI are evident, with increased dermal inflammation, dLN cellularity, and 
augmented sensitization noted for the 4% dose (Figures 3.1-3.4).  A key difference between the low 




irritation.  As noted in Chapter 3, the irritant response appears to be a prerequisite for strong 
sensitization responses in the case of dermal TDI sensitization.  This observation has been noted in 
models of contact dermatitis as well, Bonneville, et al. noted the conditioning role that acute skin 
irritation appeared to play in a murine model of DNFB contact dermatitis (44).  Protein allergens 
typically require the exogenous administration of adjuvants or additional innate signaling to cause 
irritation (91), illustrating the unique ability of many LMW chemicals to serve as their own “second 
step” in the journey to allergenicity. 
The mechanisms of innate responses involved in dermal sensitization have been investigated 
in a variety of models of contact hypersensitivity.  The dual absence of TLR2 and 4 in a murine 
model of contact hypersensitivity prevented TNCB, oxazolone, and fluorescein isothiocyanate 
sensitization from occurring, revealing the importance of these two pattern recognition receptors in 
the development of contact hypersensitivity (92).  This study also revealed that mice lacking both 
IL-12Rβ2 and TLR2 or 4 were also resistant to contact hypersensitivity; this was not demonstrated 
in mice lacking only one of the following components (92).  These results indicate that allergic 
sensitization may depend on several innate factors, including: an IL-12-dependent mechanism 
mediated in concert with TLRs and an IL-12-independent mechanism that involves TLR2 and 4 (92).  
IL-12 likely plays a role in dendritic cell and Th1 activation and function, further contributing to the 
pathogenesis of allergic disease.  Interestingly, TNCB sensitization and contact hypersensitivity was 
sustained in germ free mice (92), suggesting a role for skin-derived TLR ligands in the innate 
response to chemical allergens. 
While significantly augmented miR-210 expression was observed in the dLN (0.5 and 4% 
TDI) and ear (4% TDI) at various time points post chemical exposure, 4% TDI is a dermally-




this response.  To investigate this, a range of TDI concentrations were selected to encompass both 
non-irritant (0.5%) and irritant (1, 2, and 4%) doses based on ear swelling and inflammatory cytokine 
mRNA levels in the ear, as reported by Long, et al. (93).  dLN and ear miR-210 expression was 
quantified 4 days post 0.5 and 4% TDI exposure.  dLN miR-210 levels were significantly 
upregulated at all TDI concentrations, regardless of irritant status (Figure 4.2A), indicating that dLN 
miR-210 expression is not dependent on dermal irritation.  Ear miR-210 levels appeared to be more 
affected by the irritant status of the TDI concentration, revealing significantly increased miR-210 
levels following 0.5, 2, and 4% TDI exposure yet the magnitude of miR-210 fold change is much 
higher in 4%-treated ears (Appendix 4.1 B).  While irritation is considered by many to be an 
important component of sensitization, this is not unexpected; however, the increased expression of 
miR-210 in the 0.5%-treated ears further suggests a role for miR-210 in the sensitization response 
and not solely the irritant response.  The expression of additional miRNAs that were previously 
shown to be upregulated during TDI sensitization (62) was investigated at non-irritant and irritant 
TDI levels and dLN miR-22 and -31 siginficantly increased at various time points post 0.5, 1, 2, and 
4% TDI exposure (data not shown).  An additional study was completed in order to further confirm 
the sensitization-related expression of miR-210.  Dermal application of a known irritant, nonanoic 
acid (NA),which lacks sensitization capabilities, was carried out followed by confirmation of dermal 
irritation  and no significant changes in dLN miR-210, -22, nor -31 expression following NA 
exposure and the development of an irritant response in the absence of sensitization (data not shown).  
Altogether, this data suggests that several miRNAs are significantly increased due to the TDI 






5.5.2. Of Mouse and Man: Important Considerations  
Clearly, murine and human immunology share many conserved features, emphasizing the 
utility and popularity of experimental murine models.  Mouse research has been a staple in many 
landmark immunologic discoveries of the past century.  Mice, in particular, are very useful for the 
study of human diseases because of the highly conserved gene repertoire between the two species.  
While these models are extremely useful and can mimic the human disease state in many instances, 
they are not a perfect reflection of the human condition.  Regarding immunology in particular, many 
key differences in the two organisms should be noted.  Murine blood contains a high percentage of 
lymphocytes (75-90% of all cells) while human blood is mostly composed of neutrophils (50-70% 
of all cells) (94).  This may be significant in systemic responses such as TDI sensitization, as a 
determinant of cellular responsiveness.  Several innate immune structures are altered in mice and 
humans, including TLR expression, defensing production, and inducible nitric oxide synthase  
production by macrophages (94).  In terms of adaptive immunity, humans express several FcRs that 
mice do not, there is variation in antibody isotype structure between the two species, several 
chemokines and receptors have been identified in one species but not the other (e.g. CXCR1, CCL6, 
and MCP-4), and T-helper skewing may not be as “clear cut” in humans as it is in mice (94).  T cell 
activation is characterized by several key steps, one being inward calcium flux which is thought to 
be mediated by the outward flow of potassium via the Kv1.3 K+ channel; murine T cells do not 
express this channel, calling into question the mechanism of calcium flux sustainability by murine T 
cells (94).  In addition to the basic mechanistic differences in murine and human models, many 
differences exist in the manifestation of disease in models of illness such as delayed type 
hypersensitivity, where the cellular components of the response are divergent (humans- neutrophils 




response) and where mice typically require higher antigen concentrations for the elicitation of the 
allergic response than humans (94).  In terms of TDI-induced asthma, the choice of mouse strain 
determines the asthma phenotype (e.g. severity and cellular involvement) (95), demonstrating 
intraspecies variability.  As previously noted, several important species-to-species disparities remain 
in the study of TDI-allergic disease, including the role of IgE (Ref Chapter 2).  Additionally, Tregs 
vary considerably in rodents and humans; CD103 is robustly expressed on naïve and activated 
murine Tregs (Ref Chapter 3) yet this molecule is essentially nonexistent on human Tregs (96).  This is 
an important consideration in regards to extrapolation of data from studies utilizing CD103 as a Treg 
marker in mice.              
It is very important to consider species-specific differences when utilizing animal models in 
both basic and preclinical research.  One of the most haunting examples of failure to take into account 
these differences is the 2006 TGN1412 (CD28 superagonist) clinical trial which resulted in life 
threatening cytokine storms in six healthy young male volunteers.  This agent, which was intended 
to stimulate the production of Tregs (97) and Th cells (98) underwent preclinical evaluation in rodents 
and nonhuman primates, showing no significant adverse effects.  The unprecedented, nearly fatal 
cytokine storm (primarily IFN-γ, IL-2, and TNF) in Phase I human volunteers has been determined 
to be due to CD4+ effector memory T cells (TEM) which are produced by exposure to infectious 
agents, which is not experienced by laboratory animals housed in pathogen-free conditions, resulting 
in a disadvantageous Treg:TEM  balance not seen in rodents utilized in preclinical studies (97).  
Nonhuman primates, which are virtually genetically analogous to humans, were also utilized in 
preclinical studies and cynomolgus macaques were administered TGN1412 at doses up to 500 times 
higher than the dose given to the human volunteers in the absence of negative effects (97).  One 




TEM differentiation, while human TEM cells retain CD28 expression (97), possibly accounting for the 
massive TEM activation and cytokine release following TGN1412 administration.  Additionally, the 
human CD28 extracellular domain varies by four amino acids from the macaque molecule, one of 
the substitutions occurring in the C”D binding loop which is the site of TGN1412 binding (98).  This 
tragic event emphasizes the sometimes subtle yet critical species-specific differences between 
humans and model organisms that should be fully investigated and always considered both in basic 
and preclinical research.  Additionally, retrospective studies with humanized mice revealed 
concerning effects of TGN1412 administration on the immune system of these mice, including rapid 
peripheral lymphopenia, which was also evidenced in the human volunteers during the clinical trial 
(98).  This emphasizes the utility of humanized animal models, particularly in immunologic studies.  
The divergent immune systems of humans and mice can be explained by natural selection; 
each unique mechanism was likely adopted as a selective advantage for each species based on their 
environment, lifespan, size, and specific pathogens encountered.  These differences are inevitable 
and do not invalidate the use or validity of murine models in immunology research.  Rather, the 
careful consideration of species-specific differences and the resultant thoughtful extrapolation of this 
data to human disease is required for these studies to reach their maximum impact on human health.    
 
5.5.3 Summary 
Overall, much progress has been made in the understanding of TDI sensitization and allergic 
disease; however, there is still a pressing need for hazard identification strategies for respiratory 
sensitizers like TDI.  The involvement of novel mediators of sensitization like Tregs and miRNAs has 




sensitization, but presumably it is relevant to many chemical sensitizers.  We have identified a 
functional role for Tregs in a murine model of epicutaneous TDI sensitization.  This role appears to 
be significant in the dampening of allergic responses; however, the overall sensitization response is 
not abrogated due to the expansion of these cells.  Although Tregs may be suppressive in the TDI 
sensitization response, the proliferation of allergic cells and their secretion of cytokines may be 
overwhelming to the Tregs that are present during the response.  This concept has been applied to 
autoimmune responses in murine models of atherosclerosis, rheumatoid arthritis, and primary biliary 
cirrhosis where peak inflammatory conditions and peak Treg levels occur at the same time, suggesting 
that the suppressive capabilities of these cells are overtaken by the strong autoimmune response that 
originally resulted in their induction (99).  This is not to say that the Tregs aren’t having a regulatory 
effect at all in conditions such as TDI sensitization and autoimmune disorders; however, their 
presence is not enough to diminish symptoms completely and stop the response “in its tracks”.   
The hypothesized action of miR-210 and other miRNAs such as miR-31 as Treg antagonists 
suggest more intricate regulatory mechanisms at play than are currently understood in chemical 
sensitization.  While Tregs expand and are functionally active during TDI sensitization, these cells are 
likely being regulated by a number of factors including miRNAs, as reported in this work.  miRNAs 
display great promise as biomarkers of disease in a number of conditions and these molecules could 
potentially be investigated as sensitization biomarkers in chemical sensitization or utilized to 
distinguish contact and respiratory sensitizers.  Additional miRNAs were upregulated in the dLN 
during TDI sensitization, including miR-21, -22, -126, and -301a (62).  While these miRNAs were 
not investigated in this work, they may also play important regulatory roles in the TDI sensitization 
response.  Further research characterizing the miRNome during TDI sensitization and elicitation 




Altogether, this work represents insight into the regulatory mechanisms involved in the 
complex TDI sensitization immune response.  Both Tregs and miRNAs are significant in their 
regulatory functions and their newfound roles in TDI sensitization are illustrated in figure 5.1.  These 
insights may aid in the further exploration of immunoregulatory mechanisms and novel effectors of 
chemical sensitization.  Ultimately, this work may promote the development of novel hazard 
identification strategies that are designed in regard to the complex regulatory mechanisms that are a 
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A 3.1 Treg Phenotyping Gating Strategy 
Treg gating strategy for dLN flow cytometric analysis of CTLA4 (A), Neuropilin-1 (B), and 
CCR6, CD103, and ICOS (C) expression.  Examples are shown for populations positive for each 



































































































































A 3.2 Treg Depletion Study Model Confirmation 
(A) Blood Treg gating strategy for flow cytometric analysis.  Examples are shown for baseline (left 




baseline (left panel), day -2 (center panel), and day 7 (right panel) samples and is presented as percent 
of CD45+ CD4+ or CD4+ cells.  (C)  dLN Treg flow cytometric analysis is shown for day 7 as 
percentage of CD45+CD4+ cells (left panel) and number of cells (right panel) based on extrapolation 
of this data with total dLN cellularity.  Bars represent mean (± SE) of 5 mice per group.  Statistical 
significance was determined by Student t-test and is indicated as follows: p value <0.05 and (**) p 
value <0.01.  P values are represented by asterisks (comparison of acetone to TDI-exposed group 
from the same antibody treatment regimen) or horizontal bars with asterisks above (comparison of 





















































































































































A 3.3 Treg Depletion Study Supplemental Data  
Percent change in total body weight (tracked per individual mouse, presented as SEM) as determined 
from day -11 to 7 (A).  dLN T cell phenotyping was performed 7 days following dermal TDI 
exposure as in Figure 3.4.  Th2 (CD3+CD4+Gata3+) frequency (B) and Th2 
(CD3+CD4+Gata3+Foxp3-) MFI (C) were determined based on flow cytometric analysis (frequency 
and MFI) and extrapolation of this data with total dLN cellularity.  Bars represent mean (± SE) of 5 
mice per group.  Statistical significance was determined by Student t-test and is indicated as follows: 




to TDI-exposed group from the same antibody treatment regimen) or horizontal bars (p <0.05; 
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dLN T cell phenotyping was performed 7 days following dermal TDI exposure.  CD3+ frequency 
(A) and number (B), CD3+CD4+ frequency (C) and number (D), CD3+CD8+ frequency (E) and 
number (F), Th1 (CD3+CD4+Tbet+) frequency (G) and number (H), and Th17 (CD3+CD4+Rorγt+) 
frequency (I) and number (J) were determined based on flow cytometric analysis and extrapolation 
of this data with total dLN cellularity.  Bars represent mean (± SE) of 5 mice per group.  Statistical 
significance was determined by Student t-test and is indicated as follows: p value <0.05 and (**) p 
value <0.01.  P values are represented by asterisks (comparison of acetone to TDI-exposed group 
from the same antibody treatment regimen) or horizontal bars (p <0.05; comparison of identical 
















































































































































A 4.1 miR-210 Expression in a Variety of Tissues During 4% TDI Sensitization 
RT-PCR analysis of miR-210 expression in the ears (A) and blood (B) 4 days post TDI exposure.  
Bars represent mean relative fold change (± SE) of 4-5 mice per group.  P values are represented by 
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Figure A 5.1 Ear Treg Phenotyping Gating Strategy 
Treg gating strategy for dLN flow cytometric analysis of CD45 (A), CD3 (B), CD4 (C), CD25 (D), 
Foxp3 (E), CCR7 (F), CD103 (G), and ICOS (H) expression.  Examples are shown for populations 
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